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Breast cancer is the most commonly diagnosed and second highest
cause of cancer-related mortality in women, with the majority of deaths
associated with metastatic spread of tumors to distal organs. The
metastatic process involves multiple sequential steps including invasion
of the surrounding stroma, intravasation into lymph or blood vessels,
survival during transport with successful evasion of the immune system,
extravasation and final outgrowth in the new microenvironment. At each
step cells acquire new properties through the alteration of gene expression
profiles. While a great deal of effort has been made towards
understanding the underlying genetic mutations associated with
enhanced motility and invasiveness, it is becoming increasingly apparent
that post-transcriptional modification of gene expression at the RNA level
contributes substantially towards gain of metastatic potential.

In eukaryotic cells RNA is subject to multiple layers of regulation
that together generate extensive phenotypic and temporal complexity
from a relatively small number of genes. RNA regulation is achieved
through the concerted action of multiple RNA binding proteins (RBPs)
which themselves are subject to tight regulation. Recent studies have
implicated the aberrant expression of multiple RBPs in tumor

development and metastatic spread, while technological advances have
provided methods by which unbiased, transcriptome-wide footprints of
RBP-RNA interactions can be mapped. High-throughput cross-linked
immunoprecipitation (HITS-CLIP) provides both the identity of regulated
transcripts and the location of RBP regulation within a transcript. For the
post-transcriptional regulatory protein Argonaute (AGO), which binds
mRNA in complex with small non-coding microRNAs (miRNAs), HITSCLIP derived 3’UTR binding sites have been shown to correspond to sites
of functional miRNA-mediated target downregulation.

In this study, a molecularly characterized cell culture based model
system of breast cancer metastasis has been employed to investigate the
role of RNA binding proteins in the inhibition of metastatic progression.
AGO-mRNA

regulation

mediated

by

endogenous

miRNAs

and

exogenous anti-metastatic pre-miR-335 has been interrogated by HITSCLIP to identify on a genome-wide scale differentially regulated targets
with respect to metastatic potential. Furthermore, HITS-CLIP has been
used to characterize a novel anti-metastatic RNA binding protein, RBM47,
uncovering multifunctional regulation of target transcript stability and
alternative splicing.

For the women behind the identifiers
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CHAPTER 1: INTRODUCTION

Breast cancer is the most commonly diagnosed tumor in women,
with an estimated ~230,500 newly diagnosed invasive cases expected in
2011, and is the second highest cause of female cancer-related mortality
(American Cancer Society, 2012). Metastasis, a complex multistep process
in which cells shed from the primary tumor disseminate throughout the
body to colonize and proliferate in organs distant from the site of the
original tumor, is the leading cause of death from breast cancer. The 5year relative survival rate of patients presenting with distal metastases
drops to 23.3% from 98.6% in patients with localized disease (Siegel et al.,
2012). Dissemination of tumor cells can occur early in primary breast
cancer progression leading to both primary tumor re-seeding and
accelerated primary tumor growth (Kim et al., 2009b), and colonization of
secondary metastatic niches leading to eventual outgrowth as distal
metastatic lesions (Husemann et al., 2008). The metastatic process is
inherently inefficient (Luzzi et al., 1998, Cameron et al., 2000) and is
thought to require both tumor cell intrinsic adaptation and cell extrinsic
metastatic niche modulation (Nguyen et al., 2009).

Metastatic cells show differing abilities to grow in certain organs
with varying latencies to outgrowth that are dependent upon tumor type
or sub-type, and in a way that cannot be solely be explained by circulatory
patterns (Mendoza and Khanna, 2009, Nguyen et al., 2009). In breast
adenocarcinoma, metastases are most commonly found in the auxiliary
1

lymph nodes, bone, lung, brain and liver (Hess et al., 2006, Patanaphan et
al., 1988). Both general poor-prognosis and tissue-specific gene expression
signatures have been described that clinically correlate with metastatic
relapse (van 't Veer et al., 2002, van de Vijver et al., 2002, Bos et al., 2009,
Kang et al., 2003, Li et al., 2011a, Minn et al., 2005a). However,
understanding the exact molecular and cellular processes involved in both
gain of metastatic ability and organ-specificity remains challenging (Sethi
and Kang, 2011).

RNA Binding proteins and cancer-associated alterations in RNA
metabolism
RNA metabolism is an integral part of both normal cellular
complexity and the altered transcriptomes observed during both
tumorigenesis and gain of metastatic ability. Central to this complexity are
the concerted actions of multiple RNA binding proteins (RBPs) that
regulate the spatial, temporal and functional dynamics of target RNAs
from transcription to maturation, from modulation of content through to
eventual degradation (Moore and Proudfoot, 2009). This includes (but is
not limited to) alternative splicing, alternative polyadenylation and the
regulation of transcript stability predominantly mediated through
interactions in 3’ untranslated regions (3’UTRs). Thus, RNA is no longer
considered solely as a template for protein synthesis; rather its precise
regulation is fundamental in the generation of biological complexity in
both normal and disease states (Sharp, 2009, Licatalosi and Darnell, 2010).

2

Alternative Splicing
In eukaryotes precursor messenger RNA (pre-mRNA) is subjected
to

multiple

post-transcriptional

modifications

including

the

intramolecular joining (splicing) of regions of coding sequence that will be
transcribed into protein (exons), and the removal of intervening noncoding sequences (introns). Splicing reactions are catalyzed by a large
multi-component ribonuclear complex called the spliceosome, which is
comprised of five subcomponent small nuclear ribonucleoproteins
(snRNPs U1-6) that assemble in a stepwise manner on core sequence
elements within the intron to be removed. The sequences recognized by
the spliceosome are relatively degenerate and in most cases the strength of
the splicing signal is influenced by flanking pre-mRNA sequences,
intronic or exonic splicing silencers or enhancers, which mediate their
effects primarily by serving as binding sites for additional trans-acting
regulatory RBPs (Wahl et al., 2009).

Alternative splicing was first described in 1980, when it was
discovered that two protein products, one soluble and one membrane
bound, could be produced from the same immunoglobulin gene (Alt et al.,
1980, Early et al., 1980). Multiple types of alternative splicing have since
been described; alternative 5’ and 3’ splice site selection, single exon
(cassette-exon) inclusion or exclusion, mutually exclusive cassette-exon
inclusion or exclusion, intron retention, and alternative promoter or
3’exon selection (Keren et al., 2010). Recent studies using high-throughput
sequencing of the human transcriptome indicate that alternative splicing
3

is major contributor to proteomic diversity, with over 90% of human
genes showing evidence of alternative transcripts (Pan et al., 2008, Wang
et al., 2008). Additionally, patterns of tissue-specific regulation have been
observed indicating that the enormous diversity of proteins that can
potentially be generated by alternative splicing is regulated in a
coordinated manner (Wang et al., 2008). For example, the neuronal
specific splicing factor Nova has been found to regulate the alternative
splicing of a biologically coherent set of transcripts involved in synaptic
plasticity, providing the first demonstration of an RBP-coordinated
biological network (Ule et al., 2003, Ule et al., 2005b, Licatalosi et al., 2008).

The regulation of alternative splicing is dependent upon
interactions between multiple RBPs, and between splicing factor RBPs and
their binding motifs in target pre-mRNAs (Licatalosi and Darnell, 2010). It
has been shown that splicing factors can be differentially expressed
between human tumors and normal tissues, although for most splicing
factors it is not known whether these tumor specific expression patterns
are a consequence or causative of the oncogenic process (KirschbaumSlager et al., 2004). It is interesting to note that alternative splicing patterns
can be used to distinguish normal tissue from serous ovarian tumors
(Venables et al., 2009), breast tumors (Venables et al., 2008) and colon
cancers (Gardina et al., 2006) suggesting that alteration in alternative
splicing is a common feature of tumorigenesis.

4

Cancer-associated mutations resulting in alternative splicing
Germline mutations in high penetrance susceptibility genes such as
BRCA1, BRCA2, PTEN and TP53 contribute approximately 20% of familial
genetic risk in breast cancer (Thompson and Easton, 2004), with BRCA1
and BRCA2 mutations conferring a lifetime risk of 80-90% (Meindl et al.,
2011). The BRCA proteins are tumor suppressors involved in homologous
recombination and error-free repair of DNA double strand breaks (Roy et
al., 2012). Interestingly, previously unclassified germline variants of
BRCA1/2 associated with breast cancer, those that do not have predicted
effects on protein function, are being characterized as anomalous splicing
variants resulting from disruption of regulatory splicing elements (Sanz et
al., 2010, Wappenschmidt et al., 2012) or by activation of cryptic exons
(Anczukow et al., 2012a).

It is estimated that 10% of human inherited diseases result from
mutations disrupting components of 5’- or 3’-splice sites (Cooper et al.,
2009). However, this estimate does not take into consideration exonic
mutations as these are generally presumed to result in missense mutations
and altered protein function, or to be neutral due synonymous mutations.
Exonic mutations have the potential to create or destroy regulatory
sequences known as exonic splicing enhancers (ESE) or silencers (ESS).
Recent bioinformatic analyses of exonic disease-causing human mutations
have

found

a

strong

association

between

single

nucleotide

polymorphisms (SNPs) and both the creation of ESS motifs and ablation of
ESEs suggesting that exon skipping may play a prominent role in human
5

inherited disease (Sterne-Weiler et al., 2011, Lim et al., 2011). Furthermore,
trait associated SNPs, mutations significantly and reproducibly associated
with but not causative of particular inherited diseases, are also enriched
for exon-exclusion inducing intronic mutations (Lee et al., 2012)
suggesting that mis-splicing is a common feature of genetic disease.

Large-scale changes in splicing patterns have been observed in
multiple tumor types during the transition from normal to cancerous
tissue, making widespread germline or gain of tumor-associated
mutations highly unlikely. Mutations in proteins involved in the core
splicing machinery have been found in myelodysplasia, a neoplasm that
predisposes for acute myeloid leukemia (Yoshida et al., 2011), however
deregulation of trans-acting alternative splicing modulators are more
commonly described.

Splicing regulators as oncogenes – SRSF1
The SR protein family members, serine/argenine rich splicing
factor (SRSF) 1-12, are defined based on the presence of 1-2 RNA
recognition motif (RRM) domains followed by an ~50nt >40%
serine/argenine domain of consecutive RS or SR repeats (Manley and
Krainer, 2010). SR proteins are involved in both constitutive and
alternative splicing of pre-mRNA through binding to ESEs (Busch and
Hertel, 2012). Karni et al. (2007) discovered that SRSF1 (previously known
as SF2/ASF) is upregulated in lung, colon and breast tumors when
compared to normal tissues, and that ectopic expression of SRSF1 is
6

oncogenic both in vitro and in vivo. Over-expression of SRSF1 leads to the
alteration of alternative splicing patterns of endogenous target genes,
including increased expression of an oncogenic isoform of RPS6KB1, and
increased inclusion of an alternative exon12a of BIN1 that abolishes its
tumor suppressor activity (Karni et al., 2007).

Subsequently it has been shown that SRSF1 is transformative in
mammary epithelial cells (Anczukow et al., 2012b), and is upregulated in
lung adenocarcinoma and squamous cell lung cancer (Gout et al., 2012),
non-small cell lung cancer (Ezponda et al., 2010), and pediatric acute
lymphoblastic leukemia (Zou et al., 2012). SRSF1 regulates the inclusion of
exon 3b of Rac1 in colon cancer cells (Goncalves et al., 2009) resulting in
the expression of a constitutively active Rac1b isoform that has been
shown to promote transformation of NIH3T3 cells through AKT
phosphorylation and activation (Singh et al., 2004). Additionally, the
transforming ability of SRSF1 in immortal fibroblasts has been
demonstrated to be dependent upon mTORC activity (Karni et al., 2008),
while SRSF1 expression is both directly regulated by, and necessary for,
the oncogenic activity of Myc in lung cancer cells (Das et al., 2012). A
genome-wide binding map of SRSF1 has been generated in mouse
embryonic

stem

cells

using

high-throughput

cross-linked

immunoprecipitation (HITS-CLIP) which, in conjunction with splicingsensitive microarray analysis, has identified 498 SRSF1-dependent
alternative splicing events (Pandit et al., 2013), although it is not known
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how many of these targets are expressed and regulated in the tumor
tissues associated with SRSF1 transformation.

Splicing regulators as oncogenes – FOX2
Using genome-wide, high throughput RT-PCR, Venables et al.
(2009) identified multiple alternative splicing events common to tumors of
the breast and ovary that can discriminate between normal and cancer
tissues. Analysis of sequences in the 100nt flanking regions of these cancer
associated-exons revealed enrichment of FOX1/2 binding motifs. FOX1
mRNA is detected almost exclusively in the brain and striated muscle,
while FOX2 is more broadly expressed in heart, brain and the ovary (Jin et
al., 2003, Lieberman et al., 2001, Underwood et al., 2005). Subsequent
analysis of breast cancer and non-malignant immortalized breast
epithelial cell lines have revealed that FOX2 regulates alternative splicing
patterns associated with claudin-low, basal breast cancer sub-types
(Lapuk et al., 2010). Computational analyses of the genome-wide
distribution of FOX1/2 binding motifs have revealed a positiondependent relationship between alternative exon inclusion or exclusion
(validated by semi-quantitative RT-PCR) in transcripts enriched in gene
ontology

terms

associated

with

cytoskeletal

organization

and

neuromuscular functions (Zhang et al., 2008). Genome-wide mapping of
FOX2 on target mRNAs in human embryonic stem cells (hECS) has
confirmed this positional bias in splicing and identified FOX2 as necessary
for hECS survival, although this phenotype was not found in 293T cells or
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human fetal neural stem cells suggesting cell type specific FOX2 target
regulation (Yeo et al., 2009).

Splicing regulators as tumor suppressors – RBM5
Allele loss at 3p21.3 is both the earliest pre-malignant change thus
far detected in lung cancer (Sundaresan et al., 1992) (Hung et al., 1995,
Sundaresan et al., 1992, Wistuba et al., 1999), and the most frequent lung
cancer-associated genetic alteration (Zabarovsky et al., 2002). This ~630kb
deletion is also observed in multiple other tumor types including breast,
and spans multiple putative tumor suppressor genes including the RNA
binding protein RBM5 (Lerman and Minna, 2000, Zabarovsky et al., 2002).
RBM5 encodes two RRM domains, a zinc finger motif, a bipartite nuclear
signal and a G-patch domain (Timmer et al., 1999). Unlike the protumorigenic

splicing

factors

mentioned

above,

RBM5

is

tumor

suppressive; inhibiting growth in MCF-7 breast cancer cells (Oh et al.,
2002), A549 non-small cell lung cancer (NSCLC) cells (Oh et al., 2006, Shao
et al., 2012) and CEM-C7 leukemia cells (Mourtada-Maarabouni et al.,
2003).

RBM5 is reported to promote apoptosis (Mourtada-Maarabouni et
al., 2003, Shao et al., 2012) in part through binding to and positively
regulating the splicing of a pro-apoptotic isoform of caspase 2, casp-2L
(Fushimi et al., 2008). Conversely, RBM5 can interfere with a late step in
spliceosome assembly, promoting exon exclusion and production of a
non-membrane-bound Fas molecule that inhibits apoptosis (Bonnal et al.,
9

2008, Cheng et al., 1994). Additionally, RBM5 causes cell cycle arrest in G1
in lung cancer cells, and induces the expression of the apoptotic activator
BCL2-associated protein X (Bax) although the mechanisms by which this
occurs remain unknown (Oh et al., 2006).

Alternative splicing in metastasis
Multiple transcripts that promote tumor cell invasive behavior are
regulated by alternative splicing (David and Manley, 2010). The
transmembrane protein CD44 is encoded by 20 exons, 10 of which can be
regulated by alternative splicing leading to multiple different functional
proteins (Ponta et al., 2003). Alternative splice isoforms of CD44 were
among the first to be associated with induction of metastasis (Gunthert et
al., 1991) and have subsequently been found to promote metastasis in
multiple tumor types. Regulation of CD44 splicing is reported to be
controlled by multiple candidate RBPs including SFRS10 (Watermann et
al., 2006, Takeo et al., 2009), PCBP-1/hnRNP-E1 (Zhang et al., 2010b, Lian
et al., 2012), Sam68 (Matter et al., 2002) in association with SRm160 (Cheng
and Sharp, 2006), and ESRP1 (Reinke et al., 2012, Yae et al., 2012). While
the majority of these RBPs enhance inclusion of various combinations of
alternative CD44 exons, PCBP-1/hnRNP-E1 promotes exon exclusion
suggesting that over-all splicing outcome in any given cellular context
depends upon the regulatory proteins expressed.

Altered patterns of alternative splicing have been observed when
comparing primary tumors with differing metastatic capacity (Dutertre et
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al., 2010), and during the acquisition of the invasive phenotype that
accompanies the epithelial-mesenchymal transition (EMT) (Warzecha et
al., 2010, Shapiro et al., 2011). The EMT involves loss of cell polarity and
cell-cell junctions and the acquisition of a more motile, invasive cellular
phenotype via extensive transcriptional changes and reorganization of the
actin cytoskeleton. While direct evidence linking EMT to metastasis in vivo
is difficult to obtain, the same processes commonly involved in
developmental EMT bear striking similarity to those involved in
metastasis (Yilmaz and Christofori, 2009).

Three RBPs are currently implicated as major regulators of EMTassociated alterations in alternative splicing patterns: ESRP1 and ESRP2,
and RBFOX2 (Shapiro et al., 2011). The switch between the mutually
exclusive inclusion of fibroblast growth factor receptor 2 (FGFR2) exon3b
(epithelial) or exon3c (mesenchymal) that occurs during EMT and
metastasis (Yan et al., 1993) is thought to be a direct result of
downregulation of the epithelial specific splicing factors ESRP1 and
ESRP2 (Warzecha et al., 2009). Knockdown of ESRP1 and 2 in mammary
epithelial cells induces both the cellular changes indicative of EMT and
extensive alterations in splicing of transcripts associated with vesicular
transport (Warzecha et al., 2010), while re-expression of ESRP1 in
mesenchymal cells causes partial reversion to the epithelial phenotype
(Shapiro et al., 2011). Analysis of RBP expression levels in mammary
epithelial cells undergoing EMT have confirmed both the loss of ESRP1/2,
and identified a slight up regulation of RBFOX2 (Shapiro et al., 2011) a
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known driver of mesenchymal-specific splicing patterns (Venables et al.,
2013). Depletion of RBFOX2 in mesenchymal cells leads to partial
reversion to the epithelial phenotype, while EMT associated up-regulation
of RBFOX2 leads to altered splicing patterns of predicted targets
associated with invasion (Braeutigam et al., 2013).

RNA binding proteins and modulation of transcript stability
The relative abundance of mRNA is a function both of the rate of
transcription and degradation, with each altered in response to stimuli in
order to adjust the resulting protein level. Aberrant gain or loss of a
transcript in disease may reflect either DNA mutation or dysregulation of
trans-activating transcription factors, or could result from altered posttranslational regulation of stability of the message. mRNA stability can be
regulated by RBPs, either alone or in complex with non-coding RNAs,
through binding to cis-regulatory elements within the transcript (Wu and
Brewer, 2012). Several well characterized mRNA stabilizing and
destabilizing factors are known to be deregulated in tumorigenesis and
metastasis, influencing the establishment of aberrant target mRNA
expression profiles.

Nonsense mediated decay in cancer
Nonsense mediated decay (NMD) is a translation-coupled mRNA
surveillance process that selectively eliminates transcripts containing
premature stop codons to minimize synthesis of truncated proteins.
During splicing of pre-mRNA, the exon junction complex (EJC) is
12

deposited approximately 20-24 nucleotides upstream of the exon-exon
junction, providing a position dependent memory of the splicing event (Le
Hir et al., 2000, Le Hir et al., 2001). If a translating ribosome encounters a
stop codon >50-55nt upstream of an EJC, translational pausing occurs
leading to the recruitment of the SMURF complex (SMG1, UPF1 and
eukaryotic release factors) and SMG1 phosphorylation of UPF1 (Kashima
et al., 2006). This in turn leads to the recruitment of decapping enzymes,
the endoribonuclease SMG6 and deadenylation, resulting in the rapid
decay of the mRNA (Lejeune et al., 2003, Huntzinger et al., 2008).

Meta-analysis of predicted human disease-causing mutations has
revealed a disproportionately high number of nonsense mutations in
tumor suppressor genes when compared to missense mutations, with the
opposite being true for oncogenes (Mort et al., 2008). NMD has been
shown to prevent the translation of truncated proteins in breast cancer
that arise from germline mutations in BRCA1, CHK2 and TP53 (PerrinVidoz et al., 2002, Anczukow et al., 2008). In hereditary diffuse gastric
cancer, ~80% of the causative germline mutations in e-cadherin generate
premature stop codons leading to NMD and transcript down regulation
(Karam et al., 2008). In addition to DNA mutation, introduction of
premature stop codons can also be achieved through alternative splicing,
by inclusion of occult, poorly conserved exons that result in frame-shift
mutations (Green et al., 2003, Lewis et al., 2003).
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While it has been argued that the inclusion of the majority of
mammalian alternatively spliced NMD exons results from “noisy”
splicing rather than regulated events (Zhang et al., 2009), the onconeural
antigen proteins Nova1 and Nova2 have been shown to bind and regulate
the alternative splicing of multiple NMD exons in brain in an activity
dependent manner (Eom et al., 2013). This would suggest that inclusion of
NMD exons and hence down regulation of target mRNA can proceed in a
coordinately regulated manner. The NOVA proteins were first identified
as the target antigens in paraneoplastic opsoclonus-myoclonus ataxia
(POMA) syndrome (Darnell et al., 1991), a neurological degenerative
disorder commonly associated with ectopic NOVA expression in breast
and gynecological cancers (Luque et al., 1991). Ectopic NOVA expression
is also reported in Hodgkin lymphoma cells (Relogio et al., 2005) and in
primary serous ovarian tumors (Darnell lab, unpublished data).
Additionally, multiple splicing factors have been shown to be auto- or
trans-regulated via inclusion or exclusion of NMD exons. For example,
PTBP1-dependent skipping of exon11 in PTBP2 leads to a frame-shift
mutation that targets PTBP2 mRNA for NMD and establishes mutually
exclusive expression patterns of the two splicing factors (Rahman et al.,
2002, Boutz et al., 2007). It has been discovered that NMD is inhibited in
the tumor microenvironment leading to enhanced tumorigenesis (Wang et
al., 2011b) that is dependent upon c-myc activity (Wang et al., 2011a).
Since many NMD isoforms are expressed at extremely low levels, the
extent of NMD-associated transcript regulation by RBPs in tumorigenesis
and metastasis may currently be underestimated.
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Transcript stability, ARE-binding proteins and cancer
AU-rich elements (AREs) are 50-150nt sequences rich in adenosine
and uracil bases predominantly found in the 3’UTRs of mRNAs with short
half-lives, including those involved in transient biological processes such
as immune responses, cellular growth and external stress-mediated
pathways (Bakheet et al., 2001). AREs were first identified as destabilizing
sequences when it was found that fusing the AT-rich 3’UTR segment of
the unstable granulocyte-macrophage colony stimulating factor (GM-CSF)
to the normally stable rabbit globulin transcript induced rapid
degradation (Shaw and Kamen, 1986). Many of the over twenty AREbinding proteins identified to date have been shown to promote target
instability by recruiting mRNA decay proteins to their targets (Wu and
Brewer, 2012). Among this destabilizing cohort is AUF1/hnRNP-D, a
family of four proteins generated from a single gene through alternative
splicing (Wagner et al., 1998) that interact with AREs via two tandemly
arranged, non-identical RRM domains (DeMaria et al., 1997). AUF1 has
been shown to interact with and destabilize the mRNA of multiple cancer
related proteins, including Bax and junD (Mazan-Mamczarz et al., 2008b,
Zou et al., 2010, Zucconi and Wilson, 2011).

Conversely, direct interactions with ARE-binding proteins can lead
to stabilization of targets, for example, binding by the ELAVL family of
proteins (ELAVL1/HuR, nELAV: HuB/C/D) generally stabilizes mRNAs
bearing AREs and U-rich sequences. The neuronal ELAVL family
members (nELAV) (Okano and Darnell, 1997) were discovered as the
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auto-antigens in paraneoplastic encephalomyelitis (PEM) (Szabo et al.,
1991), a neurological disorder associated with small cell lung cancer
(SCLC) (Dalmau et al., 1990, Manley et al., 1995). PEM is one of a diverse
group of paraneoplastic neurologic disorders (PNDs) characterized by
high-titer antibodies recognizing neuronal antigens that are expressed in
occult tumors. Patients with PEM have high titers of anti-nELAVL
antibodies (anti-Hu, which were used to clone the cDNAs encoding HuC
and HuD (Szabo et al., 1991)), but while all SCLCs appear to express
nELAVL antigens (Budde-Steffen et al., 1988, Dalmau et al., 1995) the
neurological syndrome is rare. HuD expression has also been associated
with neuroblastoma (Dalmau et al., 1992, Ball and King, 1997) where it is
believed to stabilize N-myc (Lazarova et al., 1999), with loss of
heterozygosity of HuD associated with N-myc gene amplification
(Grandinetti et al., 2006). Upregulation of the ubiquitously expressed
ELAVL1 is associated with multiple cancers including colon (Lopez de
Silanes et al., 2003), lung (Blaxall et al., 2000), and breast (Denkert et al.,
2004, Heinonen et al., 2005, Mazan-Mamczarz et al., 2008a, MazanMamczarz et al., 2008b). The repertoire of ELAVL-family regulated
transcripts has been greatly expanded by use of RNA cross-linking
methodologies (Keene et al., 2006, Mazan-Mamczarz et al., 2008a,
Mukherjee et al., 2011, Lebedeva et al., 2011, Ince-Dunn et al., 2012 and
Darnell lab unpublished data), with many of the identified targets
implicated in the acquisition of cancer-related phenotypes (Simone and
Keene, 2013).
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MicroRNA mediated control of gene expression in oncogenesis and metastasis
MicroRNAs (miRNA) are a major class of evolutionarily conserved,
small (~22nucleotide (nt)) non-coding RNA (ncRNA) molecules that are
associated with diverse biological processes including proliferation,
differentiation,

and

stress

response

through

post-transcriptional

regulation of target mRNAs. miRNA are transcribed by either RNA
polymerase II or III from intergenic regions of the genome, or as introns in
the pre-mRNA of coding and ncRNAs, and can be transcribed either as
the sole miRNA in that region or as part of a co-regulated cluster. miRNA
begin as longer RNA molecules (primary or pri-miRNA) that are cleaved
in the nucleus by the RNase III endonuclease Drosha to liberate a ~60-70nt
stem loop with one defined mature miRNA end. This pre-miRNA is
actively exported out of the nucleus by Ran-GTP and Exportin-5, and
processed by a second RNase III endonuclease, Dicer. Dicer recognizes the
double stranded portion of the pre-miRNA hairpin structure and cuts at a
fixed distance to generate a double stranded imperfect duplex with a
characteristic ~2nt 3’-overhang. One of these strands (mature miRNA) is
loaded into Argonaute (AGO), the core component of the miRNA-induced
silencing complex (miRISC). The second, passenger strand (miRNA*) is
generally found at lower levels than the mature miRNA and is presumed
to be degraded (Bartel, 2004). Complementarity between the 5’ end of the
mature miRNA in positions 2-8, or seed region, targets the AGO-miRNA
complex predominantly to 3’UTRs of target mRNA. AGO-ternary
complex binding leads to translational repression and/or target mRNA
destabilization (Filipowicz et al., 2008), although miRNA mediated
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upregulation of targets has also been described under certain cellular
conditions (Vasudevan, 2012).

A general downregulation of miRNAs has been observed in
tumors, with patterns of individual miRNA expression being highly
informative for both classification and prognosis (Lu et al., 2005, Calin et
al., 2005, Rosenfeld et al., 2008). Such general downregulation may be
achieved by transcriptional repression of multiple miRNAs by oncogenic
transcription factors such as Myc (Chang et al., 2008), by loss of p53
transactivation (Suzuki et al., 2009), or downregulation/altered activity of
the miRNA biogenesis pathway (Thomson et al., 2006, Kumar et al., 2007).
Haploinsufficiency of Dicer has been detected in multiple human tumors
(Hill et al., 2009, Kumar et al., 2009), with loss of a single allele leading to
accelerated tumor formation in vivo (Kumar et al., 2009, Lambertz et al.,
2010).

In addition to being regulated by oncogenes and tumor
suppressors, individual miRNA or miRNA clusters can themselves be
either pro- or anti-tumorigenic depending on cellular context. Greater
than 50% of miRNAs are located in fragile chromosomal regions that
frequently undergo deletion and amplification in human tumors (Calin et
al., 2004, Zhang et al., 2006), and many can be epigenetically regulated
(Choudhry and Catto, 2011, Scott et al., 2006). Loss or gain of a single
miRNA can have a profound effect on cellular physiology due to the
concordant regulation of potentially hundreds of target mRNAs
18

(Hendrickson et al., 2009, Lim et al., 2005). Multiple miRNAs have been
implicated in the development of breast cancer as both tumor suppressive
and oncogenic factors (Spizzo et al., 2009, Tang et al., 2012a). For example,
upregulation of miR-155 has been found in multiple breast cancer
subtypes where it is associated with more aggressive tumors and poor
prognosis (Mattiske et al., 2012). Overexpression of miR-155 in breast
cancer cells leads to enhanced proliferation and survival, while deletion
sensitizes cells to apoptosis and chemotherapeutic reagents (Jiang et al.,
2010, Kong et al., 2010). Interestingly, wild-type BRCA1 function has been
associated with the epigenetic silencing of miR-155 through promoter
region binding and recruitment of HDAC2 (Chang et al., 2011).
Conversely, loss of the tumor suppressive miR-205 promotes anchorageindependent breast cancer cell growth (Wu et al., 2009b), in part through
derepression of HER3 tyrosine-protein kinase receptor and subsequent
increased activation of the PI3K/AKT survival pathway (Iorio et al., 2009).

Recent studies have identified several miRNAs with roles in both
metastasis suppression and promotion. miR-10b is upregulated in
metastatic breast cancer cells compared to immortalized human
mammary epithelial cells (hMECs), with knockdown reducing the
invasive ability of MDA-MB-231 cells and ectopic expression enhancing
the invasion and migration of weakly metastatic cells both in vitro and in
vivo (Ma et al., 2007). miR-10b expression is positively associated with
high-grade malignancy of various cancer types, with expression shown to
be eleveated in the primary breast tumors of metastasis-positive patients
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(Baffa et al., 2009). Systemic treatment with a miR-10b antagonist has been
shown to suppress lung metastasis in a mouse breast cancer model if
given during early stages of tumor cell dissemination (Ma et al., 2010b). In
contrast, down regulation of multiple endogenous miRNAs has been
shown to promote metastasis in breast cancer. Loss of miR-335, miR-126
and miR-206 promotes a highly aggressive metastatic breast cancer
phenotype both in vivo and in vitro (Tavazoie et al., 2008), while reexpression of miR-31 both inhibits breast cancer metastasis (Valastyan et
al., 2009) and can elicit regression of already established lung metastases
(Valastyan et al., 2011). While some progress has been made in identifying
targets of these pro- and anti-metastatic miRNAs, current studies have
been limited by lack of knowledge of direct sites of AGO-mRNA binding
and by restricting target searches to only those transcripts that both
contain bioinformatically predicted or conserved seed sites and show
large miRNA-dependent downregulation.

Alternative polyadenylation site selection
With the exception of some histone transcripts, all eukaryotic
mRNAs

undergo

a

two-step

maturation

process

involving

endonucleolytic cleavage and subsequent untemplated polyadenine
(polyA) tail addition. The specificity and efficiency of 3’end processing is
dependent upon a multiprotein complex binding to cis-acting sequence
elements in the pre-mRNA known as the polyA signal (Danckwardt et al.,
2008). Approximately 50% of human transcripts exhibit conserved
alternative polyadenylation site usage as a result of tandem polyA sites,
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polyA sites within the terminal intron, alternative splicing of the terminal
exon, or polyA site usage within an internal exon (Tian et al., 2005, Yan
and Marr, 2005). While the intrinsic strength of the polyA site sequence
and the concentration/activity of polyadenylation factors can together
determine alternative polyA site usage, various other tissue or stagespecific RBPs can also influence polyA site choice (Barabino and Keller,
1999). For example, alternative polyA site usage can be regulated by Nova
binding in 3’UTR regions flanking polyA sites (Licatalosi et al., 2008).

Use of alternative polyA sites has the potential to alter transcript
stability via elimination of large stretches of the 3’UTR, enabling escape
from any negative cis-regulatory elements located in the longer 3’UTR
isoform. Systematic analysis of human and mouse transcriptomes have
shown that shorter 3’UTR isoforms are most abundant when transcripts
are expressed at high levels, while longer 3’UTRs are associated with
lower expression levels (Ji et al., 2011). Oncogenic chromosomal
rearrangements in benign tumors that involve the loss of the c-terminal
coding sequence and entire 3’UTR of HMGA2 (Geurts et al., 1997,
Schoenmakers et al., 1995) have been shown to result in relief of let-7mediated repression (Mayr et al., 2007). Widespread shortening of 3’UTRs
with subsequent loss of miRNA regulatory sites has been described both
in activated T cells compared to resting T cells, and as a general feature of
proliferating cells (Sandberg et al., 2008). Furthermore, cancer cell lines
have been found to express shorter 3’UTR isoforms than non-transformed
cells, with 3’UTR shortening leading to activation of oncogenes (Mayr and
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Bartel, 2009). The mechanism (or RBPs responsible) for the phenomena of
alternative polyA site selection and global shortening of 3’UTR length in
oncogenic activation remains unexplored.

Mapping the transcriptome-wide regulatory networks of RNA binding
proteins
Evidence of functional roles for RBPs in tumorigenesis and
regulation of metastasis is extensive. In the studies outlined above, a
reductionist approach is commonly taken to identify one or two targets
that can partially explain the pro- or anti-metastatic consequences of
altered RBP expression. However many RBPs are multifunctional and can
regulate multiple steps in RNA metabolism. For example, the onconeural
Nova proteins can regulate transcript content via alternative splicing, and
stability through regulation of NMD and alternative polyA site usage. The
ELAVL proteins while generally recognized as ARE-binding modulators
of transcript stability also have roles in alternative splicing (Ince-Dunn et
al., 2012, Lebedeva et al., 2011). Additionally, the FET family of RBPs
(FUS/TLS,

EWSR1

and

TAF15)

associated

with

chromosomal

rearrangements in Ewing’s sarcoma, a highly aggressive primary tumor of
the soft tissue and bone with a high propensity to metastasize (Sankar and
Lessnick, 2011), have multiple roles in RNA metabolism, including
regulation of transcription (Bertolotti et al., 1996, Bertolotti et al., 1998,
Lagier-Tourenne et al., 2012), alternative splicing (Paronetto et al., 2011,
Ishigaki et al., 2012, Lagier-Tourenne et al., 2012, Rogelj et al., 2012,
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Ibrahim et al., 2013) and the biogenesis of miRNAs (Gregory et al., 2004,
Ballarino et al., 2012, Morlando et al., 2012).

Given the potential for complex patterns of RNA regulation,
comprehensive evaluation of directly regulated transcripts is necessary to
fully understand the downstream mediators of the anti- or pro-metastatic
activities of any given RBP or miRNA. While it is possible to predict
targets via observations of genome-wide changes in transcript levels upon
RBP/miRNA modulation in combination with bioinformatic assessment
of associated cis-elements (where consensus regulatory sequences are
known), this type of analysis does not discern direct versus indirect
effects. This is particularly pertinent when considering regulation by RBPs
that have the potential to influence the activity of multiple other RBPs, for
example, PTBP1 down regulation of PTBP2 via alternative splicing. These
limitations also apply to AGO-mediated miRNA regulation of transcripts
as bioinformatic predictions of regulatory sites suffer from high false
positive rates even when taking conservation and extended regions of
seed match into consideration (Baek et al., 2008, Selbach et al., 2008).
Furthermore, reporter assays may produce false-positive or false-negative
results if not carefully designed to include the native 3’UTR context,
particularly when considering the potential for regulated alternative
polyA site usage.

Multiple techniques have been developed to biochemically identify
functional RBP-RNA interactions in vivo. Immunoprecipitation of an RBP
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under mild conditions coupled with purification of co-precipitating RNA,
either in the presence or absence of formaldehyde crosslinking, allows for
coarse mapping of an RBP on target RNA (Keene et al., 2006). However
this technique suffers from low signal-to-noise, has poor binding site
resolution, and favors capture of the most stable RBP-RNA interactions
(Mukherjee et al., 2011). Additionally, this technique does not discriminate
between direct RBP-RNA interactions and those occurring due to either
co-immunoprecipitation of other RBPs or random RNA-RBP reassociation
post-lysis (Mili and Steitz, 2004, Riley et al., 2012).

Direct mapping of RNA-protein complexes became possible with
the development of crosslinking immunoprecipitation (CLIP) strategies
(Ule et al., 2003, Ule et al., 2005a, Jensen and Darnell, 2008). UV-irradiation
induces covalent bond formation between closely opposed RNA and
protein molecules within physiologically relevant distances (on the order
of Angstroms apart) but does not induce protein-protein crosslinks
(Darnell, 2010). Such UV-induced covalent bonds allow for rigorous
purification of RBP-RNA complexes from live cells or whole tissues,
which after reverse transcription and sequencing yield a population of
cDNA clones corresponding to the regions of RNA directly bound by the
protein of interest. By coupling CLIP to next generation sequencing (highthroughput CLIP, HITS-CLIP (Licatalosi et al., 2008)), high-resolution
unbiased transcriptome-wide footprints of RNA-protein interactions can
be generated. Furthermore, with the growing number of HITS-CLIP
binding maps now available from different tissues (brain, stem cells,
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tissue culture) and multiple RBPs with known RNA metabolic activities, it
is possible to predict functional outcomes from binding patterns on target
transcripts with no prior knowledge of an RBP of interests function. For
example, robust binding in intronic regions has been associated with the
regulation of alternative splicing by multiple RBPs, including but limited
to Nova (Licatalosi et al., 2008, Ule et al., 2003, Ule et al., 2006, Ule et al.,
2005b), the ELAVL proteins (Ince-Dunn et al., 2012, Lebedeva et al., 2011,
Mukherjee et al., 2011), and FUS (Ishigaki et al., 2012, Lagier-Tourenne et
al., 2012, Nakaya et al., 2013, Rogelj et al., 2012). Binding sites in 3’UTR
regions have been used to both delimit the functional regulatory sites of
AGO and to identify the targeting miRNA through narrowed search for
complementary seed sites within these footprints (Chi et al., 2012, Loeb et
al., 2012, Zisoulis et al., 2010, Hafner et al., 2010).

Perspectives
HITS-CLIP provides a tractable methodology with which to study
both RBP regulated events in tumor cells, and by differential analysis, to
identify altered sites of regulation associated with gain in metastatic
potential. To our knowledge HITS-CLIP has not been used to interrogate
the targets of endogenous RBPs in breast cancer cells, nor has it been used
to investigate RBP-associated regulation of metastasis. Although several
cancer-related RBPs have been interrogated by HITS-CLIP, none of these
experiments were carried out in cancerous cells or tissue, therefore the
relevance of identified targets to cancer biology is unknown. Given the
important dual role of miRNAs in the positive and negative regulation of
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metastasis and the potential for the regulation of hundreds of targets
(Hendrickson et al., 2009, Lim et al., 2005), AGO HITS-CLIP provides an
attractive method by which the entire network of miRNA regulation in a
cancer cell can be mapped. In this study we have generated HITS-CLIP
binding maps of endogenous AGO in weakly and highly metastatic breast
cancer cells leading to the identification of altered AGO association with
both miRNA and target mRNAs with respect to metastatic ability and
tissue tropism. Furthermore, we have assessed the genome-wide
regulatory network of miR-335, a known anti-metastatic miRNA.
Additionally, we have used HITS-CLIP as general platform for discovery
of transcriptome-wide regulation by the previously uncharacterized,
putative metastasis suppressor RBM47.
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CHAPTER 2: EXPERIMENTAL PROCEDURES

Cell Culture
Triple reporter MDA-MB-231, 4175LM2, 1833BoM2 and 831BrM2 cell lines
were obtained from the Massagué laboratory at MSKCC. Triple reporter
4175LM2 shID and 4175LM2 miR-335 over expressing cells, plus nonreporter MDA-MB-231 and 4175LM2 cells were obtained from the
Tavazoie lab at Rockefeller University. All MDA-231 and derivative cell
lines were cultured in D10F - DMEM (Corning) supplemented with 10%
FBS (Hyclone), 1% sodium pyruvate, 1% penicillin-streptomycin and 0.4%
fungizone (Gibco). HEK293T cells were obtained from ATCC and cultured
in DMEM with 10% FBS. Non-clonal dox-inducible 831BrM2 triple
reporter stable cell lines expressing WT FLAG-tagged RBM47 or Tet-On
(empty vector) and the clonal 831BrM2 WT FLAG-tagged RBM47#10 cell
line were generated by Sakari Vanharanta (Massagué Laboratory,
MSKCC). RBM47 expression was induced using 1ng/ml or 10ng/ml
doxycycline (Sigma) respectively for three days. All cells were maintained
at 37°C in 5% CO2.

Analysis of miRNA and mRNA expression levels by quantitative-PCR
Total RNA was purified by Trizol extraction (Invitrogen) followed by
ethanol

precipitation,

DNase

treatment

(RQ1

RNase-free

DNase

(Promega) and phenol-chloroform extraction. 90ng of total RNA was used
for reverse transcription with the miScript II RT Kit (Qiagen) followed QPCR in using the equivalent of 2ng starting RNA with FastStart SYBR
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Green Master mix (Roche Applied Science) and commercially available
miScript miRNA specific primers (Qiagen) as per the miScriptII RT
protocol. Primers specific to SNORD44 were used as a normalization
control. For mRNA expression analysis, 1!g of total RNA was reverse
transcribed using the iScript cDNA synthesis kit and 100ng used per
FastStart SYBR reaction. Genorm analysis (Vandesompele et al., 2002) was
carried out using the BioGazelle software on MDA-231 and its metastatic
derivatives to select a control gene for normalization. TATA-binding
protein (TBP) showed the least variation between cell lines and was used
as the control gene for all mRNA Q-PCR. For all analyses, Q-PCR was
done in triplicate for each independently prepared RNA sample
(minimum of three per condition/cell line) using a BioRad IQ5 Real Time
PCR machine and 58°C annealing temperature, with both melt curves and
-RT controls performed. All Q-PCR primers were designed using
Primer3Plus.

HMGA1 F – agcgaagtgccaacacctaa

R – tttccttcctggagttgtgg

CD59 F - cacaatgggaatccaaggag

R - tgcagtcagcagttgggtta

CETN3 F – tggacaaaacaaagaggaaaaa

R – acatcaaaccccaaggctct

SEL1L F – agaaggcagccaggatgaat

R – gaatcaagaaatatttgaccagca

FAM105B F – agcaatggaaacttggactg

R – tttgtgaatagttcatcacaagcta

SMAD5 F – tctgcttgggtttgttgtca

R – ctgctgtcactgaggcattc

TWSG1 F – aatgttcacgcgccttattc

R - aaccagcgatatttggatgc

DKK1 F – gatcatagcaccttggatggg

R – ggcacagtctgatgaccgg

RBM47 F – ctgtcattcccactgtgtcg

R - gtaactggccccgtagatcc
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SERPINB2 F – ggtcctggtgaatgctgtct

R - ctgtacaggtgtgcgctgag

CTGF F – ggagtgggtgtgtgacgag

R – ccaggcagttggctctaatc

ANKRD1 F – gagataccccgttgcatgat

R- ttctgccagtgtagcaccag

TBP F – ggggagctgtgatgtgaagt

R- tttccagaaacaaaaataaggagaa

SNORD44 F – tgctgactgaacatgaaggtc

AGO HITS-CLIP
Bead Preparations for Immunoprecipitation
Protein A Dynabeads (Invitrogen) were resuspended and washed
3x in PBS 0.02% Tween-20. 200!l beads were used per 10cm2 dish of 80%
confluent cells. Beads were rotated with 25!l bridging antibody (rabbit
anti-mouse IgG, Jackson ImmunoResearch, 315- 005-008 at 2.3mg/ml) per
200!l beads for 35min at room temperature, then washed 3x in PBS 0.02%
Tween-20. 3!l AGO antibody (2A8 ascites provided by Dr. Zissimos
Mourelatos, (Nelson et al., 2007)) was loaded per 200!l beads. For
irrelevant antibody controls, no 2A8 AGO antibody was added. Beads
were rotated for 2hrs at 4°C then washed 3x in 1X PXL lysis buffer (1X PBS
[tissue culture grade; no Mg2+, no Ca2+, GIBCO], 0.1% SDS, 0.5% NaDOC, 0.5% NP-40) containing complete protease inhibitor (mini EDTA
free tablets, Roche, 1 tablet/10 ml buffer).

Cell Lysate Preparation
Media was removed from MDA-231, 4175LM2, 1833BoM2 and
831BrM2 cells, and the cells washed with cold 1X PBS before 254nm UV
crosslinking 1x at 400mJ/cm2 on a bed of ice (Stratalinker2400,
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Stratagene). Cells were harvested by scraping in 1X PBS and pelleted.
Non-crosslinked samples were collected at the same time for RNAseq
analysis. Crosslinked cell lysates were prepared by adding 1ml PXL lysis
buffer plus complete protease inhibitor and vortexing to disrupt cells.
Lysates were DNase treated with RQ1 RNase-free DNase (Promega) for
5min, shaking at 1000rpm at 37°C. Aliquots from each cell line were
pooled to the same total volume as experimental lysates and 10!l of a
1:100 RNaseA solution (diluted in lysis buffer) added for the high
RNAseA control. 10!l of a 1:5000 RNaseA solution was added to all other
lysates, and all samples incubated at 37°C, 5min, 1000rpm. Lysates were
spun at 4°C, 30,000rpm, 20min to clear cell debris and the supernatant
harvested to a new tube for immunoprecipitation (IP). Aliquots of each
low RNase treated sample were again pooled for the control IgG IP.

Samples were rotated with antibody-loaded beads at 4°C for 2hs.
Following IP, beads were washed sequentially (all washes 1ml) twice with
1X PXL lysis buffer, twice with 5X PXL (5X PBS [tissue culture grade; no
Mg2+, no Ca2+, GIBCO], 0.1% SDS, 0.5% Na-DOC, 0.5% NP-40), twice
with high stringency buffer (15mM Tris-HCl, pH7.5, 5mM EDTA, 2.5mM
EGTA, 1% TritonX-100, 1% Na-deoxycholate (DOC), 0.1% SDS, 120mM
NaCl, 25mM KCl), high salt buffer (15mM Tris-HCl, pH 7.5, 5mM EDTA,
2.5mM EGTA, 1% TritonX- 100, 1% Na-DOC, 0.1% SDS, 1M NaCl) and
twice with low salt buffer (15mM Tris-HCl, pH7.5, 5mM EDTA) followed
by two washes with PNK buffer (50mM Tris-HCl, pH7.5, 10mM MgCl2,
0.5% NP-40). After each capture on the magnet beads, the beads were
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resuspended by end-over-end rotation, with the samples washed in a
random order throughout. 1.5ml SlickSeal microfuge tubes (National
Diagnostics) were used throughout the CLIP protocol to reduce noncrosslinked RNA binding to tubes.

Dephosphorylation of RNA, 3’ Linker Ligation, and Rephosphorylatoin of 5’ end
of RNA Tags
IPs were treated with calf intestinal phosphatase to remove the 5’
phosphate from RNA crosslinked to AGO to prevent RNA circularization
during ligation, an otherwise competing intramolecular reaction. Beads
were resuspended in 60!l 1X dephosphorylation buffer with 3 units of
CIAP (Roche) and RNAsin Plus RNase Inhibitor (Promega), and
incubated at 37°C, shaking at 1000rpm for 15s every 2min, 20 min. This
was followed by 5X 1ml washes, once with PNK Buffer, twice with PNK
buffer plus EGTA (10mM Tris pH7.5, 20mM EGTA, 0.5% NP-40), and
twice again with PNK buffer (no EGTA).

For AGO CLIP, 32P-labeled RNA linker is ligated to the 3’ end of
crosslinked RNA. 50pmol of puromycin-blocked linker (L32, 5’-OHGUGUCAGUCACUUCCAGCGG-3’-puromycin, Dharmacon) was labeled
using T4 phosphonucleotide kinase (PNK, NEB) by adding 15!l
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P-"-

ATP, 1!l RNAsin and 2!l of T4 PNK in a 50!l total volume 1X PNK buffer
and incubating for 30min at 37°C. 0.02ml 1mM ATP was added with an
additional 5min incubation to drive the reaction to completion.
Radiolabeled linker was purified from free ATP by spinning through a G31

25 column (Amersham). 30pmol labeled 3’RNA linker was used per 60!l
T4 RNA ligase reaction (Fermentas) according to kit instructions. On-bead
ligation reactions were incubated at 16°C for 1hr, 1000rpm 15s every 4min,
then 80pmol of unlabeled L32 RNA linker (with 5’ phosphate) added and
the reaction incubated overnight. Following linker ligation, beads were
washed once each with 1XPXL and 5XPXL, and 3X with PNK buffer to
remove any free linker. 80!l of T4 PNK mix (6!l 1mM ATP, 4!l T4 PNK
enzyme [NEB], 1!l RNasin in 1X T4 PNK buffer) was added to sample
and incubated at 37°C, 1000rpm 15s every 4min, for 20 min to
phosphorylate the 5’ end of the AGO bound RNA for later 5’ linker
ligation.

SDS-PAGE Separation of RNA-binding Protein:RNA Complexes
Beads were washed three times with 1ml PNK buffer then
resuspended in a 60!l solution of 1X NuPAGE loading buffer (LDS,
Invitrogen), 1X NuPage Reducing Agent (Invitrogen) and 1X PNK buffer.
Beads were incubated at 70°C, 1000rpm for 10min. Supernatants were run
on Novex NuPAGE 8% Bis-Tris gels (Invitrogen) in SDS-MOPS running
buffer (Invitrogen) for 2.5hrs, 175V, at 4°C. Two lanes per sample were
used to prevent over-loading. Protein-RNA complexes were transferred to
Protran BA85 nitrocellulose (Whatman) using a Novex wet transfer
apparatus (Invitrogen). After transfer, the nitrocellulose was rinsed with
RNase-free 1X PBS, dried, and exposed to Biomax MR film (Kodak).
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Recovery of AGO-RNA Complexes, Protease Digestion, and 5’ Linker Ligation
Nitrocellulose membranes were aligned carefully with the exposed
film and regions of membrane excised from low RNase IP lanes at a size
directly above that of the over-digested band, approximately 110-125kD
for AGO-miRNA and 130-150kD for AGO-mRNA. The nitrocellulose
membrane sections were cut into smaller pieces and proteinase K treated
with a 0.2ml 1:5 dilution of proteinase K (4mg/ml, Roche) in PK buffer
(100mM Tris-HCl pH 7.5, 50mM NaCl, 10mM EDTA)) at 37°C, 1100 rpm
for 20min. 0.2ml of 1X PK buffer 7M urea solution was added and
incubated for further 20min at 37°C, 1100 rpm. RNA fragments were
isolated

by

adding

0.4ml

of

RNA

phenol

(pH

6.8,

Applied

Biosystems/Ambion) and 0.13ml of 49:1 CHCl3:isoamyl alcohol,
incubating a further 20min at 37°C, 1100rpm, and spinning at 20,000g in a
desktop microcentrifuge at room temperature. The aqueous phase was
taken to a new tube, 0.8!l glycogen (Applied Biosystems/Ambion), 50!l
3M NaOAc pH 5.2, and 1ml of 1:1 ethanol:isopropanol added, and RNA
precipitated overnight at -20°C.

RNA was pelleted by spinning at 20,000g, 4°C for 30min, and
washed twice with 75% ethanol. The dried pellet was dissolved in 6!l
RNase-free H2O. 1!l 10X T4 RNA ligase buffer (Fermentas), 1!l BSA (0.2
!g/!l), 1!l ATP (10mM), 0.1!l T4 RNA ligase (3U, Fermentas), and
20pmol of 5’ RNA linker (RL5D) were added in a total volume of 10!l and
incubated for 5hrs at 16°C with intermittent shaking. (RL5D: 5’-OHAGGGAGGACGAUGCGGr(N)r(N)r(N)r(N)G3’-OH). Ligated RNA was
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DNase digested by adding 79!l H2O, 11!l 10X RQ1 DNase buffer, 5!l
RQ1 DNase and 5!l RNasin and incubating at 37°C for 20 min, then
purified by phenol:chloroform extraction (300!l H2O, 300!l RNA phenol
(Ambion), 100!l CHCl3). RNA was precipitated from the aqueous phase
overnight at -20°C by adding 50!l 3M NaOAc pH5.2, 0.5!l glycogen and
1ml 1:1 ethanol:isopropanol.

RT-PCR and High-Throughput Sequencing of PCR Products
RNA was pelleted, washed, dried as before, and then resuspended
in 10!l RNase-free H2O. 2!l of RNA per sample plus an additional 6!l
H2O were taken for a –RT control. RNA was mixed with 2!l of 5pmol/!l
P32 primer (3’ DNA primer 32, 5’- CTTCACTCACCTCGCAACCG-3’,
Operon) and 3!l 3mM dNTPs, incubated at 65°C for 5 min in a
thermocycler, chilled, and spun briefly. 1!l 0.1M DTT, 4!l 5X SuperScript
RT buffer, 1!l RNasin, and 1!l SuperScript III (Invitrogen) were added
and the mix incubated in a thermocycler at 50°C for 45min, 55°C for
15min, 90°C for 5min and then moved onto ice. Superscript III was
omitted from –RT control reactions. PCR was performed immediately
with 27!l Accuprime Pfx Supermix (Invitrogen), 0.75!l 20pmol/!l P51 (5’
DNA primer 51, 5’- AGGGAGGACGATGCGG-3’, Operon), 0.75!l
20pmol/ul P32 primer, and 2!l of the RT reaction, 4 reactions per sample.
PCR conditions were: 95°C for 2min, 20-35 cycles 95°C 20s denature, 58°C
30s anneal, and 68°C 30s extension. Purified miRNA were amplified to 20,
22, 24 and 26 cycles, mRNA to 24, 26, 28 and 30 cycles, while –RT reactions
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were taken to +4 and +6 cycles above the highest corresponding +RT
reaction.
The entire PCR reaction was loaded in 95% formamide (Sigma), 5%
100mM EDTA pH8, bromophenol blue, xylene cyanol buffer in a 10%
denaturing polyacrylamide gel, using 3!l Amplisize Molecular Ruler
(Biorad). To visualize DNA, gels were immersed in a 1:10,000 dilution of
SYBR Gold (Molecular Probes) in 1X TBE for 10min. PCR product was
excised from the lowest cycle number giving visible signal, and the
remaining RT reaction was then brought up to this minimal cycle number,
gel purified and the products pooled. Acrylamide bands containing DNA
of ~60nts were excised from miRNA samples, and ~100-150nt for mRNA.
DNA was purified by crushing gel slices in diffusion buffer (0.5M
ammonium acetate, 10mM Mg acetate, 1mM EDTA, 0.1% SDS), incubating
at 50°C for 30min, 1200rpm, then filtering through Whatman GF/D filters
in Nanosep columns (VWR). DNA was recovered from filtrate using
Qiaquick gel purification buffers and columns (Qiagen) and eluted in 30!l
TE. An additional PCR reaction was performed using the following fusion
primers to permit sequencing on the Illumina platform.
SP5fusion: AATGATACGGCGACCACCGACTATGGATACTTAGTCAG
GGAGGACGATGC
GG3’#SP3fusion: #CAAGCAGAAGACGGCATACGACCGCTGGAAGTGA
CTGACAC
PCR amplification was performed using Accuprime Pfx (Invitrogen) and
ranged between 6 and 10 cycles. The PCR product was separated on 2%
Metaphor agarose gel (Lonza) and the lowest cycle number visible
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purified using Qiaquick spin columns (Qiagen). A total of 10-30!l of 10nM
DNA (quantified using Quant-IT, Invitrogen) was sequenced using primer
SSP1 on an Illumina HiSeq.
SSP1: CTATGGATACTTAGTCAGGGAGGACGATGCGG.
All data analysis was done using the Galaxy platform (Hillman-Jackson et
al., 2012) and the R Statistical Analysis Software (http://www.Rproject.org) running edgeR (Robinson et al., 2010).

RBM47 polyA-tailed HITS-CLIP
Immunoprecipitation, CIP treatment, direct 32P-!-ATP labeling, SDS-PAGE
and nitrocellulose transfer
Beads were prepared as per the AGO HITS-CLIP protocol, omitting the
bridging antibody and using 50!l of ProteinG dynabeads loaded with 5!l
anti-FLAG mouse monoclonal (Sigma F3165) per sample. Cell lysates were
prepared as for AGO HITS-CLIP from duplicate dishes of UV crosslinked
1ng/ml dox treated 831BrM2 Flag-RBM47 WT, one crosslinked dox
treated Tet-On control dish, and one non-crosslinked dox treated RBM47WT dish. A lower concentration of RNaseA was used as a 1:10,000
dilution was shown to give optimal digestion of RBM47 bound fragments.
IPs and subsequent washing was carried out as described. RBM47-RNA
complexes were treated on bead with calf intestinal phosphatase, washed,
then directly labeled on bead with 32P-"-ATP using 4!l 10X PNK Buffer
(NEB), 2!l 32P-"-ATP, 2!l T4 PNK enzyme (NEB) and 32!l H2O at 37C,
1200rpm 15s/2min, 20min. 1!l of non-radiolabeled 10mM ATP was added
and the reaction incubated a further 5min. Beads were then washed once
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with 1XPNK, once with high salt buffer, then twice with 1XPNK. SDSPAGE and nitrocellulose transfer were carried out as for AGO with the
addition of 10X Reducing Agent (NuPage) during elution of complexes
from the bead.

RNA Purification, polyA Tailing and BrdU Reverse Transcription
RNA was purified as in AGO HITS-CLIP from excised membrane
fragments corresponding to RBM47-WT crosslinked lanes at ~76-100kD.
Pelleted RNA recovered from the first phenol:chloroform extraction were
resuspended in 6.25!l H2O and denatured at 65C for 5min with no
shaking, then placed on ice. The polyA tailing reaction mix was prepared
on ice by adding 1!l 10X E-PAP Buffer (Promega), 1.5!l 1mM ATP, 1.5!l
RNAsin Plus (diluted to 5U/!l) and 1!lE-PAP (3U/!l, NEB M0276) to the
purified RNA. The reaction was incubated for 15min at 37C, then 20min at
65C in a pre-warmed thermocycler. 2.5!l of each polyA-tailed reaction
was taken for a –RT control with an additional 2.5!l H2O. Reverse
transcription was carried out using 5!l polyA tailed RNA, 1!l 0.752M
Tris, 1!l 8.2mM dATP, 1!l 8.2mM dCTP, 1!l 8.2mM dGTP (all
Invitrogen), 1!l 8.2mM Br-dUTP (Sigma), 1!l 25!M RT Primer and 1!l
H2O. This mix was incubated for 3min at 75C then ramped down to and
held at 48C. 1!l 82mM DTT, 1!l 10U/!l RNasin and 1!l SuperscriptIII (or
H2O for –RT) pre-warmed to 48C were added to the mix, then incubated
for 45min 48C, 15min 55C, 5mi 85C then held at 4C. RT-primers with
different index sequences were used, one per replicate:
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NV20T-RTAP2:
pGCACTGTTN6GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGA
AGACGGCATACGAT20VN
NV20T-RTAP4:
pGCGAAACTN6GATCGTCGGACTGTAGAACTCT/idSp/CAAGCAGA
AGACGGCATACGAT20VN

cDNA purification
50!l of ProteinG dynabead per sample were washed three times in 1XPBS
0.02% Tween-20, resuspended in 22!l of wash buffer plus 25!l 50X
Denhardt’s Solution (Sigma) and rotated at room temperature for 1hr.
Beads were washed three times with 1X IP buffer (0.3X SSPE (Ambion),
1mM EDTA, 0.05% Tween-20), resuspended in 25!l IP buffer plus 25!l of
anti-BrdU antibody (5g, Santa Cruz, sc-32323), rotated at room
temperature a minimum of 45min then washed 3X in 1X IP buffer. The
equivalent of 25!l starting volume of beads were used per anti-BrdU IP.
After completion of the RT reaction, 1!l of 2U/!l RNaseH (Invitrogen)
was added and the mix incubated at 37C for 20min, 10!l RNase-free H2O
added and the cDNA purified by spinning through a G-25 column. The
total volume of cDNA was brought up to 40!l with H2O, and 10!l 50X
Denhardt’s solution plus 50!l 2X IP buffer added, and incubated for 5min
70C, 2min 25C. This mixture was added to the equivalent of 25!l starting
volume of the prepared anti-BrdU beads per sample. Tubes were rotated
at room temperature for 30mins and washed once with 1X IP buffer plus
5X Denhardt’s, twice with low salt buffer plus 2.5X Denhardt’s, twice with
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stringent buffer plus 2.5X Denhardt’s, and twice with 1X IP buffer. cDNA
was eluted from the beads via BrdU competitive elution by adding 50!l
100!M BrdU (Sigma) in 1X IP buffer, rotating for 30min and collecting the
eluate. Eluted cDNA was purified by spinning through a G-25 column, the
volume adjusted to 97.5!l with H2O, and 37.5!l 4X IP buffer, and 15!l
Denhardt’s solution added. Purified cDNA was heated to 70C 5min, then
25C for 2min then added to the remaining 25!l of prepared anti-BrdU
beads and rotated again for 30min, room temperature. Beads were washed
once with 1X IP buffer plus 5X Denhardt’s, twice with low salt buffer plus
2.5X Denhardt’s, twice with stringent buffer plus 2.5X Denhardt’s, and
twice with 1X CircLigase Wash Buffer (33mM Tris-acetate, 66mM KCl,
pH7.8).

On-bead cDNA Circularization and ApeI Linearization
cDNA was circularized by incubation for 1hr, 160C, 1300rpm 15s/30s with
2!l CircLigase 10X Reaction Buffer (Epicentre), 4!l 5M betane, 1!l 50mM
MnCl2, 0.5!l CircLigase ssDNA Ligase II (50U, Epicentre) and 12.5!l H2O.
Beads were washed by rotating for 5min twice each with low salt buffer,
stringent buffer and ApeI buffer (50mM potassium acetate, 20mM Trisacetate, 10mM magnesium acetate, pH7.9). cDNA was linearized by
adding 2!l 10X NEB Reaction Buffer 4, 1.25!l ApeI (10U/!l NEB) and
16.75!l H2O, and incubating 1hr, 37C 1300rpm 15s/30s. Beads were
washed twice with low salt buffer, twice with stringent buffer and twice
with Phusion wash buffer (50mM Tris, pH8.0).
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PCR Amplification, DNA purification and quantification
To elute cDNA from beads 10!l 5X Phusion HF Buffer (NEB), 1!l 10mM
dNTPs and 37.5!l H2O were added, the mix transferred to a thin walled
PCR tube and incubated at 98C for 45 seconds. Beads were transferred
back to a microfuge tube and the eluate collected from the beads by
magnet and transferred to a fresh PCR tube. To this was added 0.5!l
20!M P5 primer, 0.5!l 20!M P3 primer, 0.5!l Phusion DNA polymerase
and 0.5!l 50X SYBR Green I (Invitrogen).
P5 – aatgatacggcgaccaccgacaggttcagagttctacagtccgacg
P3 - caagcagaagacggcata
PCR amplification was carried in an iQ5 real-time PCR machine in order
to monitor amplification, with the samples being removed when the RFU
signal reached ~1000. PCR cycle conditions were as follows: 1X 98C 30s,
15-20 cycles as necessary 98C 10s, 60C 15s, 72C 20s. PCR products were
purified using MinElute columns (Qiagen) as per manufacturers
instructions and quantified using Quant-It (Invitrogen). Before sequencing
samples were analyzed by Tapestation (Agilent) and pooled for Illumina
high-throughput sequencing using the Illumina small RNA sequencing
primer – cgacaggttcagagttctacagtccgacgatc. All data analysis was done
using the Galaxy platform (Hillman-Jackson et al., 2012) and the R
Statistical Analysis Software (http://www.R-project.org) running edgeR
(Robinson et al., 2010).
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RNAseq Library Preparation
RNA was prepared following the TruSeq RNA sample Preparation v2
Guide (Illumina FC-122-1001). An additional size selection step was added
by running cDNA on a 2% agarose gel, excising fragments at 250bp (+/25bp) with Genecatcher Disposable Tips (Gel Company PKB6.5) and gel
purification (QIAquick Gel Extraction Kit 28704). cDNA was sequenced
on an Illumina HiSeq 2000. All data analysis was done using the Galaxy
platform (Hillman-Jackson et al., 2012).

3’UTR Cloning into psiCheck2 and generation of mutants
Full length 3’UTRs of human genes, or shorter fragments as indicated,
were PCR amplified from MDA-MB-231 cDNA (iScript cDNA synthesis
Kit, Bio-Rad) using Accuprime Supermix1 (Life Technologies) and
individually cloned into psiCheck2 dual luciferase reporter vector
(Promega) via XhoI and NotI digestion (New England Biolabs). Mutant
constructs were made using the QuikChange Lightning Site-Directed
Mutagenesis Kit with primers designed using the Agilent Technologies
primer design program. Mutant 3’UTR vectors were sub-cloned into
psiCheck2, and all constructs were sequence verified before transfection.

HMGA1 3’UTR F – tatctcgagcccatgcgtgccgcctgctc
HMGA1 FL 3’UTR R- tatgcggccgctccagaaaaaggatattttttttattc
HMGA1 SH 3’UTR R – tatgcggccgcgtccaggagggcatgtgtgtatg
HMGA1 S1 22 MUT F – ctcctcactggaggaggtccttccttctgggactg
HMGA1 S1 22 MUT R – cagycccagaaggaaggacctcctccagtgaggag
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HMGA1 S1 28-5p MUT F – ccatgcgtgccgcctggaggtcactggaggagcagc
HMGA1 S1 28-5p MUT R – gctgctcctccagtgacctccaggcggcacgcatgg
HMGA1 S1 320 MUT F – cttccttctgggactggagaccaatgc
HMGA1 S1 320 MUT R – ggtgggagcggagcattggtctccag
HMGA1 S2 138 MUT F – tcaccaccacactacacagcacaggtcccgctgcagggc
HMGA1 S2 138 MUT R – gccctgcagcgggacctgtgctgtgtagtgtggtggtga
HMGA1 S2 142-3p MUT F- tgtgccctcaccaccactgatcacagcacaccagccgc
HMGA1 S2 142-3p MUT R- gcggctggtgtgctgtgatcagtggtggtgagggcaca
HMGA1 S2 ALL MUT F - tgccctcaccaccactcttcacacct
HMGA1 S2 ALL MUT R - ggagccctgcagcgggtcgagaggt
CD59 3’UTR F- tatctcgagtgcagtgacagcttgagtgggg
CD59 3’UTR R – tatgcggccgcaactcgattttcagccacttgt
CETN3 3’UTR F – tatctcgagagaattacaaggataaacact
CETN3 3’UTR R – tatgcggccgcttaaaattctaataaaataaatat
CETN3 miR335* MUT F – gcctggagccatgtgatataaaccaacttagttc
CETN3 miR335* MUT R – gaactaagttggtttatatcacatggctccaggc
SDAD1 3’UTR F – tatctcgagcttcctggcaagttttccattc
SDAD1 3’UTR R – tatgcggccgctatttggcattagaaaccttttattg
CDH11 3’UTR F – tatctcgagcaataacgatacaaatttggcc
CDH11 3’UTR R – tatgcggccgccaaaagattgcttcttatattg
psiCheck2 F- gtgctgaagaacgagcagtaa
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R – cgaggtccgaagactcattt

MicroRNA mimic transfections and dual Luciferase 3’UTR Reporter
Assays
All transfections were carried out using Dharmafect Duo (Dharmacon) as
per manufacturers guidelines. For Q-PCR analysis, 20x103 cells/well of
non-reporter 4175LM2 cells were plated in 12 well format 24 hours before
transfection in triplicate with 50nM specific miRNA mimic, negative
control mimic A, or with transfection reagent alone (miRIDIAN mimics,
Dharmacon). Cells were harvested at 48hrs. To assess the role of
individual miRNAs on psiCheck2 3’UTR reporter constructs, 20x103
cells/well non-reporter 4175LM2 were plated in 12 well format 24 hours
before transfection in quadruplicate with either 50ng or plasmid alone, or
with 50nM specific miRNA mimic or negative control mimic. For
endogenous miRNA regulation of 3’UTR constructs, 5x103/well of nonreporter MDA-231 or 4175LM2 cells were plated 24 hours before
transfection of 5ng of plasmid in 96-well format (n=6 or 10). Cells were
lysed 30 hours post transfection and the ratio of Renilla to firefly luciferase
measured by dual-luciferase reporter assay (Promega) using a Lumat
LB9507 luminometer (Berthold Tech) as per kit instructions. Each
construct was assayed in two independent experiments to verify
regulation.

Generation of CETN3 overexpressing stable cell lines
The coding sequence of human CETN3 was PCR amplified from MDA231 cDNA and cloned into pBabePuro (Morgenstern and Land, 1990) via
BamHI EcoRI double digestion.
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Fwd–ataggatccgccaccatgagtttagctctgagaagt
Rev–tataccggtttaatgtcaccagtcataat
Retroviruses were generated by transfecting pBabePuro-CETN3 into
HEK293T packaging cells with pCMV-VSV-G & pGAG-Pol (ratio 2:1:2)
using TransIT-292 transfection reagent (Mirus). Virus particles were
collected 48hrs after transfection, filtered and applied to triple reporter
MDA-231 and 4715LM2 miR-335OE cells in the presence of 0.8!g/ml
polybrene. Virally transduced cells were selected using 2!g/ml
puromycin. CETN3 overexpression was verified by Q-PCR.

Invasion assays
Cells were plated at ~50% confluence in 10cm dishes in D10F, with media
changed to D0.2F (as per D10F but with 0.2% FBS) 12hrs before plating in
invasion chambers. Matrigel invasion chambers (BD BioCoat™ Growth
Factor Reduced BD Matrigel™ Invasion Chamber) were thawed at room
temperature then equilibrated with D0.2F (500ul above and below the
insert) at 37°C in 5% CO2 for one hour. Cells were trypsinized, neutralized
with D10F then washed twice with 1XPBS to remove serum before
resuspending in D0.2F. The equilibration media was aspirated from the
top of the invasion chamber and 500ul of 100k/ml cells added to each
well. Cells were allowed to invade for 24hrs at 37°C in 5% CO2, then
membranes were washed twice with 1X PBS. Non-invaded cells were
scraped from the top of the membrane, and those cells that had invaded
fixed with 4% paraformaldehyde for 15min at 37°C. Membranes were
washed again with 1XPBS, excised and mounted using Vectorshield
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Mounting Medium plus DAPI (Vector Labs). Each cell line was tested in
quadruplicate. Invasive cells were imaged using a Zeiss Axiovert S100
fluorescence microscope (4X optic) in triplicate per membrane, a cells
counted using ImageJ.

Flow Cytometry Surface Staining
CD59 antibody (clone p282 (H19)) was purchased from BD Biosciences.
Cell surface expression was measured using fluorescently-conjugated
antibodies according to the manufacturer’s instructions. Cells were
resuspended in 100!l FACS buffer (PBS supplemented with 1% PHS, 1%
FBS (HyClone)), 1!g of each antibody was added and incubated for 10
minutes at room temperature in the dark. Cells were washed twice with
FACS buffer and collected immediately on a BD FACScaliber machine and
analyzed using Flowjo software (Treestar).

Western blotting
For the test of RBM47 as an RNA binding protein, after exposure of the
radioactive nitrocellulose membrane to x-ray film it was blocked for 1hr in
5% non-fat milk in PBS, followed by incubation with anti-FLAG (Sigma,
F7425) overnight at 4C. The membrane was washed 4X 5min 1X TBST
after each antibody incubation. Secondary anti-rabbit-HRP (Jackson
ImmunoResearch Labs) was added at 1:10,000 in 5% non-fat milk 1XPBS
for 40min at room temperature. HRP signal was detected by Enhanced
ChemiLuminescence (Western Lightning detection kit, Perkin Elmer)
using Kodak MR film. For all other western blots, cells were lysed in 1X
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PXL plus protease inhibitors (mini EDTA free tablets, Roche, 1 tablet/10
ml buffer), and sonicated to shear DNA. NuPAGE loading sample buffer
and reducing agent (Invitrogen) were added to 30!g protein to final
concentration of 1X, and samples heated at 70C for 10min. Lysates were
separated on 4-12% Bis-Tris NuPAGE gels (Invitrogen) is SDS-MOPS
buffer and transferred to Protran BA85 nitrocellulose by standard
methods. Membranes were blocked for 1hr at room temperature with
Odyssey Blocking Buffer (LI-COR) followed by the addition of primary
antibody (RBM47 Sigma HPA006347, HSP90 Cell Signaling) in LI-COR
Antibody buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 0.1% Tween-20,
2% BSA and 0.02% sodium azide) for two hours at room temperature or
overnight at 4C. Blots were washed 4X 5min in 1X TBST after each
antibody incubation. Fluorescently conjugated secondary antibody (Goat
anti-mouse IgG IRDye, Goat anti-rabbit IgG IRDye LI-COR) was added in
1X TBST for 40min, blots washed 3X 1XTBST and 1X 1XTBS and
fluorescence detected using an Odyssey LI-COR machine.

Alternative splicing semi-quantitative RT-PCR
Total RNA was purified from triplicate dishes of RBM47-WT#10 and
RBM47 Tet-On cells treated for three days with 10ng/ml doxycycline, or
MDA-231 and 831BrM2 cells as described above. Reverse transcription
was carried out using random hexamers and Transcriptor Reverse
Transcriptase (Roche). For each alternative splicing event investigated,
pilot RT-PCR reactions were carried out with increasing cycle number to
ensure amplification was within the linear range. Radiolabelled 32P-dCTP
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was added to each PCR reaction for the last two cycles. RT-PCR products
were separated by electrophoresis on 6% polyacrylamide/7M Urea gels
and exposed to x-ray film. In all cases, the first three lanes correspond to
an equal mixture of cDNA from each cell line tested amplified at n-2, n,
n+2 cycles. Lane 4 corresponds to PCR at cycle n+2 using an equal mixture
of –RT control reactions. The ratio of included isoforms was determined
using ImageJ analysis of scanned x-ray film. All primers were designed
using the hg18 reference genome and Primer3Plus.
MDM4 F – ccctctctatgatatgctaagaaagaa R – tagaatgtatgcatttatgctctga
MBLN1 F – catttgcaagccaagatcaa

R - agggaacacttgtggcagat

MACF1 F – cctactcgttccagctccag

R – gcaagggatgtccgactaga

KIFAP3 F – aggagccataagtcccgatt

R - acccaacccacacagatttc

SLK F – agactatcgaacgcctggaa

R – aactctgccttctgctgctg

LIMCH1 F – gaggaataccgcaagagctg

R – cttgccatttgtcgtcctct
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CHAPTER 3:
DIFFERENTIAL AGO-REGULATION IN WEAKLY AND HIGHLY
METASTATIC BREAST CANCER

INTRODUCTION
The metastatic progression of breast cancer has been modeled in
vivo in mice using two general strategies, genetic engineering and
transplantable model systems. The latter includes both syngenic models
using mouse tumor cells, and xenograft models making use of human
derived breast cancer cell lines (reviewed in Bos et al., 2010). The
xenograft model chosen for this study was developed in the Massagué
laboratory, using in vivo selection to isolate organ specific sub-lines from
the metastatic human breast cancer cell line MDA-MB-231 (MDA-231) that
was isolated from a patient with metastatic relapse years after removal of
the primary tumor (Cailleau et al., 1978). When injected into the arterial
circulation of mice, MDA-231 are able to extravasate and colonize in vivo
the organs characteristically seen in human breast cancer patients albeit at
low penetrance. By recovering those populations of cells able to
metastasize to lung, bone and brain, expanding in culture and reinoculating into mice, highly aggressively metastatic sub-lines have been
developed with specific organotropisms (Figure 1.1, (Bos et al., 2009, Kang
et al., 2003, Minn et al., 2005a, Minn et al., 2005b)).
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FIGURE 3.1: In vivo selection of human breast cancer cell lines with
enhanced metastatic ability and organ specificity. “Parental” MDA-MB231 cells, derived from the pleural effusion of a breast cancer patient with
widespread metastasis years after the removal of the primary tumor
(Cailleau et al., 1978), were inoculated into the arterial (intercardiac) or
the venous circulation (tail vein) of immunodeficient mice allowing for
systemic distribution to all organs. Organ-specific metastatic sub-lines,
visualized by bioluminescence imaging of luciferase-transduced cells,
were recovered, expanded in culture and re-inoculated to further enrich
for highly aggressive, tissue-specific cells. The three MDA-MB-231
derivative sub-lines used in this study are highly metastatic to the bone
(1833BoM2, Kang et al., 2003; Minn et al., 2005b), lung (4175LM2, Minn
et al., 2005a; Minn et al., 2005b), and brain (831BrM2, Bos et al., 2009).
Figure adapted from Minn et al., 2005b and Minn et al., 2005a.
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Extensive molecular characterization of the aggressively metastatic
sub-lines of MDA-231 has revealed that they, like their parental cell line,
express a “poor-prognosis” signature for breast cancer metastasis that is
associated with a clinically poor outcome and highly prognostic for the
development of distal metastases (Minn et al., 2005b, van 't Veer et al.,
2002, van de Vijver et al., 2002). Layered on top of this common gene set
are tissue specific gene expression signatures that both distinguish the
MDA-231 sub-lines from the parental line, and clinically correlate with
specific site of secondary tumor formation in large cohorts of breast cancer
patients. For example, those patients found to express the 54-gene lung
metastasis signature identified from multiple lung metastatic sub-lines
have markedly worse lung-metastasis-free survival (p<0.0001) but not
bone-metastasis-free survival (p=0.15, (Minn et al., 2005a, Minn et al.,
2007)).

More recently the regulatory role of small RNAs in the acquisition
of the aggressively metastatic phenotype has been investigated using this
xenograft model. Array-based profiling of miRNAs expressed in MDA231, bone and lung specific derivative cell lines has identified miRNA
expression patterns that correctly classify the three different groups, plus
and additional eight miRNAs that show consistently decreased expression
in all highly metastatic sub-lines (Tavazoie et al., 2008). Of these, miR-335,
miR-206 and miR-126 were found to inhibit both lung and bone metastasis
in vivo and to be markedly downregulated in patients with shorter times
to metastatic relapse. Together with the previous gene expression profiles,
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this data indicates the utility of this xenograft model system for
identifying clinically relevant molecular events associated with tissue
specific metastasis, in particular for identifying the role of AGO-miRNA
mediated mRNA regulation in the suppression of metastasis.

Identification of miRNA targets has classically been carried out by
searching for conserved seed matches in the 3’UTR of transcripts that
show differential gene expression above an arbitrary threshold after the
manipulation of a single miRNA. For example, in HeLa cells transfected
with miR-124 canonical 6nt seed matches have been found in the 3’UTRs
of 76% of microarray-identified downregulated transcripts, an enrichment
that is reduced when transfecting with seed mutated miR-124 mimics
(Lim et al., 2005). Inferring direct miR-124 regulation from this kind of
data set is problematic. The bioinformatic prediction of regulatory seed
sites is limited by high false positive rates and reliance on conservation
(Baek et al., 2008, Selbach et al., 2008), hindering the identification of direct
target gene expression levels changes that occur in a background of
indirect alterations in transcript abundance. Additionally, the degree to
which individual miRNAs are able to regulate targets is dependent upon
the concentration of both the miRNA and target mRNA (Mukherji et al.,
2011). Therefore, for any given target the degree of miRNA mediated
repression may be small yet functionally relevant and may not pass the
arbitrary threshold set.
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While it has been proposed that at least 84% of miRNA target
repression can be attributed to mRNA degradation (Guo et al., 2010)
repression can occur over a broad range (Hendrickson et al., 2009,
Mukherji et al., 2011) or can occur at the translational level without mRNA
degradation in a target dependent manner (Eulalio et al., 2007). In certain
cellular conditions, miRNA targeting can lead to activation of translation
(reviewed in Vasudevan, (2012)). Given the potential for a single miRNA
to coordinately regulate hundreds of targets (Hendrickson et al., 2009, Lim
et al., 2005), low-level miRNA-mediated changes in multiple nodes within
the same cellular pathway may sum to large physiological effects on
downstream targets that are not directly regulated by the miRNA (Ebert
and Sharp, 2012).

To address these limitations, we propose using HITS-CLIP to
identify on a genome-wide scale direct RNA-protein interactions in living
cells (Licatalosi et al., 2008), which for AGO includes both miRNA and
target mRNA interactions (Figure 3.1A) (Chi et al., 2009). By mapping the
fragments of mRNA that are covalently bound to AGO after UVirradiation, we can define sites of direct endogenous interaction in vivo,
delimiting the sequence space on a per transcript basis in which seedmatch search need be carried out (Figure 3.1B). By comparing the
simultaneously derived AGO-bound miRNA profile to the sequences
found in robust and reproducible AGO-mRNA footprints, high
confidence prediction of the miRNA (or miRNA seed family) involved in
AGO targeting at any given sitecan be obtained (Chi et al., 2009).
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Furthermore, comparative AGO HITS-CLIP can be utilized to identify
sites of de novo AGO regulation, as was demonstrated by transfection of
the neuron-specific miR-124 into HeLa cells (Figure 3.1C, (Chi et al.,
2009)), or binding loss as in the genetic ablation of miR-155 in mouse T
cells (Loeb et al., 2012).

By applying the AGO HITS-CLIP methodology to the MDA-231
based xenograft model of metastatic breast cancer, we aim to produce
genome-wide binding maps of endogenous human AGO in both the
weakly metastatic parental MDA-231 cell line and the molecularly
characterized, highly metastatic bone (1833BoM2), lung (4175LM2) and
brain (831BrM2) sub-lines. Given the known contribution of miRNAs to
metastasis suppression in this model, we aim to identify differentially
regulated targets with respect to metastatic ability and tissue tropism with
no prior assumption as to the targets or resulting degree of mRNA
regulation involved.
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FIGURE 3.2: Argonaute HITS-CLIP produces two simultaneous data
sets – AGO-miRNA and AGO-mRNA. A: The X-ray crystal structure of
wild-type T. thermophiles AGO-miRNA-mRNA ternary complex (Wang et
al., 2008) reveals sufficiently close contacts between AGO-miRNA and
AGO-mRNA to allow for UV-induced covalent crosslink formation to
both RNA species. B: Overlaying robust, reproducible AGO mRNA peaks
(orange) reveals striking enrichment of seed sequences corresponding to
the top 30 CLIPed miRNAs from the same sample (purple-red) within a
62nt AGO-bound mRNA footprint centered at the peak of AGO-mRNA
binding. No enrichment of seed sequences is found for the 30 least CLIPed
miRNAs (black-grey). C: AGO HITS-CLIP can be used to identify sites of
de novo AGO-miRNA regulation. The top panel shows unique AGO
mRNA CLIP tags from non-transfected HeLa cells on known miR-124
target CD164. The lower panel shows unique AGO CLIP tags from miR124 transfected HeLa cells (each color indicating a biological replicate)
with a de novo AGO-mRNA binding site centered upon a predicted miR124 seed site (red box). (Figures 3.2A and B modified from Chi et al.,
2009.
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RESULTS
AGO-HITS CLIP in MDA-MB-231 and its highly aggressive metastatic
derivatives with tissue tropism to the lung, bone and brain
In order to map the direct sites of AGO action on mRNAs and to
identify the guide strand miRNAs in complex with AGO, HITS-CLIP was
carried out in triplicate for MDA-231, 4175LM2, 1833BoM2 and 831BrM2
triple reporter expressing cell lines (herpes simplex virus 1 thymidine
kinase:eGFP:luciferase), as outlined in Figure 3.3 and previously
published by (Chi et al., 2009). Briefly, cells were grown in parallel until
~80% confluent, rinsed in PBS and UV-B irradiated once at 400mJ/cm2.
Cells were lysed, DNAse treated and partially RNAseA digested before
being stringently immunoprecipitated using a mouse monoclonal
antibody to human AGO2 (2A8, (Nelson et al., 2007)). A portion of lysate
from each sample was taken pre-IP, pooled and subsequently split for
control IgG IP (to identify any non-specific pull down of RNA), and an
AGO IP under high RNAseA conditions to aid in later size selection of
AGO-RNA complexes.

After harsh washing, purified crosslinked AGO-RNA species were
ligated to a 5’-"P32 labeled 3’-RNA linker and size separated via SDSPAGE. AGO-RNA complexes were transferred to a nitrocellulose
membrane that was then exposed to x-ray film to allow for visualization
of radiolabelled RNA (Figure 3.4A). Regions corresponding to AGObound miRNA and mRNA of increasing modal size were excised as
indicated, proteinase K treated and the RNA purified.
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FIGURE 3.3: Argonaute HITS-CLIP schematic. A: 4 dishes each of
weakly metastatic MDA-MB-231 cells, and the three tissue-specific
aggressively metastatic sub-lines were grown to ~80% confluency. 3
dishes per cell line were UV-B crosslinked once in preparation for HITSCLIP, with the remaining dish harvested without crosslinking for
RNAseq. B: UV-B irradiation penetrates live cells inducing covalent bond
formation between RNA and protein complexes in close association
(~1Angstrom), which for AGO includes both miRNA and mRNA species.
Irradiated cells are lysed and DNAse treated before partial RNAseA
digestion to reduce the modal size of bound RNA fragments. Purification
of RNA-AGO complexes is achieved by IP under stringent conditions to
remove both non-crosslinked RNA and potential contaminating proteins.
While still on bead a 3’-RNA linker is ligated to the bound RNA that is
then radiolabelled on the 5’end and further purified by SDS-PAGE and
transfer to nitrocellulose. Bound RNA is visualized by autoradiogram to
allow for size selection of sections of nitrocellulose corresponding to AGO
plus ~22nt (miRNA) and ~50nt (mRNA). These sections are excised,
proteinaseK treated and RNA purified. A 5’ degenerate linker is ligated to
allow for reverse transcription, followed by PCR amplification and highthroughput sequencing.
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FIGURE 3.4: AGO HITS-CLIP in MDA-231 and derivative cell lines. A:
Autoradiogram of crosslinked immunoprecipitates from breast cancer cell
lines with irrelevant antibody (IgG lane) and 2A8, a mouse monoclonal
antibody to human AGO. 32P-labeled RNA is evident in only the 2A8
immunoprecipitated lysates. With high RNaseA treatment (+++) the
RNA-protein complexes approach the modal size of AGO bound to
miRNA (~110kD, bounded by blue dots) and AGO bound predominantly
to short mRNA fragments (~130kD, red dots). With low RNaseA
treatment (+), a smear of radiolabelled AGO-RNA of increasing modal
size is evident for each cell line immunoprecipitation. The regions excised
for purification and amplification are outlined (blue-miRNA, red-mRNA).
B: PCR products amplified from the excised portions of the 1833BoM2
lanes in A, after 5’ linker ligation and reverse transcription. cDNA from
the lowest PCR cycle at which product is visible (dashed boxes) were
purified and used for high-throughput sequencing. Minus RT reactions at
cycle numbers +2 and +4 above that of the highest plus RT PCR reaction
show no amplification.
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After 5’-linker ligation and a second DNAse digestion to remove any
contaminating DNA, isolated RNA fragments were reverse transcribed
and PCR amplified (Figure 3.4B) in preparation for high-throughput
sequencing. Fragments corresponding to AGO-bound mRNA and miRNA
from each replicate experiment were pooled before sequencing.

The bioinformatics pipeline used for processing AGO-bound RNAs
is summarized in Figure 3.5. Reads were filtered to remove exact
duplicates and low quality sequences, adapter sequences trimmed, and
reads then aligned to both the human genome (hg18) and a database of
mature human miRNAs downloaded from the current release of miRBase
(Kozomara and Griffiths-Jones, 2011). Tags that map to single unique
locations in the hg18 reference genome are collapsed to retain single
representative tags and remove presumed PCR duplicate sequences based
on multiple criteria; a 4nt degenerate sequence in the 5’-linker, an
algorithm that estimates sequencing error through mismatches in
alignment to the genome, and genomic coordinates. The multiple filtering
steps applied to mRNA reads returns a highly curated set of sequences,
termed “tags”, representing 20-50nt mRNA fragments directly bound by
AGO. miRNA reads are not collapsed in this manner due to the restriction
in possible 5’ degenerate linker sequences and the pre-determined length
of miRNAs. The number of miRNA and unique mRNA tags obtained for
each replicate AGO HITS-CLIP library are shown in Table 3.1.
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FIGURE 3.5: Bioinformatic pipeline for processing AGO HITS-CLIP
high-throughput sequencing data.
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TABLE 3.1: Summary of AGO HITS-CLIP sequencing results from
triplicate experiments in MDA-231, 4175 LM2, 1833BoM2 and 831BrM2.
Read counts are shown for each stage of data processing outlined in
Figure 3.5. Total miRNA and unique mRNA tags per replicate library are
bold, with the total number of unique mRNA tags for each cell line boxed.
831BrM2 sample B was sequenced on the Illumina HiSeq platform giving
>10 fold higher sequencing depth than other experiments.
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AGO-miRNA profiles of MDA-231 and its metastatic sub-lines are highly
similar
AGO-miRNA tags were mapped against a reference set of 1,100
miRNAs including star strand sequences obtained from miRBase
(Kozomara and Griffiths-Jones, 2011). Individual miRNAs were deemed
expressed if they were represented by a minimum of 10 tags in two or
more libraries derived from an individual cell line (termed biological
complexity greater than 2, or BC≥2, although it is noted that duplicate cell
culture based experiments may more accurately represent technical rather
than true biological replicates). 660 miRNAs were expressed representing
542 seed families, defined as groups of miRNAs sharing the same 7-mer
seed sequence in positions 2-8. This number is higher than the previously
reported 179 expressed miRNAs identified in MDA-231 and derivative
lines by microarray (Tavazoie et al., 2008), which may be due to increased
sensitivity of crosslinked AGO-miRNA deep sequencing versus array
hybridization and the ongoing addition of newly identified human
miRNAs to the miRBase database.

To assess the global distribution of miRNA reads between cell lines,
miRNA tags per 7-mer seed family were normalized for read depth per
individual HITS-CLIP library and expressed as a percentage of the total
number of miRNA reads in that library, then percentages averaged across
triplicates for each cell line. The top 30 miRNA seed families for each cell
line ranked by average percentage are shown in descending order in Table
3.2. miR-27a/b is the most frequently cloned AGO-associated miRNA
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TABLE 3.2: Top 30 miRNA seed families represented in the AGO HITSCLIP for each cell line ranked by percentage of reads.
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family representing between ~24% to ~38% of all miRNAs, with miR-27a
being the predominant family member. The top three miRNA seed
families identified by HITS-CLIP represent >50% of all the miRNA reads
in each cell line. The variation in the total number of relatively rare
miRNA families represented in each cell line is reflected in the total
number of the most CLIPed miRNA families that together contribute 95%
of the miRNA profile for each cell line (Figure 3.6). 6.14% of the total
4175LM2 miRNA profile is comprised of seed families that individually
represent <1% of the total population compared to 11.13% of the
1832BoM2 profile, 8.6% in MDA-231 and 8.0% in 831BrM2.

Identification of differentially CLIPed miRNA with respect to tissue tropism
To identify potential differences in the AGO-miRNA profiles of the
highly versus weakly metastatic cell lines we used EdgeR, a Bioconductor
software package which examines changes in counts (AGO-miRNA reads)
between two or more groups (cell lines) with replicated measurements
(Robinson et al., 2010). AGO-miRNA HITS-CLIP reads for each individual
miRNA were tabulated and normalized to total read depth in that library
to give counts per million (cpm). miRNAs with cpm>2 in >9/12 HITSCLIP libraries were retained for difference analysis (296 miRNAs). EdgeR
was used to calculate log2 fold change, p-values and associated FDR in a
pairwise fashion between cell lines using an estimation of dispersal
calculated on a per miRNA basis (“tagwise dispersal”). Given the
dominance of relatively few miRNA seed families in the AGO-miRNA
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FIGURE 3.6: Distribution of miRNAs bound to AGO in MDA-231,
4175LM2, 1833BrM2 and 831BoM2 cells. The cumulative percentage of
miRNA reads per seed family averaged across triplicate libraries shows
that for all cell lines >95% of all reads are represented by the top 30
miRNA families. 4175LM2 cells show the least diversity in AGO-miRNA
seed families with 16 7mer seed sequences representing 95% of sequenced
miRNAs, followed by MDA-231 and 1833BrM (20 and 21 seed families),
with 831BoM2 having the most diversity in seed families (30).
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profile of each cell lines, the search for differentially CLIPed miRNAs was
limited to the top 30 miRNA seed families listed in Table 3.3.

Microarray analysis of MDA-231, 4175 and 831BoM cells had
previously identified 20 miRNAs specifically downregulated in bone
metastatic derivatives, lung metastatic derivatives or both (Tavazoie et al.,
2008). Of those 20 miRNAs previously identified, the majority of are either
absent from miRNA profile (less than 10 AGO-miRNA reads, 35%) or are
present at very low levels with no statistically significant difference in the
AGO-miRNA profile by EdgeR analysis (60%). However, four miRNAs in
the top 30 list of AGO-miRNA were found to have statistically significant
miRNA tag counts with FDR≤0.01 when comparing MDA-231 to one or
more metastatic sub-lines. 4175LM2 cells showed significant decrease in
miR-99a, let-7c, miR-20b and miR-142-3p counts compared to all other cell
lines, while both 1833BoM2 and 831BrM2 had significantly more AGOmiRNA reads corresponding to miR-142-3p than both MDA-231 and
4175LM2 (Table 3.3).

Global analysis of AGO-mRNA binding
Before looking for differential binding between cell lines, the AGOmRNA binding events in each cell lines were characterized. Unique tags
mapping to single locations on hg18 were analyzed based on two
definitions of robust binding sites: clusters (Figure 3.7A) and significant
peaks (Figure 3.7B) with detailed definitions of each provided in the figure
legend. Briefly, “clusters” are derived from tags with minimum of 3nt
65

TABLE 3.3: EdgeR analysis of AGO-miRNA HITS-CLIP reads. Reads
counts for each miRNA were tabulated and converted to counts per
million (cpm) on a per library basis to normalize for read depth. miRNAs
with cpm>2 in >9 of the 12 libraries were retained for further analysis (296
miRNAs). Using EdgeR, log2 fold change in miRNA count, p-values and
FDR were calculated in a pairwise fashion between cell lines using an
estimation of dispersal calculated on a per miRNA basis (“tagwise”
dispersal, see (Robinson et al., 2010)). miRNAs in top 30 seed families
with significant difference in CLIP tag counts between more than two cell
lines are shown. Consistent significant decrease in the number of CLIP
AGO-miRNA reads for miR-142-3p, miR-99a, miR-20b and let-7c is seen in
4175LM2 cells when compared to all other cells, while a significant
increase in miR-142-3p is seen in both 1833BrM2 and 831BoM2. Line
indicates no significant difference as calculated by EdgeR.

miR-142-3p

Log2 FC

p-value

FDR

miR-99a

Log2 FC

p-value

FDR

LM2/MDA

-2.64

1.10E-05

0.0019

LM2/MDA

-6.23

1.83E-05

0.0019

BoM/MDA

3.99

1.27E-07

3.76E-05

BoM/MDA

-

-

-

BrM/MDA

4.67

1.05E-10

3.10E-08

BrM/MDA

-

-

-

BoM/LM2

6.63

3.74E-17

1.11E-14

BoM/LM2

6.91

3.82E-07

5.65E-05

BrM/LM2

7.31

1.05E-20

3.10E-18

BrM/LM2

4.65

2.87E-07

4.25E-05

BrM/BoM

-

-

-

BrM/BoM

-

-

-

Log2 FC

p-value

FDR

miR-20b

Log2 FC

p-value

FDR

LM2/MDA

-3.30

4.37E-05

0.0032

LM2/MDA

-3.64

0.0007

0.0223

BoM/MDA

-

-

-

BoM/MDA

-

-

-

let-7c

BrM/MDA

-

-

-

BrM/MDA

-

-

-

BoM/LM2

3.83

4.88E-06

0.0005

BoM/LM2

3.54

0.0003

0.0099

BrM/LM2

2.53

5.00E-06

0.0004

BrM/LM2

3.55

2.91E-05

0.0014

BrM/BoM

-

-

-

BrM/BoM

-

-

-
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FIGURE 3.7: Definition of HITS-CLIP clusters and significant peaks A:
Schematic representation of cluster definition. Genomic localization of
unique mRNA tags from triplicate experiments from one cell line (red
lines, each shade representing a replicate library) are shown on a premRNA transcript (blue). Clusters are considered reproducible if they
contain tags derived from ≥2 replicates that overlap my a minimum of 3
nucleotides (biological complexity, BC≥2), and robust if they contain a
minimum scaled number of unique tags proportional to the total read
depth of the cell line (tag≥5 - MDA & LM2, ≥12 – BoM2, ≥13 – BrM2).
Therefore, binding sites 2 & 4 would be considered clusters in MDA or
LM2 despite differing peak height and widths, but only site 2 would be a
cluster in BoM2 or BrM2. B: Schematic representation of significant peak
definitions with binding events as described in A. In silico normalization
on a per transcript basis defines a threshold of significance (dotted line)
for AGO-binding sites based the observed vs. expected peak height
calculated from random shuffling of unique tags along the exonic regions
of the gene. Reproducibility and robustness were determined as for
clusters (dashed line) therefore only binding site 2 is considered a
significant peak.
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overlap that are reproducible (BC≥2), and contain a minimum scaled
number of unique tags proportional to the total read depth of the cell line.
“Significant peaks” represent those clusters whose maximal number of
overlapping tags (peak height) is above that of the expected peak height
resulting from random shuffling of all CLIP tags mapping to that
transcript along its genic length. As per (Chi et al., 2009), a narrow
footprint of +/-32nt centered on the significant peak is used to determine
the AGO footprint while clusters are delimited by the genomic
coordinates of the most exterior tags in that cluster. Significant peak
analysis allows for more stringency in defining binding sites by narrowing
the footprint of AGO binding to -30nt/+32nt centered on the peak which
is useful for identification of the regulatory miRNA involved in targeting
(Chi et al., 2009). However, cluster analysis is more sensitive when
searching for differential binding, allowing for identification smaller
clusters may not reach statistical significance due to a background of
robust, common binding elsewhere on a transcript.

The threshold for the minimum number of tags required to define a
binding site (cluster or significant peak) was set at 5 tags for MDA-231 and
4175LM2 cells, with the threshold increasing proportionally to 12 and 13
tags for 1833BoM2 and 831BrM, respectively due to ~2.5 fold greater
unique tag numbers in these cell lines. All binding sites were required to
be BC≥2, and those mapping to chrY, RNA genes (defined by the
RNAgenes track on the UCSC genome browser) and pre-miRNA loci were
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removed from the analysis. Setting these thresholds defined 6947, 8802,
7716 and 8514 clusters, and 3422, 2636, 3233, and 3259 significant peaks in
MDA-231, 4175LM2, 1833BoM2, and 831BrM cells respectively.

The genomic localization of BC≥2 clusters was highly reproducible
between cell lines, with the majority of binding occurring in genic regions
(5’UTR, coding sequence and 3’UTR, Figure 3.8A). Despite the welldefined role of Argonaute in regulation of transcripts via interactions in
the 3’UTR and to a lesser extent in coding sequence and 5’UTRs, a
surprisingly high proportion of binding was evident in intronic regions.
While the biologic consequence of AGO intronic binding is not fully
understood, it is highly reproducible and has been consistently observed
in published AGO HITS-CLIP data sets (Chi et al., 2009), (Loeb et al.,
2012), including those derived from Dicer null mouse embryonic stem
cells (Leung et al., 2011), and multiple unpublished data sets (Darnell
Lab). Annotation of significant peaks revealed a relative enrichment of
3’UTR binding (Figure 3.8B).

AGO-mRNA binding patterns are highly reproducible between cell lines
Unique tags from all 12 AGO HITS-CLIP mRNA libraries were
pooled and clustered as one data set to define all possible AGO binding
sites. Cluster analysis was chosen rather than significant peak analysis due
to the uneven sequencing depth between cell lines. Clusters were filtered
to remove those that did not meet the minimum criteria outlined in Figure
3.7A in any one cell line (BC≥2 tags≥5 in MDA & LM2, tags≥12
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FIGURE 3.8: Genomic distribution of reproducible AGO-mRNA
binding. A: Unique mRNA reads from each cell line were clustered based
genomic coordinates and annotated to give genomic location. Binding
sites on chrY, RNA genes (coordinates derived from the RNAgenes track
from UCSC genome browser) and pre-miRNA loci were removed before
annotation. B: Reproducible significant peaks as defined in Figure 3.7B
were annotated as in A.
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BoM, or tags≥13 BrM), leaving a total of 18,444 robust and reproducible
AGO binding sites. To globally assess AGO binding between the four cell
lines, the number of tags contributed by each cell line in each cluster were
plotted and pairwise correlation coefficients calculated (Figure 3.9). The
global distribution of AGO-mRNA tags in clusters from each of the four
cell lines were highly reproducible, with correlation coefficients between
0.80 and 0.92, indicating that the majority of AGO binding is common to
all cell lines. The top two clusters, corresponding to the full-length
transcripts of the non-coding RNAs MALAT1 and NEAT1, were removed
from this analysis as inclusion artificially increased the correlation
coefficients.

Bioinformatic identification of differential AGO binding sites
To identify AGO-mRNA binding sites disproportionally enriched
in one of two compared cell lines, the total number of tags per cluster from
each cell line were analyzed in a pair-wise fashion, normalized to the total
number of tags in clusters in that cell line. Fold change and associated pvalue for each cluster were calculated using scripts developed in-house by
Chaolin Zhang for the Galaxy bioinformatics platform (Hillman-Jackson et
al., 2012), and an FDR derived using the Benjamini-Hochberg correction
for multiple hypothesis testing. Clusters were annotated to give both gene
identity

and

genomic

location,

subsequently limited to 3’UTRs.
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FIGURE 3.9: Pairwise correlation of tags in AGO-mRNA clusters. All
unique tags from the 12 HITS-CLIP experiments were pooled and
clustered with minimum 3nuclotide overlap. Clusters meeting the
minimum definition of a robust and reproducible cluster in any single cell
line were retained (BC2 tags≥5 - MDA or LM2, BC2≥12 – BoM2, or BC2≥13
– BrM2, 18,466 clusters), and the number of tags contributed from each
cell line per cluster was counted. Upper half of figure: Pairwise scatter
plots of unique tags per cluster for each cell line as indicated. Lower half
of figure: absolute value of the Pearson correlation coefficient of tags per
cluster.
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The most robust differential binding site commonly gained in the
three metastatic sub lines compared to MDA-231 was located in the 3’UTR
of secreted protein, acidic, cysteine-rich (osteonectin), SPARC. The 3’UTR
of SPARC is shown in Figure 3.10A, with the unique mRNA tags from
each library shown as horizontal bars grouped by cell type (indicated by
color), with each individual replicate library shown in a different shade.
Multiple peaks of BC=3 AGO binding are evident in the 4175LM2 and
1833BrM data sets, while AGO binding is relatively absent in the parental
MDA-231 cells. The 831BoM2 data set predominantly contains tags from
one replicate HITS-CLIP library (118/120 tags), therefore after visual
inspection this cluster was not deemed reproducible despite being BC=2.
Given the variable sequencing depth between cell lines, the number of
overlapping unique tags at any given genomic position were calculated
and normalized to the total read depth in that cell line (tags per million
unique tags) in order to more easily visualize binding differences (Figure
3.10B). The major AGO-binding site on SPARC is centered on two
previously validated, TargetScan predicted miR-29 seed sequences
(Kapinas et al., 2009, Wang et al., 2012).

SPARC has previously shown to be highly expressed in 4175LM2
and 831BrM2 cells, but is absent from MDA-231 and bone metastatic sublines (Minn et al., 2005a). Therefore the de novo AGO binding identified in
4175LM2 and 831BrM2 when compared to MDA-231 occurs as a function
of target expression level. While this type of binding is not informative for
the identification of alterations in AGO-mediated transcript regulation
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FIGURE 3.10: Identification of de novo AGO binding sites on the
SPARC 3’UTR in metastatic derivatives of MDA. The most robust
changes in AGO-mRNA binding between cell lines identified by
difference analysis occurs in the 3’ UTR of SPARC, a gene previously
shown to be highly expressed in 4175LM2 and 831BrM but absent from
MDA-231 & bone metastatic sub-lines. A: Unique tags are plotted for each
cell line as indicated by color, with different hue indicating tags derived
from different replicates. Several robust, reproducible AGO-binding sites
are evident on the 3’UTR of SPARC in LM2 and BoM2 cell lines, with the
largest peak proximal to the stop codon and centered on two miR-29 seed
sites. Although BC2 binding is evident in BoM2 cells, these clusters are
predominantly comprised of unique tags from one data set (118/120 tags
from BoM2 replicate A) and therefore are not reproducible. MDA cells
lack any robust, reproducible AGO binding sites, consistent with the lack
of expression of SPARC in these cells. B: The same view of SPARC as in A,
showing normalized AGO-mRNA binding calculated on a per cell line
basis as: number of overlapping unique tags/(total number of unique
tags/106). Normalization reveals that the poorly reproducible BoM2 AGO
binding occurs at a much lower level than that in LM2 and BrM2
consistent with the low level of expression of SPARC in BoM cells.
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with respect to gain in metastatic potential, it is a valuable independent
read out of transcript steady state mRNA level changes between cell lines.
Inspection of all genes previously identified as part of the 54 gene lung
metastasis signature revealed de novo AGO binding events in the majority
of transcripts known to be upregulated in 4175LM2 cells relative to MDA231, while known downregulated genes showed no evidence of additional
AGO regulation in 4175LM2 cells (data not shown). This was not
unanticipated given that the relative impact of miRNAs on a target
transcript levels is generally small (Ebert and Sharp, 2012), and the
expression level changes of the genes defining the lung metastasis
signature were high, 3-fold or greater, although once expressed the
majority show evidence of robust AGO-mRNA binding.

To control for transcript steady state levels between cell lines,
previously published Affymetrix microarray data was incorporated into
the difference analysis (Kang et al., 2003, Minn et al., 2005a, Bos et al.,
2009), with the assumption that loss of AGO binding, and hence loss of
negative regulation, should lead to increase in expression and vice versa.
Given that non-expressed targets cannot by definition be bound by AGO,
differentially bound transcripts were required to be expressed in both cell
lines in which differential binding was detected. RNAseq libraries were
prepared from non-crosslinked dishes of cell harvested at the same time
as those samples used for AGO HITS-CLIP analysis, however due to low
numbers of reads obtained from 1833BoM2 and 831BrM2 samples these
were not reliable indicators of differentially expressed transcripts across
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the four cell lines. The RNAseq profiles for MDA and LM2 were used to
corroborate the previously published microarray profiles (data not
shown).

Identification of AGO-mRNA binding sites gained in metastatic derivatives of
MDA-231
Two 3’UTR clusters were found to have significantly enriched AGO
binding in all three metastatic sub-lines (p≤0.05) that was coupled with
reduced expression levels when compared to MDA-231. These clusters
were located in an ~1kb region of cyclin-dependent kinase 6 (CDK6)
spanning the terminal exon and extending into the 3’UTR, and in an
~330bp region of the tumor suppressor candidate 2 (TUSC2/FUS1). The
AGO binding sites on the 3’UTRs of CDK6 and TUSC2 are shown in
Figure 3.11, with the AGO clusters identified as being significantly
differentially bound highlighted. Both clusters identified are comprised of
multiple peaks of AGO binding embedded in a background of low-level
scattered tags. Adding to the complexity of regulation is a background of
extensive AGO binding in other regions of the 3’UTR that is particularly
pronounced in CDK6, with multiple cell type specific gains and losses in
binding that may play equally as important a role in down regulation of
the transcripts in metastatic sub lines relative to the parental MDA-231
cells.
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FIGURE 3.11: Identification of AGO-mRNA binding sites gained in
metastatic derivatives of MDA-231. A: CDK6 shows gain of AGO binding
a section of the 3’UTR spanning in an ~1kb region containing multiple
individual peaks of binding (black dashed box). Upper panel: Unique
mRNA AGO tags aligned to the 3’UTR of CDK6. Lower panel:
Normalized binding maps reveal increased AGO binding at the proximal
end of the annotated 3’UTR in the three metastatic sub-lines relative to the
parental MDA-231. The number of tags in the highlighted cluster is
increased 2.5-fold in 4175LM2 (p=0.0003, FDR 0.039), and 1.7-fold in
1833BoM2 cells (p=0.031, FDR=0.316) and 2.5-fold in 831BrM2 cells
(p=2.56e-5, FDR= 0.027). B: TUSC2 3’UTR contains a cluster gained in all
three metastatic sub lines when compared to MDA-231. The number of
tags in the highlighted cluster is increased 2.5-fold in 4175LM2 (p=0.022,
FDR 0.498), and 2.4-fold in 1833BoM2 cells (p=0.011, FDR=0.215) and 2.8fold in 831BrM2 cells (p=0.002, FDR= 0.019).
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Identification of AGO-binding sites commonly lost in highly metastatic sub-lines
To identify loss of 3’UTR AGO-binding events common to all
highly metastatic cell line derivatives of MDA-231, clusters were filtered
to return positive and significant fold changes in tags per AGO CLIP
clusters (MDA/sub-line, p≤0.01) with corresponding transcript level
changes greater than 0.8 fold by microarray. Unexpectedly, only three
clusters passed this threshold (Table 3.4), located in ras-related C3
botulinum toxin substrate 1 (RAC1), high mobility group AT-hook 1
(HMGA1) and tumor protein p53 binding protein, 2 (TP53BP2).
Subsequent Q-PCR analysis of TP53BP2 levels in MDA-231 and LM2 cells
revealed strong down regulation in LM2 cells contrary to the microarray
data (6.4 fold decrease in LM2, p= 0.0017, data not shown). HMGA1 was
selected for follow up assays due to the relatively high tag counts in AGO
clusters, positive confirmation by Q-PCR of increased steady state
transcript levels both 4175LM2 and 831BoM2 cell lines correlating with
loss of AGO-mRNA binding (Figure 3.12), and the extensive literature
associating increased HMGA1 expression with multiple aggressively
metastatic cancers (Fedele and Fusco, 2010).

Differential AGO binding in the 3’UTR of HMGA1
The HMGA1 3’UTR cluster identified by differential AGO binding
analysis is proximal to the stop codon (Figure 3.13, black dashed box).
Multiple additional peaks of AGO binding with equal normalized peak
height are seen in all four cell lines at more distal 3’UTR positions,
suggesting specific loss of AGO binding only in the identified cluster.
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TABLE 3.4: AGO 3’UTR binding sites lost in all three highly metastatic
sub-lines of MDA-MB-231. FC= fold change, FDR = false discovery rate
(Benjamini-Hochberg correction).
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FIGURE 3.12: Loss of AGO binding correlates with increased steady
state levels of the HMGA1 transcript. HMGA1 mRNA steady state levels
are higher in 4175LM2 and 1833BoM2 cells relative to the parental MDA231. Normalized to TATA-binding protein (TBP), selected as the least
variable housekeeping gene across the four cell lines from a panel of ten
potential normalization genes (GeNorm analysis (Vandesompele et al.,
2002)). n=3, error bars = s.e.m, p-values calculated by t-test.
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FIGURE 3.13: HMGA1 shows evidence of differential AGO binding
between parental and metastatic derivative sub-lines. Upper panel:
Unique mRNA AGO tags aligned to the 3’UTR of HMGA1. Lower panel:
Normalized binding maps reveal decreased AGO binding X proximal to
the stop codon in the cluster identified in Table. Binding on other regions
of the transcript is unchanged suggesting specific loss of AGO regulation
at this site. The two peaks of binding within the differentially bound
cluster are labeled as site 1 and 2.
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No alternative splicing of the HMGA1 3’UTR in the region bound
by AGO differential binding was evident in EST tracks on the UCSC
genome browser, the RNAseq profiles of MDA-231 and 4175LM2, or by
RT-PCR analysis (data not shown). The MDA-231 enriched cluster is
comprised of two individual peaks of binding, designated site 1 and 2,
with low levels of adjoining tags bridging the two peaks. None of the
published HMGA1 miRNA regulatory sites are located within the
differentially bound cluster region of the HMGA1 3’UTR (D'Angelo et al.,
2012, Kaddar et al., 2009, Palmieri et al., 2012, Wei et al., 2011). Shown
below the HMGA1 3’UTR in Figure 3.13 are Targetscan miRNA target
predictions

showing

miR-142-3p

and

miR-138

regulatory

sites

overlapping binding site 2, while no miRNA seed sites are predicted for
site 1. miR-142-3p was is significantly lower in the 4175LM2 AGO-miRNA
profile than MDA-231 by EdgeR consistent with a loss of binding,
however, however miR-142-3p levels are significantly increased in both
1833BoM2 and 831BrM2 inconsistent with loss of binding in these cell
lines (Table 3.3). miR-138 is not within the top 30 most CLIPed miRNA in
any cell line, but shows slight decreases in AGO-miRNA profile in both
4175LM2 (log2 FC=-1.5, p=0.03, FDR=0.35) and 831BoM2 (log2 FC=-2.0,
p=0.14, FDR=0.99) when compared to MDA-231. The miRNA seed
matches in binding site 1 corresponding to the most frequently cloned
AGO-miRNA reads include miR-22, a top 30 miRNA, and miR-320a/b/c.
Neither of these miRNAs showed significant differences in AGO-miRNA
profile by EdgeR analysis.
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FIGURE 3.14: Seed sites of expressed miRNAs in the differentially
bound region of the HMGA1 3’UTR. The sequences defined by the two
peaks of MDA AGO-mRNA binding were searched for seed matches to
miRNAs expressed in MDA-231 cells as determined by the AGO-miRNA
profile. Site 1 contains a seed match to a top 30, miR-22 (see Table 3.2),
plus seed matches to miR-320a (ranked 45th MDA, 50th LM2, 35th BoM, 48th
BrM). Mutant constructs were made as indicated in either in the context of
full-length HMGA 3’UTR or in a shorter fragment corresponding to chr6:
34,320,641-34,320,915. miR-28-5p mutants were used as a negative control
due the consistent, low level representation in the miRNA profile of all
four cell lines (<0.015%). Site 2 contains seed matches to both miR-142-3p
and miR-138.
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To determine whether the loss of AGO binding to HMGA1 in
metastatic cells occurs as a result of any of the above AGO-miRNA
interactions, dual luciferase reporter constructs were made in psiCheck2
using either full length HMGA1 3’UTR or a shorter fragment
corresponding to the region spanning the differential AGO-binding (chr6:
34,320,641-34,320,915). The rationale behind using a smaller fragment was
based on the hypothesis that relatively minor alterations in AGOmediated regulation might be difficult to detect in a background of more
robust distal regulation. Mutations were made as indicated in Figure 3.14
to attempt to disrupt the most likely AGO-miRNA seed sites as predicted
by AGO-miRNA sequencing, with the expectation that derepression
would only be evident in MDA-231 where endogenous AGO binding
occurs. Mutations in the miR-28-5p seed site were used as a negative
control since this miRNA is cloned at consistently low levels in all cell
lines, representing less than 0.015% of the total AGO-miRNA population.

Pilot experiments using 50ng of vector showed no significant
change in luciferase activity with any mutant constructs in either MDA231 or 4175LM2 cells (data not shown). Given the relatively low
expression of the miRNAs whose seeds are represented in the differential
binding sites, the amount of transfected plasmid was decreased to 5ng to
attempt

a

more

stoichiometric

relationship

between

target

and

endogenous miRNA. Transfections were carried out in sextuplet in 96well plates using either full length (Figure 3.15A) or short HMGA1 3’UTR
(Figure 3.15B) and are shown normalized to empty vector control.
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FIGURE 3.15: HMGA1 3’UTR Dual luciferase reporter assays in MDA
and LM2 cells reveal unexpected differential miRNA regulation.
Reporter constructs were transfected into MDA-231 and 4175LM2 nonreporter cell lines and luciferase activity assayed at 30hrs. Relative
luciferase activity is shown normalized to empty vector, mutants are as
outlined in Figure X. A: Relative expression of luciferase fused to full
length HMGA1 3’UTR is unaffected by single seed mutations in site 1 and
2 in both MDA and LM2 cells. Combinatorial mutations of miR-142-3p
and miR-320 seeds lead to increase in luciferase activity in MDA cells,
although this increase failed to reach significance (MUT ALL Site2,
p=0.089). Mutations in the seeds miR-138 or miR142-3p of site 2 (but not
both) lead to repression in LM2 cells. B: 3’ UTR reporter assays using a
short fragment of HMGA1 spanning only the region of differential
binding reveal significant de-repression in MDA cells transfected with
miR-320a mutant, while unexpectedly all mutations lead to significant derepression in LM2. N=10, p-values calculated by t-test compared to WT in
that cell line, * p≤0.05 **p≤0.01, error bars = s.e.m.
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As anticipated, mutations in seed sequences in the differentially bound
AGO-mRNA cluster region of the full length HMGA1 3’UTR had no effect
on relative luciferase activity 4175LM2 cells when compared to WT. In
MDA-231cells, no significant derepression was seen in luciferase activity
with mutant full length 3’UTRs, but a trend towards derepression in
mutants with combined abrogated miR-142-3p and miR-138 seed sites was
seen in multiple replicate experiments (MUT ALL site 2), suggesting that
combinatorial loss of AGO regulation of these two miRNAs may influence
HMGA1 expression levels to a small degree (Figure 3.15A).

In the context of the short HMGA1 3’UTR, mutations in the miR320a/b/c seed sequence lead to significant increase in luciferase activity
in MDA-231 cells. Surprisingly, in the context of the shorter HMGA1
3’UTR fragment significant derepression of all mutant constructs was
observed in 4175LM2 cells, contrary to the predicted lack of AGOregulation in these cells (Figure 3.15B). This would suggest that deletion of
the distal region of the HMGA1 3’UTR allows for 4175LM2-specific
derepression of the luciferase reporter construct independent of the seed
mutated, and therefore, that loss of AGO binding on the HMGA1 3’UTR
in metastatic cells may result from a decrease in accessibility of the
transcript for AGO rather than being indicative of a loss of a specific
miRNA.
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FIGURE 3.16: The 3’UTR of CD59 shows differential binding of AGO in
single location with reduced binding in both 4175LM2 and 831BrM2
cells. Normalized AGO binding maps a single peak of AGO binding in
the 3’UTR of CD59 that is decreased 1.6-fold in 4175LM2 (p=0.002) and
1.5-fold in 831BrM2 cells (p=0.0003), but is unchanged in 1833BoM2 cells
(0.8-fold, p=0.05) relative to MDA-231 cells.
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Differential AGO binding in the 3’UTR of CD59
In order to simplify the search for metastasis-associated loss of
AGO binding, the criteria for selection was relaxed to identify clusters
with significant enrichment in binding in any two metastatic sub lines
compared to MDA-231, where AGO binding occurred predominantly in a
single location in the 3’UTR. Complement regulatory protein 59 (CD59)
was identified as having a single peak of AGO binding in the 3’UTR that
decreased 1.6-fold in 4175LM2 (p=0.002) and 1.5-fold in 831BrM2 cells
(p=0.0003) relative to MDA-231, but is relatively unchanged in 1833BoM2
cells (0.8-fold, p=0.05) (Figure 3.16). Previous microarray data and
subsequent Q-PCR validation (Figure 3.17A) confirmed that CD59
transcript levels are approximately two-fold higher in 4175LM2 than
MDA-231, consistent with a loss of negative regulation. FACS analysis of
CD59, a cell surface protein, confirmed that this increase in mRNA
translated into increased CD59 protein expression in 4175LM2 but not
831BrM2 relative to MDA-231 (Figure 3.17B).

The ~80bp footprint of AGO binding on the 3’UTR of CD59
contains seed sequences for multiple miRNAs, of which miR-125a-5p/a
and miR-183 are the most highly represented in the combined AGOmiRNA HITS-CLIP profile (Figure 3.18A, ranked 13th and 39th in MDA-231
respectively). Neither miR-125a-5p/b nor miR-183 show significant
changes in AGO-miRNA tag counts between cells lines. The regulation of
CD59 3’UTR by miR-183 was assessed in a 326nt CD59 3’UTR fragment
spanning the AGO binding site (chr11:33,687,643-33,687,968).
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FIGURE 3.17: Decreased AGO 3’UTR binding in CD59 correlates with
increase in both mRNA and protein levels in 4175LM2 cells. A: Q-PCR
for CD59 reveals a two-fold increase in mRNA levels in LM2 cells
consistent with previous microarray studies. (n=3, normalized to TBP, ttest, error bars = s.e.m). B: FACS staining for CD59 reveals increased
protein levels in 4175LM2 but not 1833BoM2 cells.
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Co-transfection of this WT sequence construct into 4175LM2 cells
with 50nM of miR-183 mimic or a negative control mimic had no effect on
relative luciferase activity (Figure 3.18B) suggesting that miR-183 does not
mediate the AGO-mRNA interactions identified by AGO HITS-CLIP.
Further mimic transfections need to be carried out in order to establish the
identity of the miRNA targeting AGO to CD59 at this site. Alternatively, a
modification of the HITS-CLIP protocol that utilizes intermolecular
ligation to produce chimeric AGO-miRNA-mRNA, termed CLASH
(Helwak et al., 2013), may be useful to identify with high confidence the
miRNA responsible for targeting AGO to this site.
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FIGURE 3.18: The differentially bound site in CD59 3’UTR contains
seed sequences for miR-183 and miR-125a-5p/b, but it not regulated by
miR-183. A: The AGO footprint region of the CD59 3’UTR with seed
matches to miR-183 and miR-125a-5p highlighted. B: Dual luciferase
reporter assays show that miR-183 does not regulate the full-length WT
CD59 3’UTR. Transfections were done in triplicate with 50nM of miR-183
mimic or a negative control mimic that does not target any known human
transcripts, or with plasmid and transfection reagent alone. Error bars =
s.e.m.
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DISCUSSION
Altered miRNA expression is a common hallmark of cancer, with
general down regulation miRNAs compared to normal tissues occurring
in patterns that can be used as classifiers of tumor type (Lu et al., 2005).
Conversely, gain of miRNA expression can be oncogenic or tumor
suppressive depending upon the specific mRNA targets co-expressed and
the cellular context (reviewed in Lujambio and Lowe, 2012). An increasing
body of work has implicated altered miRNA regulation both in breast
cancer metastasis suppression and promotion (Wang and Wang, 2012),
with miR-335 and miR-126 known to regulate metastasis in the model
system interrogated here (Png et al., 2011, Tavazoie et al., 2008). By
applying the AGO HITS-CLIP methodology in this well-established and
molecularly characterized model of breast cancer metastasis with known
miRNA regulatory components, we aimed to identify both miRNAs
differentially bound to AGO with respect to metastatic potential and the
resulting sites of altered AGO-mRNA regulation on a genome-wide scale.

This study has generated a comprehensive binding map of
endogenous human AGO bound to endogenously expressed miRNA and
cognate mRNA targets in the human metastatic breast cancer cell line,
MDA-MB-231, and its aggressively metastatic sub-lines with tissue
tropism to lung, bone and brain (Bos et al., 2009, Kang et al., 2003, Minn et
al., 2005a). This is in contrast to previously published human AGO-mRNA
data sets that have been generated after transfection with exogenous
tagged-Argonaute or miRNA mimics (Chi et al., 2009, Hafner et al., 2010,
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Helwak et al., 2013), or were done in virally infected cells (Riley et al.,
2012). The transcriptome-wide AGO-mRNA binding sites described here
provide a valuable reference set for researchers; providing independent
and direct biochemical evidence of robust, endogenous AGO-mRNA
interactions to supplement experimental validation of miRNA mediated
effects on predicted target mRNA and (reporter) protein levels. As an
example, several reports have implicated miR-29a in the regulation of
SPARC in both breast cancer cells (MCF-7 (Wang et al., 2012), MDA-MB435 (Gerson et al., 2012)) and osteoblasts (Kapinas et al., 2009). The
greatest relative AGO occupancy on the SPARC 3’UTR (Figure 3.10)
occurs in a cluster comprised of two peaks directly corresponding to two
TargetScan predicted, conserved miR-29 seed sequences. Given that miR29a is one of the most abundantly CLIPed miRNA in all four cells lines,
and the consistent finding that the most frequently cloned AGO-miRNAs
have significantly more seed pairs within the AGO-mRNA binding sites
than the least cloned miRNAs (Chi et al., 2009, Zisoulis et al., 2010),
binding at this site is highly predictive of miR-29a regulation of SPARC in
lung and brain metastatic sub lines on MDA-231.

The most frequently CLIPed miRNA in all four cell lines, miR-27a,
has previously been identified as a potential oncomiR in gastric cancer
(Liu et al., 2009) and MDA-MB-231 cells (Mertens-Talcott et al., 2007), and
high levels are associated with poor prognosis in invasive breast cancers
(Tang et al., 2012b). The abundance of the top 20 AGO-miRNA derived
from HITS-CLIP in MDA-231 cells was found not to correlate with
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previously published high-throughput sequencing profiles of MDA-MB231 total miRNA (data not shown, (Mayr and Bartel, 2009)). This is in
contrast to previous reports of high degree of correlation between
Photoactivatable-Ribonucleoside-Enhanced

Crosslinking

and

Immunoprecipitation (PAR-CLIP) derived AGO-miRNA counts and the
total miRNA abundance profile in HEK293 cells (Hafner et al., 2010). PARCLIP is a HITS-CLIP variation that utilizes the incorporation of 4thiouridine (4SU) into transcripts of cultured cells, which upon UV 365nm
irradiation causes T to C transitions in the cloned CLIP library. The
discrepancy between published miRNA profiles and the AGO-miRNA
HITS-CLIP profile in MDA-231 may reflect true biological differences
between absolute expression levels and preferential incorporation into
RISC, or could result from technical differences in cloning (Jayaprakash et
al., 2011), cell stocks or culture conditions; for example, increasing cell
density is known to lead to widespread increase in miRNA abundance
(Hwang et al., 2009). Parallel high-throughput miRNA sequencing of the
cell lines used in this study will be required to distinguish between these
two possibilities.

Assessment of the AGO-miRNA profiles obtained from MDA-231,
4175LM2, 1833BoM2 and 831BrM2 cells revealed a striking degree of
correlation within the 30 most frequently CLIPed miRNAs, with very few
having statistically significant differences in the HITS-CLIP profiles. This
was unanticipated given the number of miRNA previously identified as
differentially expressed in these cells with respect to both metastatic
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ability and tissue tropism (Tavazoie et al., 2008). The virtual absence from
the MDA-231 AGO-miRNA profile of the previously validated antimetastatic miR-335 (0.0009 % of miRNA) and miR-126 (not cloned)
indicates that the previously reported correlation between miRNA
expression and AGO-miRNA CLIP profiles may not extend to minority
miRNA species. This represents an unforeseen limitation on the use of
differential AGO HITS-CLIP to determine on a genome-wide scale the
mRNA targets of known metastasis-inhibitory endogenous miRNAs in
MDA-MB-231 cells.

Comparative analysis of the HITS-CLIP derived AGO-miRNA
profiles identified one miRNA, miR-142-3p, with read counts significantly
decreased in 4175LM2 and increased in both 1833BoM2 and 831BrM2
relative to MDA-231. Expression of miR-142 has previously been reported
to be highly specific to hematopoietic cells (Landgraf et al., 2007), with
high levels of expression in naïve CD8+ T cells (Wu et al., 2007) and a
reported role in the regulation of monocyte terminal differentiation
(Lagrange et al., 2013). Recent studies have implicated miR-142-3p in
tumor suppression of both colon cancer and hepatocellular carcinoma,
while mutations in both strands of pre-miR-142 have been found in
diffuse large B cell lymphoma (Kwanhian et al., 2012, Shen et al., 2013, Wu
et al., 2011a). While miR-142-3p is a relatively minor miRNA in all four
cell lines, small changes in miRNAs expressed at low levels have been
shown to have profound functional consequences, for example the antimetastatic miR-335, miR-126 and miR-206 (Tavazoie et al., 2008) and the
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miR-183/96/182 cluster in light adaption in the retina (Krol et al., 2010).
The differential AGO-CLIP profiles obtained for miR-142-3p identify it as
an interesting candidate for further investigation to determine whether it
functions as a cell type specific metastasis suppressor (4175LM2) or
activator (831BrM2 and 1833BoM2), and whether differential expression
clinically correlates with the site of distal metastases in breast cancer
patients.

The AGO-miRNA profiles of three additional miRNAs represented
in top 30 most abundant seed families were found to be specific decreased
in 4175LM2 cells; let-7c, miR-99a and miR-20b. miR-99a and let-7c, along
with miR-125b-2, are expressed as a cluster derived from an intron of the
non-coding RNA, C21orf34. The miR-99a/let-7c/125b-2 cluster is located
on chromosome 21 in in a region commonly deleted in both primary
breast (Ohgaki et al., 1998) and lung cancers (Calin et al., 2004, Yamada et
al., 2008). Interestingly, miR-125b is transcribed from two locations within
the genome and while the mature miR-125b AGO-miRNA counts were
unchanged between cell lines, miR-125b-2* was significantly lower in
4175LM2 than all other cell lines (LM2/MDA log2 FC=-2.58 p=0.024,
BoM/LM2 log2 FC=4.0 p=1.61e-4, BrM/LM2 log2 FC=3.5 p=6.2e-5). This
strongly suggests specific decrease in the incorporation of all three
members of the miR-99a/let-7c/125b-2 cluster into AGO in lung
metastatic cell lines, identifying this cluster as a potential novel regulator
of lung specific metastasis.
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Given the unexpectedly similar AGO-miRNA profiles of MDA-231,
4175LM2, 1833BoM2 and 831BrM2 and the relatively low expression of
those miRNA that showed significantly altered AGO-miRNA profiles, the
potential scope for seed-directed searches for alternatively regulated
mRNAs were limited. This was further compounded by the potential for
redundant targeting by other seed family members, as the seed sequences
of individual miRNA showing significant differences in AGO-miRNA
profiles were still abundantly represented in all cell lines. For example, let7c has been demonstrated to negatively regulate the oncogene HMGA2 in
uterine leiomyoma via multiple target sites in the 3’UTR (Klemke et al.,
2010). However, this regulation has also been demonstrated when using
exogenous let-7a (Mayr et al., 2007), mixtures of let-7b/d/g (Guo et al.,
2013) or let-7b/e (Lee and Dutta, 2007), and by family member miR-98 in
head and neck squamous cell cancer (Hebert et al., 2007). Accordingly, the
multiple robust AGO-mRNA peaks corresponding to HMGA2 3’UTR let-7
seed sites are unchanged in 4175LM2 when compared to the other four
cell lines (data not shown).

Therefore, differential AGO-mRNA binding was assessed without
prior assumption as to the miRNA involved in targeting, with the
simplistic view that commonly gained or lost clusters in aggressively
metastatic sub-lines would identify deregulated targets related to breast
cancer biology. This approach allowed for inclusion of both miRNAdriven binding changes resulting from miRNA expression level changes,
and non-miRNA driven effects such as shortening of 3’UTRs via
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alternative splicing or polyadenylation site usage. Unexpectedly, very few
AGO-mRNA binding sties were either commonly gained or lost in the
highly metastatic sub-lines of MDA-231, however those transcripts
identified in this study as having altered AGO-mRNA binding sites with
corresponding changes in transcript level include several with strong links
to metastasis.

Gain of AGO-mRNA binding was identified in the 3’UTR of
TUSC2, a gene that is located in a region of the genome frequently deleted
in breast and lung cancer (3p21.3 (Zabarovsky et al., 2002)). TUSC2 is proapoptotic when ectopically expressed in non-small cell lung cancer cells
harboring 3p21.3 deletions (Ji et al., 2002, Kondo et al., 2001), and ectopic
re-expression via nanoparticle delivery is currently in phase I clinical trials
for the treatment of recurrent or metastatic lung cancer (Lu et al., 2012).
Previously described miRNA regulation of TUSC2 by miR-93 and miR-98
corresponds with the AGO-mRNA binding peaks commonly found in all
four breast cancer cell lines (Du et al., 2009). Interestingly, deletion of the
distal portion of the TUSC2 3’UTR, the region containing metastatic subline specific AGO-mRNA de novo binding, leads to increased TUSC2
protein level in human lung cancer cells (Lin et al., 2011) suggesting that
these sequences contain potent negative regulators of translation.

CD59 is a membrane-bound protein that protects against
complement-mediated lysis by interacting with C8 and C9 to preventing
membrane attack complex (MAC) formation (Meri et al., 1990). Up
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regulation of CD59 has been described in multiple malignant cell types
(Fishelson et al., 2003) including in breast cancer, where CD59 has a role in
both resistance to complement-mediated lysis and HBXIP-mediated
proliferation and migration (Cui et al., 2012). CD59 is expressed
throughout the human respiratory tract (Varsano et al., 1995), with
increased levels reported in lung cancer cell lines (Varsano et al., 1998).
Decreased AGO binding, the correlated increase in both mRNA and
protein levels of CD59 seen in 4175LM2 cells may be beneficial in
providing protection against complement attack during colonization and
out growth in the lung metastatic niche. It will be interesting to determine
whether knockdown of CD59 in these cells negatively influences their
ability to form metastatic lesions in the lung.

Both HMGA1 and HMGA2 are oncofetal proteins, with high levels
of expression found during embryogenesis and several tumor types and
undetectable or very low expression in differentiated adult tissues
(Chiappetta et al., 1996, Zhou et al., 1995). While HMGA proteins can
function as anti-proliferative components of cellular senescence, they can
also promote proliferation depending on cellular context (Narita et al.,
2006) and are overexpressed in multiple human malignancies (Fedele and
Fusco, 2010). Overexpression of HMGA1 in MCF-7 cells leads to enhanced
tumor formation and metastasis (Liu et al., 1999, Reeves et al., 2001) with
reciprocal decrease in both orthotopic tumor growth and lung metastasis
found with HMGA1 knockdown in MDA-231 cells (Shah et al., 2013).
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While the posttranscriptional regulation of HMGA2 by let-7 is well
documented and corroborated by the robust AGO HITS-CLIP binding
data generated in this study, the regulation of HMGA1 by miRNAs in
breast cancer is less clear. AGO-mRNA binding is seen in regions
corresponding to previously validated miR-26, miR-15/16 and let-7 sites
(Figure 16, (Palmieri et al., 2012)), however none of the previously
validated regulatory miRNA seed sites found in the literature map to the
region of differential AGO binding identified by HITS-CLIP. Mutation of
the most likely candidate miRNA seeds within these sites (based on AGOmiRNA profiling) failed to lead to consistent significant derepression in
MDA-231. It remains to be tested whether other relatively minor miRNA
are able to regulate HGMA1 at the sites identified by HITS-CLIP.
However, the seemingly anomalous result whereby removal of the distal
portion of the 3’UTR allows for mutation-mediated derepression of
HGMA1 reporter constructs specifically in 4175LM2 would suggest that
other cis-regulatory elements may be responsible for the loss of AGObinding seen in these cells under endogenous full length 3’UTR
conditions. Such antagonistic regulation has been described in zebrafish,
where cis-regulatory elements in the 3’UTR of nanos1 are sufficient to
inhibit ubiquitously expressed miR-430-mediated deadenylation and
translational repression in primordial germ cells but not the soma
(Mishima et al., 2006).

Identification of the miRNAs involved in targeting AGO to the sites
of differential binding described in this chapter has proven challenging.
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Potential regulatory miRNAs were selected for mutational reporter assay
analysis based on both the seed sequences within the AGO footprint of
differential binding and the abundance of the complementary miRNA in
the AGO-miRNA profile. While miRNAs known to mediate metastasis
suppression were below the threshold of AGO-miRNA HITS-CLIP
detection, it is not clear how this lack of detectable miRNA binding
translates in the AGO-mRNA profile. Rare miRNA targeting may result in
robust AGO-mRNA clusters under certain conditions, for example, if
regulated targets were present at high concentration and/or the miRNA
in question regulated relatively few transcripts thereby increasing the
relative concentration of a rare AGO-miRNA at the target sites. Such
binding may help to explain the “orphan” clusters found in previous AGO
HITS-CLIP experiments that do not contain seed matches to the top 30
miRNAs in the AGO-miRNA profile (Chi et al., 2009).

The AGO-mRNA footprints derived from HITS-CLIP are valuable
for delimiting the sequence space in which to search for miRNA seed
matches, however increasing HITS-CLIP-derived evidence points to
substantial non-canonical yet functional AGO-miRNA-target pairing. For
example, it has been recognized for some time in C.elegans that the lin4::lin-14 interaction accommodates a C-bulge (Ha et al., 1996, Wightman et
al., 1993), and that the let-7::lin-41 interaction involves a G:U wobble (Vella
et al., 2004), with both of these direct interactions confirmed by alg-1 HITSCLIP (Zisoulis et al., 2010). Analysis of multiple AGO HITS-CLIP libraries
indicates a high degree of functional miRNA-mediated AGO-mRNA
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regulation at non-canonical sites including various seed-like motifs (Gbulges at position 5-6 (Chi et al., 2012), single mismatches (Loeb et al.,
2012)) and interactions outside of the seed that are complementary to the
middle and 3’ end of the miRNA (Helwak et al., 2013). Furthermore, it has
been noted that AGO binds mRNA preferentially in G-rich motifs in a
similar genomic distribution in mouse embryonic stem cells with or
without mature miRNAs (Leung et al., 2011). These alternate rules of
regulation add a further layer of complexity to the search for miRNAs
responsible for targeting AGO to the de novo clusters identified in MDA231 and its derivatives. The newly developed protocol CLASH, in which
intermolecular ligation is used to drive the formation of chimeric miRNAtarget mRNA AGO HITS-CLIP tags (Helwak et al., 2013), may be useful
for identifying the miRNAs involved in regulating the differentially AGO
bound targets identified in this study.

Close inspection of the previously published expression data
comparing MDA-231 and 4175LM2 (Minn et al., 2005a) or 831BrM2 (Bos et
al., 2009) revealed an additional potential variable regarding regulation of
AGO-mRNA binding, namely altered expression of other RNA binding
proteins. Muscleblind 2 (MBNL2) is among the downregulated genes
identified in 4175LM2 cells (Minn et al., 2005a), with CUGBP2/CELF2 and
ELAVL4/HuD being upregulated in 831BrM2 (Bos et al., 2009, Li et al.,
2011a). Additionally, two-dimensional difference gel electrophoresis has
identified hnRNPA2B1 as upregulated in independently derived brain
metastatic clones of MDA-231 (Yoneda et al., 2001, Li et al., 2011b). Both
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MBNL2 and CUGBP2 have been implicated in accelerated mRNA decay
mediated by 3’UTR binding of targets (Du et al., 2010, Masuda et al.,
2012), with recent HITS-CLIP data confirming that the majority of MBNL2
binding occurs in 3’UTRs (Charizanis et al., 2012). Conversely,
hnRNPA2BP1 has been shown to stabilize long-lived mRNA transcripts in
MDA-231 cells via interactions with RNA structural motifs in their 3’UTRs
(Goodarzi et al., 2012).

While no direct link between the 3’UTR binding of these proteins
and AGO-mediated regulation has been investigated to date, the potential
for ELAV-modulation of miRNA target site accessibility is known.
Jacobsen et al. (2010) have shown that the binding motif for ELAVL4 is the
most enriched motif in mRNAs with altered expression levels following
small RNA transfection in HeLa cells. ARE motifs were found to be
significantly enriched in regions ~50nt upstream of endogenous miRNA
targets previously defined by AGO HITS-CLIP, correlating with both
attenuated and augmented transfected miRNA-dependent destabilization.
Significantly, overlapping genome-wide patterns of HuR and AGO
binding have been described using PAR-CLIP in HEK293 cells (Mukherjee
et al., 2011) and with endogenous proteins via HITS-CLIP in resting and
activated human T-cells (Darnell Lab, unpublished data), suggesting a
potential role for agonistic or antagonistic HuR regulation of AGO
binding on common target transcripts. Indeed examples of both types of
interaction exist. HuR binding is required for let-7 mediated c-Myc
repression (Kim et al., 2009a) and has been shown to relieve miR-122
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repression of CAT-1 mRNA (Bhattacharyya et al., 2006). Comparing AGOmRNA binding across cell lines where potential “unseen” RBP
modulators of transcript stability and AGO targeting are known to be
differentially expressed further complicates the seed-directed approach
towards validation of differential AGO-mRNA binding.

Perspectives
By pairing differential AGO–mRNA HITS-CLIP analysis with
expression data, we have identified potential for miRNA-mediated
regulation of metastatic organotropsim, with miR-142-3p and the miR99a/let-7c/miR-125-b2

cluster

specifically

downregulated

in

lung

metastatic cell lines. We have shown that it is possible to identify
transcripts in which gain or loss of AGO binding correlates with decrease
or increase in steady state mRNA levels and, in the case of CD59, protein
levels. Those transcripts identified as having de novo AGO-mRNA binding
have well documented roles in cancer biology and metastasis. While the
particular miRNA involved at the identified differential AGO binding
sites are currently unknown, it will be interesting to investigate the
function of metastasis-specific de novo AGO-mRNA binding in the
promotion or inhibition of metastasis via transfection with antisense
oligonucleotides that block AGO binding to specific target mRNA. For
simplicity we have focused on identifying differential binding common to
the aggressively metastatic phenotype in 3’UTRs, however the genomewide nature of the data presented allows for future analysis of binding in
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other regions of transcripts and in identifying differentially regulated
targets with respect to tissue tropism.
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CHAPTER 4: TRANSCRIPTOME-WIDE TARGET IDENTIFICATION
OF THE ANTI-METASTATIC miR-335

INTRODUCTION
Deregulation of miRNA expression in tumors can be accomplished
by multiple mechanisms. Many miRNA loci are located in fragile sites,
common breakpoint regions, and cancer-associated sites of loss of
heterozygosity or amplification (Calin et al., 2004, Zhang et al., 2006).
miRNAs may be epigenetically silenced by promoter DNA methylation
(Choudhry and Catto, 2011) and histone modifications (Scott et al., 2006).
Furthermore, mature miRNA abundance can be affected by posttranscriptional regulation of miRNA processing and stability. For
example, DNA-damaged induced up regulation of a subset of mature
miRNAs is dependent upon p53 interaction with Drosha (Suzuki et al.,
2009), while estrogen receptor-alpha can suppress the maturation of miR125a and miR-145 in breast cancer cells (Yamagata et al., 2009).

Using the xenograft model outlined in Chapter 3, (Tavazoie et al.,
2008) have identified three endogenously expressed human miRNAs,
miR-126, miR-206 and miR-335, that robustly suppress breast cancer
metastasis to lung and bone, and whose expression levels negatively
correlate with patient metastasis free survival. Loss of miR-206 expression
has been independently associated with lymph node metastasis and poor
prognosis in a cohort of breast cancer patients (Li et al., 2013), and has
been reported to enhance metastatic spread of rhabdomyosarcoma
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(Missiaglia et al., 2010), endometrioid adenocarcinoma (Chen et al., 2012),
and lung cancer cells (Wang et al., 2011c). Loss of miR-126 in breast cancer
leads to increased proliferation and number of metastatic nodules in lung,
indicating a role in the regulation of metastatic initiation and colonization.
Interestingly, de-repression of miR-126 targets IGFBP2, MERTK and
PITPNC1 leads to enhanced endothelial cell recruitment and angiogenesis
(Png et al., 2012) indicating a non-cell autonomous role for miR-126 in
metastasis suppression. Loss of both miR-126 and miR-126* expression
has been shown to enhance metastasis in a murine model of breast cancer
via up regulation of the endothelial cell recruiting chemokine SDF-1&
(Zhang et al., 2013).

The miR-335 locus is located in the second intron of mesoderm
specific transcript (MEST). Decrease in miR-335 expression is associated
with enhanced invasiveness of breast cancer (Heyn et al., 2011, Png et al.,
2011, Tavazoie et al., 2008), gastric cancer (Xu et al., 2012) and
neuroblastoma (Lynch et al., 2012). For miR-335, both genetic loss and
promoter hypermethlyation of the MEST host gene has been described in
clinical breast cancer samples (Png et al., 2011) and hepatocellular
carcinoma (Dohi et al., 2013), with loss of expression correlating with
higher rates of distal metastasis formation. In contrast, miR-335 expression
is pro-oncogenic in malignant astrocytoma where it promotes growth and
invasion (Shu et al., 2011). Expression of miR-335 has been proposed to
control proliferation in U2OS cells in a p53-dependent manner via direct
retinoblastoma 1 (Rb1) targeting (Scarola et al., 2010), while this same Rb1
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interaction is proposed to enhance meningioma cell growth (Shi et al.,
2012). MDA-231 cells express a non-functional mutant p53 (Petitjean et al.,
2007), and therefore this pathway is unlikely to influence metastatic
potential in these cells or its derivatives. An additional a role for miR-335
in the regulation of stem cell self-renewal has been proposed. Low miR335 expression in breast cancer stem cells promotes cell growth
(Polytarchou et al., 2012), while up-regulation of miR-335 in mouse
epithelial stem cells promotes differentiation by targeting Oct-4 and
retinoblastoma protein (Schoeftner et al., 2012). Conversely, miR-335 has
been found at high levels in human mesenchymal stem stems where it
both prevents differentiation and inhibits motility (Tome et al., 2011).

miR-335, miR-126 and miR-206 were identified as potent
endogenous inhibitors of metastasis by comparative microarray profiling
of the relatively weakly metastatic MDA-231 cell line and its aggressively
metastatic sub-lines with tropism to lung and bone (Tavazoie et al., 2008).
While the fold changes in expression level of these miRNAs were large,
between 50-70% for miR-335, the absolute levels of each miRNA were low
in the parental cells. Consequently, these miRNA were not amenable to
the differential AGO HITS-CLIP analysis carried out on MDA-231 and
4175LM2 cells where miR-335 and miR-335* together comprise <0.01% of
all MDA-231 crosslinked AGO-miRNA clones. Therefore to globally
identify miR-335 targets, we made use of previously characterized lung
metastatic cell lines with restored miR-335 expression and reduced
metastatic ability. These cells were created by cloning an approximately
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500bp region of the second intron of MEST (spanning the miR-355
genomic location) into a pMSCV-Blasticidin vector, allowing stable
integration and overexpression of pre-miR-335 under the control of a
CMV promoter (miR-Vec, (Tavazoie et al., 2008, Voorhoeve et al., 2007).
This system requires the normal cellular processing machinery to produce
both pre- and mature- miRNA guide strand so maintaining any
endogenous regulation of processing and miRNA stability.

Given the multiple roles described for miR-335 in metastasis
progression and the strong negative correlation between expression levels
and clinical metastasis-free survival, miR-335 was selected for further
analysis using AGO HITS-CLIP. By mapping AGO-mRNA interactions in
the presence and absence of miR-335 expression, we aimed to generate a
comprehensive catalog of directly regulated miR-335 target mRNAs to
more fully understand its anti-metastatic action.
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RESULTS
AGO HITS-CLIP in 4175LM2 Control and 4175LM2 pre-miR335
overexpressing cells
Argonaute HITS-CLIP was carried out in triplicate as described in
Chapter 3 using stable 4175 LM2 cell lines expressing either a control, nontargeting hairpin designed against inhibitor of DNA binding 1, ID1 (Minn
et al., 2005a) or pre-miR-355 (Tavazoie et al., 2008), termed LM2 Control
and LM2 335OE, respectively. Overexpression of miR-335 and miR-335*
were confirmed by Q-PCR before HITS-CLIP experiments were
undertaken, with both detected at ~120 fold higher levels in LM2 335OE
compared to LM2 Control (Figure 4.1). The resulting high-throughput
sequencing data was processed and filtered as in Figure 3.5, with the
number of miRNA and unique mRNA tags obtained from each replicate
library outlined in Table 4.1. Read depth between the two experiments
was more equally distributed than previously described for MDA-231
cells and metastatic sub lines, with ~1.7 million unique mRNA tags
obtained for LM2 Control cells and ~1.4 million unique mRNA tags from
LM2 335OE.

Characterization of the AGO-miRNA profiles of LM2 control and LM2 335OE
AGO-miRNA data sets were analyzed to determine whether
overexpression of pri-miR-335 disrupts the global miRISC profile of LM2
cells. Read counts per miRNA tallied as previously described, miRNAs
grouped by 7-mer seed family and the percentage of reads calculated
based on read depth in that experiment. The average percentage per seed
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FIGURE 4.1: Verification of miR-335/* over expression in stable cells
lines. Q-PCR verification of miR-335 and miR-335* over-expression in
LM2 335OE prior to AGO HITS-CLIP analysis. N=3, expression levels
normalized to Snord44, error bars= s.e.m, p-value calculated by t-test.
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Table 4.1: AGO HITS-CLIP sequencing results from triplicate LM2
Control and LM2 335OE cell lines. Read counts are shown for each data
processing step as outlined earlier in Figure 3.5.
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family was plotted in pair-wise scatter plots comparing LM2 Control and
LM2 335OE with each other, and to the previously described 4175LM2
AGO-miRNA data set. Extremely high Pearson correlation coefficients
were obtained when comparing all three data sets, indicating that neither
the selective overexpression of pri-miR-335 nor the non-targeting control
shRNA lead to a significant shift in the overall composition of miRNAs
bound to AGO in 4175LM2 cells (Figure 4.2). Correlation coefficients were
unaffected by removal of the top three most CLIPed miRNAs (data not
shown).

AGO HITS-CLIP reveals strand bias towards miR-335*
Plotting the percentage of miRNA CLIP tags from each LM2 cell
line on a log scale revealed a clear increase in the representation of both
miR-335 and miR-335* in LM2 335OE compared to both LM2 Control and
4175LM2 (Figure 4.3). The miRNA profiles of LM2 335OE and LM2
Control cells were compared using EdgeR software as described
previously, with miRNAs having counts per million>2 in >4/6 HITS-CLIP
AGO-miRNA profiles retained for analysis (Table 4.2). Surprisingly, while
miR-335 showed a significant increase in the LM2 335OE AGO-miRNA
profile, this fold change did not pass the FDR threshold (log2FC=4.01,
p=0.0025, FDR=0.12). However miR-335*, the presumed pre-miR-335
passenger strand, had the greatest and most significant positive fold
change of all AGO-miRNA (log2FC=6.65, p= 7.61E-15, FDR= 5.29E-12). Six
miRNA showed significant decrease in the LM2 335OE miRNA profile
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FIGURE 4.2: AGO-miRNA profiles in LM2 cell lines are unaffected by
pri-miR-335 over expression. Expressed miRNAs (BC≥2 tags≥10)
common to 4175LM2, LM2 Control and LM2 335OE cells were
compressed into seed families based on position 2-8 (7-mer) seed match.
The percentage of reads per miRNA was calculated per library using the
total number of reads mapping to miRNAs in that library as a
denominator. Percentages were then averaged across replicates per cell
line. Upper half: Pairwise scatter plots of miRNA family % in 4175LM2,
LM2 Control and LM2 335OE. Lower half: absolute value of the Pearson
correlation coefficient.
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FIGURE 4.3: Over expression of pri-miR-335 leads to an increase in the
percentage of AGO-miR-335 and AGO-miR-335* in LM2 335OE.
Percentage of miRNAs as in Figure 4.2 on a log scale. miR-335 and miR335* are highlighted.
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compared with LM2 Control (FDR≤0.05), however the majority of these
miRNA are rare components of the miRNA profile (average%<0.1).
Despite ~120 fold increased expression of miR-335 and miR-335* in LM2
335OE cells, both mature miRNAs processed from this precursor remain
minor components of the AGO-miRNA profile representing only 0.42%
and 0.045% of the total miRNA population respectively.

The asymmetrical increase in miR-335 and miR-335* representation
in AGO-miRNA HITS-CLIP libraries raised the possibility that miR-335* is
the dominant guide strand in LM2 335OE cells. Given that the selected
strand determines the functional specificity of the miRISC complex, this
would have profound implications for the targets regulated by pre-miR335. The stem-loop structure of human miR-335 is shown in Figure 4.4.
Functional miRNAs have been found to have lower thermodynamic
stability at the 5’ end, leading to more efficient loading into RISC
(Khvorova et al., 2003). The 5’ end of miR-335 contains multiple G-C base
pairs, while the miR-335* 5’ end is comprised of a stretch of five A-T base
pairs, suggesting that miR-335* 5’ end would be relatively less stable.
Consistent with miR-335* being the guide strand, it is detected at
significantly higher levels than miR-335 in MDA-MB-231and all LM2 cell
lines used in this study indicating that processing of exogenous pre-miR335 is not responsible for the observed AGO-miRNA asymmetry (Figure
4.5).
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TABLE 4.2: Analysis of the AGO-miRNA profiles of LM2 Control and
LM2 335OE. Percentage of AGO-miRNA CLIP tags is shown as the
average across the tree libraries for each data set, log2 fold change, p-value
and FDR calculated using EdgeR.

% LM2

% LM2

Log2 Fold

Control

335OE

Change

miR-335*

0.007

0.419

miR-548o

0.134

miR-3182

miRNA

p-value

FDR

6.647

7.61E-15

5.29E-12

0.009

-3.155

1.03E-05

0.0024

0.022

0.001

-4.317

1.03E-04

0.0179

miR-665

0.046

0.003

-2.936

1.56E-04

0.0217

miR-574-5p

0.643

0.132

-1.724

2.54E-04

0.0295

miR-519d

0.025

0.001

-3.966

3.34E-04

0.0332

miR-663

0.015

0.000

-5.080

3.82E-04

0.0332

miR-335

0.005

0.045

4.007

0.003

0.119
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Figure 4.4: The stem-loop structure of human pre-miR-335. miR-335*
(miR-335-3p ) has a 5nt A-T base paired stretch at its 5’ end compared the
more G-C rich 5’ end of miR-335. Adapted from miRBase (Kozomara and
Griffiths-Jones, 2011).
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FIGURE 4.5: miR-335* is consistently detected at higher levels than
miR-335 in MDA-231 and lung metastatic sub-lines. Q-PCR for miR-335
and miR-335* were carried out in triplicate for each cell line indicated with
expression normalized to Snord44. Error bars = s.e.m, p-values calculated
by t-test.
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Global characterization of AGO-mRNA binding in LM2 Control and LM2
335OE
Uniquely mapped mRNA libraries were clustered independently
for LM2 Control and LM2 335OE, and the resulting robust, reproducible
clusters annotated (BC≥2 tags≥5). As previously described, clusters
mapping to chrY, RNA genes and pre-miRNA loci were removed before
genomic distribution was assessed, resulting in 21,403 LM2 335OE and
31,359 LM2 Control clusters. The genomic localization of both LM2
Control and 335OE clusters were highly similar, with the largest
proportion of clusters mapping to 3’UTRs plus 10kb immediately
downstream of annotated gene ends (44% and 44.1%, control and 335OE
respectively), and consistent with the previously described distribution of
AGO-mRNA binding in 4175LM2 (see Figure 3.7). The majority of the
remaining LM2 Control and 335OE clusters were distributed between
coding sequence (30.5% and 27% respectively), introns (13.8% and 17.9%
respectively), with a small degree of binding occurring in 5’UTR and deep
intergenic regions (Figure 4.6).

To assess reproducibility between the AGO-mRNA binding sites in LM2
Control and LM2 335OE cells, all unique tags were pooled and clustered.
These clusters were filtered to retain those with a minimum of five unique
tags originating from two replicate libraries of either LM2 Control or
335OE, and by removing clusters mapping to chrY, RNA genes and premiRNA loci (39,109 AGO binding sites). The number of tags per cluster
originating from each cell line was highly reproducible (Figure 4.7,
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FIGURE 4.6: Genomic distribution of robust and reproducible AGOmRNA clusters in LM2 Control and LM2 335OE cells. The three
independently derived AGO-mRNA libraries for each cell line were
pooled and clustered with a minimum overlap of 3nt. Clusters were
removed that did not meet the minimum criteria of BC≥2 tags≥5, or that
mapped to chrY, RNAgenes and pre-miRNA loci. Clusters were annotated
to give genomic location.
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FIGURE 4.7: AGO-mRNA binding is highly reproducible between LM2
Control and LM2 335OE cells. All unique AGO-mRNA reads from LM2
Control and 335OE cells were pooled together and clustered, retaining
only those clusters with BC≥2 and tags≥5 in either cell line. The scatter
plot of CLIP tag per cluster originating from Control and LM2 cells shows
a high degree of reproducibility in AGO-mRNA biding between cells lines
(R2=0.838). The overexpression of pri-miR-335 in LM2 335OE does not
lead to a global re-assortment of AGO on target mRNAs.
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R2=0.838), suggesting that overexpression of pri-miR-335 does not globally
perturb the AGO-mRNA profile of LM2 cells.

Identification of miR-335/* dependent de novo AGO-mRNA clusters
The basic principles used to identify miR-335 or miR-335*
dependent AGO binding events from AGO HITS-CLIP data are in
outlined in Figure 4.8. First, AGO-mRNA clusters were identified that
showed significant enrichment in AGO-mRNA binding LM2 335OE cells
(dark blue) when compared to the non-targeting hairpin expressing LM2
Control cells (light blue) as previously described for differential AGOmRNA analysis in Chapter 3. miR-335/*-dependent binding de novo
binding events were then screened for the canonical miR-335 and/or miR335* seed sequence (CTCTTG and TGAAAA) as evidence of direct miR335/*-mediated AGO de novo binding.

A total of 1,283 BC≥2 tag≥5 clusters were identified with significant
enrichment of AGO-binding in the presence of pri-miR-335 (log2 fold
change 335OE/Control ≥1, p-value≤0.01). 368 clusters (28.7%) contained a
minimum 6-mer sequence match to miR-335 or miR-335* within position
1-8, while 210 (16.4%) contained a canonical seed match corresponding to
position 2-7. Of those clusters with a canonical seed match, 71 contained
seed matches to miR-335 and 139 to miR-335* consistent with the
relatively higher abundance of miR-335* in the LM2 335OE AGO-miRNA
profile. Restricting the location of clusters to the 3UTR and 10kb
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FIGURE 4.8: Experimental schematic of miR335/* dependent AGObinding event identification. Triplicate AGO HITS-CLIP unique mRNA
tags from 4175LM2 cells stably expressing either a control hairpin (LM2
Control, highly metastatic, light blue) or pri-miR-335 (LM2 335OE, weakly
metastatic, dark blue) were mapped to the human genome (hg18). Sites of
robust, reproducible binding were identified as either as clusters derived
from pooled unique reads from both cell lines, or as significant peaks in
the LM2 335OE data set (both requiring a minimal BC≥2 and tag≥5). Tag
numbers from each cell line in the AGO-mRNA footprint region were
counted and those AGO binding sites showing enrichment in the LM2
335OE libraries interrogated for the presence of miR-335 or miR-335* seed
sequences as evidence of direct, de novo miR-335/* regulation. Lung
section images from (Tavazoie et al., 2008).
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downstream region left a total 107 miR-335/* canonical seed match
containing, pri-miR-335-dependent clusters. Given that the definition of a
cluster can encompass relatively large stretches of transcripts with
multiple peaks, de novo miR-335/* AGO-mRNA binding was assessed in
the -30/+32nt footprint centered on the single largest peak of each cluster
(Chi et al., 2009). Seed search in this narrower sequence space returned
106 miR-335* and 66 miR-335 6mer seed matches to positions 1-8 (13.4% of
de novo AGO-miR335 clusters). Of these peaks, 64 and 35 contained
canonical 2-7 seed matches to miR-335* and miR-335 respectively, with 44
canonical seed matches occurring in 39 3’UTR and 10kb downstream
clusters (Table 4.3).

Detailed analysis of AGO HITS-CLIP data sets have revealed
alternative rules for miRNA:mRNA target recognition involving the
inclusion of position 6 nucleation bulges (Chi et al., 2012) and various
“seed-like” sequences (Loeb et al., 2012). Interestingly, G:U wobbles can
be tolerated in various positions within the lsy-6-::cog-1 targeting site,
which like miR-335* seed pairing contains a stretch of four A-U base pairs
(TACAAAA – lsy-6, ATGAAAA - miR-335*) (Didiano and Hobert, 2006).
Taking

these

potential

alternative

seed

pairing

sequences

into

consideration, a further 133 potential seed matches for miR-335* were
identified in the 62nt AGO footprint of those de novo clusters with no
evidence of a canonical 6nt seed (Figure 4.9). The ability of miR-335* to
regulate these non-canonical seed-matched transcripts is yet to be
determined. MEME analysis of the remaining non-miR-335/* de novo
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TABLE 4.3: LM2 335OE 3’UTR clusters containing canonical seed
matches in the 62nt AGO footprint. De novo mR-335/* 3’UTR clusters
whose largest peak (-30/+32nt) contain a canonical seed match to either
miR-335 or miR-335*. Unique mRNA counts and biological complexity are
given for LM2 335OE and LM2 Control cells with log2 fold change in
binding events (normalized to read depth per cell line), associated p-value
and FDR (Benjamini-Hochberg correction). The genomic coordinates of
the AGO cluster region and the seed match are given for reference.

127

12

128

!

CTCTTG
TGAAAA

miR-335

miR-335

miR-335*

miR-335

miR-335

miR-335

miR-335*

miR-335

miR-335*

miR-335*

miR-335

miR-335*

miR-335*

miR-335*

miR-335*

miR-335

miR-335*

miR-335*

miR-335*

miR-335*

miR-335*

miR-335

miR-335*

KDSR

KDSR

SEL1L

SEL1L

CDH11

CDC7

MCM3APAS

PLAGL2

AAK1

PBX3

NEDD4L

PANX1

SDAD1

SFRS2

CETN3

PTPN3

CTR9

SMC4

SLC4A7

GPR180

TMED5

TOP2A

POLR3F

TGAAAA

CTCTTG

TGAAAA

TGAAAA

TGAAAA

TGAAAA

TGAAAA

TGAAAA

TGAAAA

TGAAAA

CTCTTG

TGAAAA

TGAAAA

CTCTTG

TGAAAA

CTCTTG

CTCTTG

CTCTTG

TGAAAA

CTCTTG

CTCTTG

TGAAAA

miR-335*

DBT

Match

miRNA

GENE

Seed

21

27

17

15

24

19

12

12

9

9

10

11

11

8

8

28

6

6

6

7

7

8

8

9

Tags

335OE

3

3

3

3

3

3

3

3

3

3

2

3

2

3

2

3

2

2

3

2

2

3

3

2

BC

10

13

7

6

8

6

3

3

2

2

2

2

2

1

1

5

0

0

0

0

0

0

0

0

Tags

Control

3

3

3

2

3

3

3

3

2

1

1

2

1

1

1

2

0

0

0

0

0

0

0

0

BC

1.51

1.51

1.68

1.70

1.99

2.03

2.21

2.21

2.25

2.25

2.39

2.51

2.51

2.68

2.68

2.78

3.32

3.32

3.32

3.51

3.51

3.68

3.68

3.83

335OE/Cont

Log2 FC

0.0041

0.0014

0.0047

0.0094

0.0002

0.0007

0.0050

0.0050

0.0110

0.0110

0.0057

0.0030

0.0030

0.0104

0.0104

7.49E-07

0.0103

0.0103

0.0103

0.0048

0.0048

0.0022

0.0022

0.0010

p-value

0.1235

0.0643

0.1398

0.1904

0.0150

0.0400

0.1308

0.1302

0.1768

0.1778

0.1375

0.0998

0.1001

0.1746

0.1751

0.0001

0.1833

0.1838

0.1817

0.1298

0.1298

0.0826

0.0826

0.0490

FDR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

Location

chr20

chr17

chr1

chr13

chr3

chr3

chr11

chr9

chr5

chr17

chr4

chr11

chr18

chr9

chr2

chr20

chr21

chr1

chr16

chr14

chr14

chr18

chr18

chr1

CHRM

18412263

35798579

93392602

94077653

27390911

161612959

10757431

111180764

89725520

72242674

77090781

93554290

54215785

127769298

69542097

30244118

46495888

91763846

63538440

81012555

81012555

59148339

59148339

100434187

Start

18412340

35798692

93392740

94077706

27391018

161613087

10757522

111180990

89725590

72242787

77090857

93554423

54215878

127769369

69542148

30244205

46495991

91763876

63538508

81012597

81012597

59148403

59148403

100434237

End

12

129

TGAAAA
TGAAAA

miR-335

miR-335*

miR-335*

miR-335

miR-335*

miR-335*

miR-335*

miR-335

miR-335

miR-335*

ABCF1

ACSL4

SMAD5

ANP32E

TMEM49

PDIA6

LPAR1

LPAR1

ATP13A3

ZBTB34

miR-335

miR-335

miR-335*

MAP1B

HN1

TMEM41B

CTCTTG

miR-335

miR-335*

CEP350

miR-335*

GLT8D3

MAP1B

TGAAAA

miR-335

MAT2B

CTCTTG

MAT2B

TGAAAA

CTCTTG

CTCTTG

TGAAAA

CTCTTG

TGAAAA

miR-335

miR-335*

ZBTB34

TGAAAA

CTCTTG

CTCTTG

TGAAAA

TGAAAA

TGAAAA

CTCTTG

CTCTTG

TGAAAA

miR-335*

FAM105B

Seed
Match

miRNA

GENE

41

86

124

124

25

29

40

40

22

22

27

43

43

29

26

41

32

18

20

22

Tags

335OE

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

BC

28

59

81

81

16

18

24

24

13

13

16

25

25

16

14

22

17

9

10

11

Tags

Control

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

BC

Log2 FC

1.05

1.05

1.12

1.12

1.12

1.17

1.23

1.23

1.23

1.23

1.23

1.27

1.27

1.33

1.36

1.38

1.39

1.44

1.44

1.45

335OE/Cont

0.0025

1.58E-05

3.74E-08

3.74E-08

0.0127

0.0055

0.0007

0.0007

0.0118

0.0118

0.0058

0.0004

0.0004

0.0026

0.0028

0.0002

0.0009

0.0127

0.0065

0.0052

p-value

0.0918

0.0021

0.0000

0.0000

0.1952

0.1345

0.0399

0.0399

0.1841

0.1841

0.1390

0.0259

0.0259

0.0966

0.0968

0.0167

0.0477

0.1954

0.1512

0.1341

FDR

3'UTR

CDS/3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

3'UTR

CDS/3'UTR

3'UTR

3'UTR

CDS/3'UTR

3'UTR

3'UTR

Location

chr11

chr17

chr5

chr5

chr1

chr12

chr5

chr5

chr9

chr9

chr3

chr9

chr9

chr2

chr17

chr1

chr5

chrX

chr6

chr5

CHRM

9261244

70643666

71540822

71540822

178348537

40766833

162877977

162877977

128687426

128687426

195607846

112677209

112677209

10841607

55271858

148458998

135541063

108773847

30666889

14751036

Start

9261449

70643957

71541150

71541150

178348783

40767085

162878152

162878152

128687576

128687576

195608126

112677394

112677394

10841810

55272050

148459325

135541291

108774036

30667074

14751131

End

Figure 4.9: Non-canonical miR-335* seed sites in the AGO 62nt footprint
in LM2 335OE enriched AGO clusters. AGO footprint regions enriched in
LM2 335OE cells were searched for potential non-canonical miR-335 and
miR-335* seed sites with bulged nucleotides at position 6 (Chi et al., 2012),
and G:U wobbles in the 4nt A-U pairing region of miR-335* (Didiano and
Hobert, 2006). 133 additional binding sites were found that contained a
non-canonical miR-335* seed-like sequence, no bulged sites were found
for miR-335.
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clusters identified two significant motifs, which did not match the seed
sequences of any miRNA in the HITS-CLIP profile, or the G-rich motifs
associated with miRNA-independent AGO binding sites identified in
mouse embryonic stem cells (Leung et al., 2011).

Identification of miR-335/* dependent de novo AGO-mRNA significant peaks
Unique mRNA tags from LM2 335OE were used to identify
significant peaks of AGO binding. 9,183 significant peaks were identified
with p≤0.01, 7305 of which contained five or more tags from two or more
replicate LM2 335OE libraries (BC≥2 tags≥5). The number of LM2 Control
AGO-mRNA tags overlapping the +/-30nt region centered on the LM2
335OE significant peak was calculated and difference analysis carried out
as for clusters. 253 LM2 335OE significant peaks showed significant
enrichment of AGO-mRNA binding (log2 fold change ≥1, p<0.01), with 82
containing a minimal 6-mer match to either miR-335 or miR-335* between
positions 1-8. Only 15 peaks contained canonical position 2-7 seed
matches, of which 9 were located in 3’UTR regions. Table 4.4 shows all
canonical seed-matched significant peaks in 3’UTRs and coding sequence.
The low number of seed containing significant peaks identified as
enriched in LM2 335OE is unsurprising considering the small proportion
of the miRNA profile represented by miR-335 and -335*, and the generally
low tag numbers found in de novo miR-335/*-dependent and seed
containing clusters.
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Table 4.4: LM2 335OE enriched significant peaks in CDS and 3’UTRs
with canonical miR-335/* seed sequences. Significant peaks were defined
in LM2 335OE cells (BC≥2 tags≥5), and overlapping tags from LM2
Control cells counted in a +/-30nt AGO footprint centered on the 335OE
significant peak coordinate. Difference analysis was carried out as
described for cluster analysis. 3’UTRs and CDS significant peaks that
contain a canonical miR335 or miR335* seed site and have significant
binding enrichment in LM2 335OE cells are shown.

132

133
1-8
2-7

miR-335

miR-335

miR-335*

miR-335*

miR-335

miR-335

miR-335

miR-335

SERPINE1

DKK1

DST

ANP32E

CEP350

DKK1

MAP1B

1-7

1-7

2-7

2-8

2-8

2-7

2-7

PLAGL2

1-8

miR-335

miR-335*

CALU

GHITM

1-8

miR-335

KDSR

Match

miRNA

GENE

Seed

95

29

22

34

17

31

43

28

11

18

8

Tags

335OE

3

3

3

3

3

3

3

3

3

3

3

BC

49

11

8

9

4

7

10

5

1

2

0

Tags

Control

3

3

3

3

3

3

3

2

1

1

0

BC

1.04

1.42

1.46

1.91

1.95

2.10

2.10

2.38

2.69

2.77

3.27

335OE/Cont

Log2 FC

2.13E-05

0.0030

0.0078

6.95E-05

0.0054

4.83E-05

2.07E-06

2.93E-05

0.0058

0.0004

0.0094

p-value

0.0015

0.0719

0.1386

0.0040

0.1102

0.0029

0.0002

0.0020

0.1146

0.0144

0.1506

FDR

3'UTR

3'UTR

3'UTR

3'UTR

CDS

3'UTR

3'UTR

3'UTR

CDS

3'UTR

3'UTR

Location

chr5

chr10

chr1

chr1

chr6

chr10

chr7

chr20

chr10

chr7

chr18

CHRM

71540874

53746972

178348632

148459186

56674647

53746593

100568166

30244117

85893789

128198240

59148338

Start

71540934

53747032

178348692

148459246

56674707

53746653

100568226

30244177

85893849

128198300

59148398

End

Initial selection of miR-335/* targets for validation
The list of candidate miR-335/* enriched targets was refined by
comparing to RNAseq analysis of transcript abundance in LM2 Control
and 335OE cells. Single-end, 50nt polyA-selected single replicate RNA
libraries were prepared from LM2 Control and LM2 335OE cells harvested
at the same time as those used for HITS-CLIP. The resulting highthroughput sequencing data was filtered based on quality score then
aligned to the human genome (hg18), giving ~20million reads for LM2
Control and ~21million reads for LM2 335OE. Gene expression levels
(RPKM) were obtained by aligning reads to a non-redundant set of
constitutive exons, and difference in expression calculated using tools
developed by Chaolin Zhang in the Darnell laboratory for use within the
Galaxy bioinformatics platform.

RPKM values per gene from LM2 Control and LM2 335OE cells are
plotted in Figure 4.10, with the previously identified miR-335
downregulated gene set (Tavazoie et al., 2008) highlighted in blue as a
positive control. A high degree of correlation in transcript abundance
(R2=0.927) was observed between LM2 335OE and LM2 Control indicating
very few transcripts with altered steady state levels. Filtering the LM2
335OE enriched clusters by log2 fold change of 335OE/Control RNAseq
reads (≤0.2, p-value≤0.01) returned 9 clusters, of which 8 clusters
contained canonical miR-335* seed matches, one contained a miR-335 seed
while three clusters contained both seed sequences (Table 4.5).
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FIGURE 4.10: RNAseq analysis of steady state transcript levels in LM2
Control and LM2 335OE cells. Scatter plot of RPKM values per gene
obtained from high-throughput polyA-selected RNAseq. Genes
highlighted in blue comprise the six miR-335 downregulated genes
previously identified in LM2 335OE cells (Tavazoie et al., 2008), with all
six showing derepression in LM2 Control cells.
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Table 4.5: miR-335/* canonical seed containing LM2 335OE-enriched AGO clusters downregulated in LM
335OE. Clusters shown are BC≥2 tag≥5, fold change ≥1 with associated p-value<0.01, filtered by RNAseq FC ≤0.2
and associated p-value ≤0.01.

Validation of centrin EF-hand protein 3 (CETN3) as a miR-335* target
CETN3 was selected for validation based on the high relative
enrichment of CLIP tags and fold change in abundance compared with the
other candidates. Additionally, the de novo AGO binding site identified by
differential analysis was the only AGO binding site in this relatively short
3’UTR (~350nt, Figure 4.11A), and contained extensive complementarity
to miR-335*; a canonical miR-335* 1-7nt seed match with an additional GU wobble base-pair at position 8 (Figure 4.11B). Endogenous CETN3
transcript levels were assayed by Q-PCR in MDA-231 parental cells (miR335/* expressing), 4175 LM2 (miR-335/* negative) and LM2 335OE.
CETN3 steady state mRNA levels were significantly higher in 4175LM2
cells suggesting derepression of the transcript (Figure 4.12A). To
determine whether this derepression was a direct consequence of
decreased levels of miR-335*, 4175LM2 cells were transiently transfected
with miR-335* mimic. This resulted in significant down regulation of
endogenous CETN3, while no effect on transcript level was seen in cells
transfected with miR-335 mimic or a negative control mimic that is nontargeting in the human genome (p=0.006, Figure 4.12B).

To determine whether the miR-335* seed site identified within the
CETN3 3’UTR de novo AGO cluster mediated miR-335*-dependent
transcript repression, full length WT CETN3 3’UTR was cloned into a dual
luciferase reporter construct (psiCheck2). A mutant construct was made
altering the miR-335* seed site at two positions, from TGAAAA to
TGATAT. Transient transfection of these constructs into 4175LM2 was
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FIGURE 4.11: Differential AGO binding identifies CETN3 as a miR335* target. A: Binding map of AGO:mRNA unique tags (top panel) and
normalized reads (bottom panel) from LM2 Control (light blue) and LM2
335OE cells (dark blue) showing increased binding in a discrete site on the
3’UTR of CETN3 in LM2 335OE. B: The footprint of the differential AGO
binding site contains a non-conserved miR-335* seed match.
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FIGURE 4.12: CETN3 mRNA level is repressed by miR-335*. A:
CETN3 mRNA levels are significantly higher in 4175 LM2 cells (miR335/* negative) than in MDA-231 cells (miR-335/* positive). CETN3
mRNA levels return the baseline level seen in MDA-231 cells in LM2
335OE cells. B: CETN3 mRNA level is negatively regulated by transient
transfection of 50nM miR-335* mimic into 4175LM2 cells, but not miR335 mimic. Mock is transfection reagent alone, negative control miRNA
mimic is non-targeting in human. n=3 cell line, n=4 transfection Q-PCR,
expression levels normalized to TBP, error bars = s.e.m, p-values
calculated by t-test.
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carried out in the presence of either negative control miRNA mimic or
miR-335* mimic. WT CETN3 3’UTR luciferase reporter activity was
significantly inhibited in the presence of miR-335* mimic (p=4.6e-5), while
the mutant CETN3 3’UTR was unaffected (Figure 4.13A). This miR-335*
seed-dependent regulation of the CETN3 3’UTR was verified in an
independent cell line (HEK 293T, Figure 4.13B).

The ability of endogenous miR-335* to repress the CETN3 3’UTR
was assayed in MDA-231 cells. Initial transfections of 50ng WT and
mutant CETN3 3’UTR reporter constructs into MDA-231 and 4175LM2
indicated increased basal reporter activity of WT CETN3 3’UTR in
4175LM2 compared to the MDA-231 parental line, however transfections
with the mutant construct failed to reveal derepression in MDA-231 (data
not shown). In attempt to introduce reporter construct at more
stoichiometric concentrations, 5ng of plasmid was transfected into cells
with high replicate numbers (n=10). Expression of WT CETN3 was
significantly repressed when compared to mutant CETN3 3’UTR in MDA231 cells where miR-335* is expressed. No significant difference between
WT and mutant reporter activity was seen in 4175LM2 cells where miR335* expression is extremely low (Figure 4.14).

To investigate whether upregulation of CETN3 in miR-335*
expressing cells could enhance or restore invasive capability, stable MDA231 and LM2 335OE cell lines were generated that overexpressed human
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FIGURE 4.13: miR-335* represses the 3’UTR of CETN3. 3’UTR reporter
assays were carried out in 4175LM2 cells (A) and verified in HEK-293T
(B). 50ng of dual luciferase reporter constructs encoding the full length
WT or mutant CETN3 3’UTR, or empty vector (psiCheck2) were
transfected in the cell line indicated either alone, or with 50nM miRNA
mimic as indicated. Luciferase activity was assayed 30h after
transfection and values normalized to WT CETN3 transfected with
negative mimic. Co-transfection of miR-335* mimic leads to significant
repression of the luciferase activity of WT CETN3 3’UTR, which is
abrogated by mutating the miR-335* seed site identified in the
differentially bound AGO-footprint. n=4, error bars = s.e.m, p-values
calculated by t-test.
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FIGURE 4.14: Endogenous miR-335* represses the CETN3 3’UTR.
Mutation of the miR-335* seed site bound by AGO in CETN3 3’UTR leads
to derepression of reporter constructs in MDA-231 cells where miR-335* is
expressed but not in 4175LM2 cells. Cells were transfected with 5ng of
psiCheck2 empty vector, full length WT CETN3 or MUT CENT3 3’UTR
and assayed for luciferase activity at 30h. Values are shown normalized to
MUT CETN3 in MDA-231, n=10, error bars = s.e.m, p-values calculated by
t-test.
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CETN3 cDNA. Overexpression was validated by Q-PCR (Figure 4.15A)
and the effect of increased CETN3 expression on invasiveness assayed by
matrigel invasion. CETN3 overexpression in LM2 335OE cells had no
effect on invasion compared to empty vector control cells. Overexpression
of CETN3 in MDA-231 lead to a significant increase in invasion (p=0.0106)
compared to MDA-231 uninfected controls (n=4, shown in Figure 4.15B),
however this result failed to repeat in independent experiments, therefore
the role of CETN3 in tumor cell invasion is currently undetermined.

Clinical association of CETN3 and metastasis free survival
Given that low miR-335 expression is negatively correlated with
metastasis free survival in breast cancer patients (Tavazoie et al., 2008), it
would be anticipated that high levels of miR-335/*- regulated targets
would negatively correlate with prognosis. To determine the relationship
between CETN3 expression levels and human breast cancer metastasis
two

data

sets

were

probed.

The

first,

“Kaplan-Meier

Plotter”

(www.kmplot.com, 2012 release, (Gyorffy et al., 2010)) uses a background
database of publicly available primary breast cancer GEO expression data
and survival information (n=2,978). In this data set, high levels of CETN3
were significantly correlated with poor metastasis-free survival (Figure
4.16A, p=0.00018 using default settings). However, using a second data set
derived from patients after taxane-anthacycline chemotherapy treatment
(Hatzis et al., 2011) that is not included in the Kaplan-Meier Plotter data
set showed an opposite correlation, with high levels of CETN3 predictive
for good metastasis-free survival (Figure 4.16B, p=0.035 calculated using
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FIGURE 4.15: Investigating the role of CETN3 in invasion. Stable
CETN3 overexpressing MDA-231 and LM2 335OE cell lines were
generated via viral transduction with CETN3 cDNA. Empty pBabe-Puro
vector was used as a control. A: Over expression of CETN3 was assayed
by Q-PCR with RNA independently prepared from triplicate samples, as
in Figure 4.12. B: Trans-well invasiveness of CETN3 OE cell lines was
assessed by comparison to empty vector transduced cells and non-infected
cells. Cells that had invaded through the matrigel inserts were counted
24h post seeding. Each cell line was tested in quadruplicate with cell
triplicated cell counts taken per insert. No effect of CETN3 overexpression
on invasion was seen in LM2 335OE cells, while over expression of CETN3
in MDA-231 cells lead to a significantly enhanced invasion (t-test)
compared to MDA-231 uninfected controls but not to MDA-231 emptyvector stable cell line controls. This result did not repeat in a replicate
experiment.

144

FIGURE 4.16: Clinical association of CETN3 expression level and
metastasis-free survival. A: High levels of CETN3 correlate with shorter
metastasis-free survival in breast cancer patients included in the KaplanMeier Plotter database (N=2978). CETN3 (209662_at) expression level
classified based on median probe intensity with all settings at default. B:
Low levels of CETN3 correlate with shorter metastasis-free survival in a
508 patient cohort whose gene expression profiles were generated after
chemotherapy treatment.
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the survdiff function in R by Hani Goodarzi, Tavazoie Lab). Whether this
difference is attributable to chemotherapy treatment, and how CETN3
expression correlates with miR-335/* levels in these patient cohorts is
unknown.

Further validation of predicted miR-335/* targets identified by AGO-HITS CLIP
SEL1L (miR-335 and -335* seed), FAM105B (miR-335*) and SMAD5
(miR-335*) steady state transcript levels were assayed by Q-PCR in MDA231, 4175 LM2 and LM2 335OE. These genes have significant enrichment
in a miR-335/* seed containing AGO binding site in LM2 335OE cells
(Figure 4.17A, log2 FC≥1, p<0.01) and a predicted decrease in transcript
level by RNAseq, although predicted expression level changes were small
(Table 4.5). All three transcripts had increased steady state levels in
4175LM2 cells compared to pre-miR-335 expressing MDA-231, although
this increase failed to reach significance for FAM105B. Transcript levels
failed to show statistically significant repression in LM2 335OE cells when
compared to 4175LM2 (Figure 4.17B).

Transient transfection of relevant miR-335/* mimics in LM2 cells
also failed to repress these endogenous transcripts when compared to
mock transfection controls (Figure 4.17C). Up regulation of both SEL1L
and FAM105B was seen upon transfection with negative control mimic,
which for FAM105B was significantly reversed by either miR-335 or miR335* mimic transfection.

This indicates both the potential for target-

dependent general derepression of transcripts as a result of off-target
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Figure 4.17: Steady state mRNA levels of predicted miR-335/* targets
show weak or no regulation by endogenous or exogenous miR-335/*.
A: Extensive AGO binding is seen in the 3’UTRs of SEL1L, FAM105B and
SMAD5 in both LM2 Control and LM2 335OE (normalized AGO binding).
The pre-miR335 seen containing de novo AGO binding site is highlighted.
B: Steady state levels of miR-335/* bound transcripts in MDA-231 (premiR-335 positive), 4175LM2 (pre-miR-335 negative) and LM2 335OE
consistently show up regulation in 4175LM2 that is not reduced to MDA231 levels in LM2 335OE. C: Transient transfection of 50nM miRNA
mimics in LM2 cells fails to repress endogenous predicted target mRNAs
when compared to mock transfection. For SEL1L and FAM105B, negative
control mimic leads to target up-regulation, possibly though competition
for AGO. The non-specific up regulation of FAM105B is reduced by miR335 or miR335* mimic transfection, however miR-335 is not predicted to
target FAM105 by HITS-CLIP. n=3 cell line, n=4 mimic transfection,
expression levels normalized to TBP, error bars = s.e.m, p-values
calculated by t-test.
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effects of exogenous miRNA mimic transfection (Khan et al., 2009), and
the potential for false positive result from reporter assays. FAM105B
contains multiple miR-335 seed sequences within its 3’UTR that show no
evidence of direct AGO binding by HITS-CLIP, suggesting that the miR335 repressive effect is an artifact. As can be seen in Figure 4.17A, the de
novo pre-miR-335 dependent AGO binding sties in these 3’UTRs are a
relatively minor component of the total AGO-mRNA binding profile. The
majority of AGO binding is common between LM2 Control and 335OE,
suggesting that any additional anticipated negative regulation exerted by
de novo miR-335/* binding sites in these transcripts is negligible or below
the level detection by our assays in the background of high levels of
shared repressive binding. Alternatively, these binding events may reflect
a degree of bioinformatically-generated noise due to the low tag numbers
associated with de novo miR-335/*-dependent AGO binding sites. Whether
miR-335* can regulate SEL1L, FAM105B and SMAD5 protein level is yet to
be determined.

miR-335/* regulation associated with de novo pri-miR-335 AGO
binding is detectable in other transcripts that have a shared background of
AGO binding. For example, enriched de novo AGO binding in twisted
gastrulation homolog 1, TWSG1 (Log2 FC CLIP cluster=1.97, pvalue=0.016), centered on a miR-335 seed with extensive additional
complementarity (Figure 4.18A) correlates with steady state expression
level changes with respect to endogenous or exogenous miR-335 (Figure
4.18B). This relatively small yet significant repression of the TWSG1
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FIGURE 4.18: Differential AGO binding identifies TWSG1 as a miR335 target. A: The de novo AGO binding site identified on the 3’UTR of
TWSG1 contains including a miR-335 seed match in position 2-9. The
miR-335 seed conservation is restricted to primates. A background of
multiple common AGO binding sites is seen in other regions of the
TWSG1 3’UTR. B: TWSG1 mRNA levels track with endogenous premiR-335 in MDA-231, 4175LM2 and are reduced to MDA-231 levels in
LM2 335OE cells. TWSG1 mRNA is downregulated by transient
transfection of miR-335 mimic into 4175LM2 cells. Mock is transfection
reagent alone, negative control miRNA mimic is non-targeting in
human. n=3 cell line, n=4 mimic transfection, expression levels
normalized to TBP, error bars = s.e.m, p=values calculated by t-test.
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mRNA failed to translate into reduced luciferase activity in TWSG1 3’UTR
reporter assays with exogenous miR-335 mimic transfection (data not
shown).

Relaxing the criteria for cluster selection identified a further two
miR-335 and miR-335* targets regulated at the protein level. SDAD1
contains an AGO peak with log2 FC CLIP cluster binding of 2.84 (10 tags
LM2 335OE, 2 tags LM2 Control, p-value=0.006) with complementarity to
miR-335* in positions 2-7 with an additional G:U wobble at position 8.
Luciferase reporter assays with WT full length SDAD1 3’UTR revealed
exogenous mir-335* mimic repression of luciferase activity (Figure 4.19A)
that was reproducible in replicate experiments. Similar results were seen
with CDH11, a transcript with de novo AGO binding on a miR-335 seed
(log2 FC CLIP cluster=3,32, p-value=0.010) and whose 3’UTR is regulated
at the translational level by miR-335 mimic in luciferase reporter assays
(Figure 4.18B). Both SDAD1 and CDH11 were unchanged at the mRNA
level with miR-335/* mimic transfection when compared to mock control
(data not shown) indicating that a portion of the de novo miR-335/*
regulation identified by AGO HITS-CLIP may lead to translational
repression of targets rather than transcript degradation.

Comparison of AGO HITS-CLIP derived de novo clusters miR-335/* targets and
previously published targets
Literature search identified multiple reported miR-335 targets in a
variety of different cell types, including the LM2 335OE cells used in this
150

FIGURE 4.19: SDAD1 and CDH11 are regulated at the protein level by
miR-335* and miR-335. A: Left - Genomic location of the pre-miR-335
dependent de novo AGO-mRNA binding site in the SDAD1 3’UTR,
centered on a miR-335* seed site (2-7 match with G:U wobble in position
8). Right - Repression of luciferase reporter activity of WT full length
SDAD1 3’UTR dual luciferase reporter construct when transfected into
LM2 cells with 50nM miR-335* mimic, but not negative control mimic. B:
As in A for miR-335 target CDH11. The reduction in luciferase activity for
both 3’UTR constructs was observed in two independent experiments. All
transfections n=4, mRNA expression levels normalized to TBP. Error bars
= s.e.m, p-values calculated by t-test.
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study (Table 4.6 with associated references). Of the previously published
targets of miR-335, only DKK1 was identified by AGO HITS-CLIP as
having gain of binding in LM2 335OE, although the miR-335/* seed
sequence containing peaks identified here do not map to the nonconserved, non-canonical miR-335 seed site previously described (Zhang
et al., 2011). Two miR-335/* dependent, LM2 335OE enriched AGO
binding sites were identified in the 3’UTR of DKK1 by differential AGO
HITS-CLIP (Figure 4.20A (raw tags) and B (normalized)). Significantly, the
miR-335/* seed containing de novo binding events identified in LM2
335OE are also present in MDA-231 cells where miR-335/* is
endogenously expressed.

Surprisingly, Q-PCR analysis of DKK1 steady state transcript levels
revealed a strong decrease in 4175LM2 cells compared to MDA-231
parental cells that was not further decreased with the stable expression of
pre-miR-335 in LM2 335OE cells (Figure 4.21A). Additionally, DKK1
mRNA levels were unchanged by the addition of exogenous miR-335/*
mimics in 4175LM2 cells (Figures 4.21B& 4.21C). Similarly, full-length WT
DKK1 3’UTR luciferase reporter constructs were unaffected by exogenous
miR-335/* transfection in either MDA-231 or 4175LM2 cells (data not
shown). It remains to be tested whether relieving miR-335/* binding of
DKK1 by LNA inhibition of miR-335/* or target protection of the miR335/*-dependent AGO-mRNA binding sites leads to derepression of the
DKK1 transcript at either the mRNA or protein level in MDA-231 cells.
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TABLE 4.6: Previously published miR-335 target sites compared to LM2
335OE AGO HITS-CLIP.

Gene

Evidence of AGO binding in LM2 335OE

Reference

SOX4

None

(Tavazoie et al.,
2008)

PTPRN2

None

MERTK

None

U2OS

Rb

Weak, no differential binding

MLO-A5

DKK1

miR-335 site not conserved in human

Cell Line
MDA-231

(Scarola et al.,
2010)
(Zhang et al.,
2011)

Strong evidence of differential binding
elsewhere on transcript
hMSCs

RUNX2

None

(Tome et al., 2011)

Rat Kidney
Malignant
Astrocytoma
Human
neuroblastoma

SOD2

None, site not conserved

(Bai et al., 2011)

DAAM1

None

(Shu et al., 2011)

ROCK1

None

(Lynch et al.,
2012)

MAPK1

None

LRG1

None

mESCs

OCT4

None

Rb

Weak, no differential binding

Gastric Cancer

SP1

None

Bcl-w

None
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(Schoeftner et al.,
2012)
(Xu et al., 2012)

FIGURE 4.20: The DKK1 3’UTR shows evidence of two miR-335/*
dependent binding events. A: Two peaks of differential AGO binding in
the 3’UTR were detected by both differential cluster (1&2) and significant
peak analysis (1) between LM2 Control and LM2 335OE cells. Both miR335/* dependent peaks are evident in MDA-231 parental cells (red) that
endogenously express pri-miR-335. B: Normalized AGO binding peaks
(left) reveal strong depletion of binding in two regions of the DKK1 3’UTR
containing seed sequences for miR-335* and miR-335 respectively (right.)

154

FIGURE 4.21: Endogenous DKK1 transcript levels are strongly
repressed in LM2 cells compared to MDA-231 and show no further
repression by exogenous miR-335/*. A: Q-PCR analysis revealed a
significant decrease in the steady state levels of endogenous DKK1 in
4175LM2 cells compared to MDA-231 that was not further decreased in
LM2 335OE. B: Transient transfection of miR-335 mimic had no effect on
DKK1 levels in 4175LM2 cells. C: Transient transfection of miR-335* mimic
had no effect on DKK1 transcript levels compared to mock transfected
4175LM2 cells. N=3 for each condition, mock transfections carried out
with transfection reagent only, error bars = s.e.m, p-values calculated by ttest.
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Multiple potential seed matches are present in the 62nt footprint of
AGO on DKK1 in the region of significant peaks 1 and 2 (Figure 4.20B,
right panel), however the majority of seed-matched miRNAs are either not
present in the AGO-miRNA LM2 libraries, or are present at levels lower
that than miR-335 and miR-335*. In peak 2, no other miRNA with a seed
match is present at higher levels than miR-335, while peak 1 contains seed
matches to both miR-335* and the miR-374a/b family. miR-374a/b
represents 2.40% of the LM2 Control miRNA profile and 3.24% of LM2
335OE, however this increase was not found to be significant by EdgeR
analysis. Additionally, miR-374a/b is not significantly different between
the MDA-231 and 4175LM2 AGO-miRNA profiles. This strongly suggests
that the de novo binding identified by differential HITS-CLIP represents
direct miR-335/* mediated AGO binding in the 3’UTR of DKK1, however
the biological consequence of de novo miR-335/*-mediated AGO binding
in the DKK1 transcript is currently unknown.
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DISCUSSION
In an attempt to map on a genome-wide scale the targets of miR335, a potent inhibitor of breast cancer metastasis, we have applied
differential AGO HITS-CLIP to a previously characterized lung metastatic
derivative of MDA-231 breast cancer cells, 4175LM2, over-expressing
either a non-targeting control short hairpin or the pri-miR-335.
Overexpression of miR-335 in 4175LM2 cells significantly reduces the
invasive capability of these cells both in vitro and in vivo (Tavazoie et al.,
2008). Comparative analysis of the AGO-miRNA HITS-CLIP profiles of
LM2 335OE and LM2 Control indicates that pri-miR-335 overexpression
does not globally alter the miRNA repertoire covalently bound to AGO in
LM2 cells. Furthermore, despite over 100-fold increase in expression
levels, we have found that miR-335 and miR-335* remain relatively minor
components of the AGO-miRNA landscape.

In LM2 335OE, miR-335* represents 0.42% of the miRNA
population and is the 21st most sequenced miRNA, with those miRNAs
ranked above representing 92.9% of all AGO-miRNAs. This would
suggest that despite using a strong promoter, pri-miR-335 is not expressed
at supra-physiological levels, mitigating the effect of potential off-target
effects through AGO saturation (Khan et al., 2009). Several rare miRNAs
decrease in AGO-miRNA tag count in LM2 335OE indicating that some
displacement

of

endogenous

miRNA

may

occur

with

miR-335

overexpression. The relatively small shift in miR-335/* AGO-miRNA
representation with stable overexpression of pri-miR-335 is in sharp
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contrast to published data using transient transfection of miR-124 mimic
into HeLa cells. In that system miR-124 becomes the 3rd most frequently
cloned miRNA in transfected HeLa cells, a shift in the percentage of AGO
HITS-CLIP miRNA reads from 0.15% to 8.4%, with the top two miRNAs
comprising approximately ~32% of cloned AGO-miRNA (Chi et al., 2009).

The AGO-miRNA profile derived from LM2 335OE cells revealed
an unexpected bias towards binding to the star, and presumed passenger
strand of pre-miR-335. By convention mature miRNAs have been defined
as the duplex strand that accumulates at a higher steady-state level than
the partner strand, with bias observed towards strands with lower
internal stability at the 5’ end (Khvorova et al., 2003). Consistent with both
these observations miR-335* contains a 5nt stretch of A-T base pairs at its
5’ end compared to the more G-C rich 5’ end of miR-335, and is
consistently detected at ~2-3 fold higher levels in MDA-231 and all LM2
cells used in this study. Additionally, miR-335* is highly conserved,
particularly in the region spanning the seed sequence, a feature which
implies potential for regulatory function (Guo and Lu, 2010, Yang et al.,
2011).

Microarrays used in the initial discovery of the anti-metastatic
property of miR-335 did not contain probes for miR-335* as the sequence
was not added to miRBase until a later date. It is clear from in vivo
metastasis assays with LNA knockdown in MDA-231 cells, that miR-335
functions a mature targeting miRNA with anti-metastatic properties
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separate from any potential concurrent miR-335* regulation of targets
(Tavazoie et al., 2008). Both miR-335 and miR-335* have been shown to
have equally repressive effects against perfect-match antisense luciferase
reporter assays when simultaneously expressed from the pri-miRNA
(Yang et al., 2011). Similar dual regulation of targets has been described
for miR-199a-3p/-5p in the promotion of melanoma metastasis (Pencheva
et al., 2012), miR-126/* in inhibition of breast cancer metastasis through
modulation of the tumor microenvironment (Zhang et al., 2013), and miR24-2/* in suppression of cell survival in MCF-7 breast cancer cells (Martin
et al., 2012). Given the predominance of miR-335* de novo peaks identified
by differential AGO HITS-CLIP cluster analysis in LM2 335OE cells, it is
probable that miR-335* also regulates the metastatic ability of these cells.

13.4% of the pri-miR-335 dependent de novo AGO clusters identified
contain a miR-335 or miR-335* 6nt seed sequence corresponding to
position 1-8 located within the 62nt AGO footprint. This is lower than the
proportion of de novo miR-124 canonical 6mer seed-containing sites
detected in HeLa cells after mimic transfection (22.4% (Chi et al., 2009, Chi
et al., 2012)), and miR-155-dependent AGO binding sites identified by
differential AGO HITS-CLIP in WT and miR-155 knockout activated
CD4+ T cells, (~57% (Loeb et al., 2012)). Positive correlation between the
fraction of the AGO HITS-CLIP derived miRNA profile and the number of
seed containing mRNA binding sites has been reported in multiple
settings, including mouse brain, embryonic stem cells and CD4+ T cells,
C.elegans and several cell lines (Chi et al., 2009, Hafner et al., 2010, Leung
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et al., 2011, Loeb et al., 2012, Zisoulis et al., 2010). miR-155 and exogenous
miR-124 mimic each represent a major component of the AGO-miRNA
profile in their respective data sets, accounting for the high signal to noise
in identification of directly targeted de novo binding sites.

The total number of miR-335/* targets identified by AGO HITSCLIP in LM2 335OE, including the potential non-canonical bulged and
G:U wobbles, is less than that reported for the most abundant miRNAs in
previous AGO HITS-CLIP experiments (>300 miR-155 (Loeb et al., 2012),
691 miR-126 (Chi et al., 2009, Chi et al., 2012)). However, the number of
miR-335/*-dependent seed containing AGO binding sites are similar in
magnitude to the number of targets identified for less abundant miRNAs
in mouse embryonic stem cells (Leung et al., 2011). The relatively minor
combined contribution that AGO-miR-335/* make to the overall LM2
335OE miRNA profile is reflected in the low total tag numbers in AGO
clusters

delimiting

functional

binding

sites.

This

represents

an

unanticipated limitation of the AGO HITS-CLIP technique in identifying
statistically significant and robust miR-335/* mediated binding sites this
cellular context.

Despite low signal to noise, we have used differential AGO HITSCLIP to successfully identify several previously unknown, direct targets
of miR-335/* regulation. De novo cluster analysis identified CETN3 as a
direct target of miR-335*, an interaction that was found to decrease both
the mRNA levels of endogenous CETN3 and protein levels of reporter
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constructs in miR-335* seed-dependent manner. Human CETN3 has
described roles in centrosome duplication, nucleotide excision repair via
putative interactions with xeroderma pigmentosum group C (XPC), and
in the connecting cilium of photoreceptor cells (Cox et al., 2005, Dantas et
al., 2011, Middendorp et al., 1997, Trojan et al., 2008). Human CETN3 is
closely related to the Saccharomyces cerevisiae Cdc31 protein, which along
with roles in cell cycle control and spindle body duplication (Paoletti et
al., 2003, Schild et al., 1981), has been implicated in both protein
degradation (Chen and Madura, 2008) and maintenance of genome
integrity as part of the THP1-SAC3- SUS1-CDC31 complex coupling
transcription and mRNA export (Gonzalez-Aguilera et al., 2008, Jani et al.,
2009).

While the previously described cellular functions of human CETN3
do not mirror those of miR-335/* loss in metastasis (altered morphology
and increased invasive capacity (Tavazoie et al., 2008)), other miR-335/*
targets identified and verified in this study have been implicated in the
regulation of breast morphology or enhanced invasiveness of tumor cells.
For example, TWSG1, a secreted protein that functions as a BMP4 agonist
in Drosophila and vertebrate embryos (Scott et al., 2001), is required for
normal mammary gland ductal elongation and lumen formation (Forsman
et al., 2013). Additionally, CDH11 (OB cadherin), a mesodermally
expressed member of the cadherin superfamily (Hoffmann and Balling,
1995), is expressed in invasive breast cancer and positively regulates cell
migration (Li et al., 2011c, Pishvaian et al., 1999, Sarrio et al., 2008).
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We did not direct AGO-mRNA binding in the seed regions of any
previously published miR-335 targets. SOX4, a previously validated miR335 target in MDA-231 cells (Tavazoie et al., 2008), was not bound by
AGO in any of the cell lines assayed by AGO HITS-CLIP in this study. The
previously published miR-335 targeting of SOX4 was validated using dual
luciferase reporter constructs encoding a 60nt region of the SOX4 3’UTR
spanning

a

region

of

complementarity

to

miR-335

(TCTTGG,

corresponding to a position 2-6 seed match with G-U wobble at position
1). Given the lack of biochemical evidence of AGO binding in the SOX4
3’UTR, the miR-335-dependent regulation of luciferase activity reported
may reflect off-target effects rather than endogenous regulation in the
context of the full length 3’UTR. Similar off target effects were seen with
3’UTR reporter assays using FAM105B, where both miR-335 and miR-335*
mimics were able to repress luciferase activity due to the presence of seed
matches in the 3’UTR, despite only miR-335* seed containing regions
showing differential AGO binding in LM2 335OE. However, it is noted
that lack of binding at the SOX4 3’UTR seen in AGO HITS-CLIP may also
result from binding occurring below the threshold of detection of HITSCLIP for a minor miRNA, and that the lack of binding at other previously
validated miR-335 target sites may also reflect false negatives.

The apparent lack of miR-335 or miR-335* mediated regulation of
DKK1 is difficult to reconcile with the robust, pre-miR-335 dependent
binding seen on the DKK1 3’UTR. No other miRNAs with canonical seed
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matches in the 62nt AGO footprint are expressed at higher levels than
miR-335/*in either MDA-231, LM2 Control or LM2 335OE cells nor do
they show significant differences in AGO-miRNA counts that correlate
with the gain and loss of AGO-mRNA binding observed between cell
lines. The regulation by miR-335/* may be below the threshold of
detection by the assays used in this study, or the 3’UTR of DKK1 may
potentially function as a neutral target with respect to miR-335/*
regulation. AGO binding to the DKK1 3’UTR may sequestering miR-335/*
in MDA-231 and LM2 335OE allowing it to function as a competitive
endogenous RNA by (Salmena et al., 2011, Seitz, 2009). Interestingly,
competitive,

DICER-dependent

antagonistic

regulation

has

been

documented between the DKK1 and PTEN 3’UTRs in diabetic
cardiomyocytes through sequestration of miR-93 and miR-106a (Ling et
al., 2013).

The ability of endogenous non-coding transcripts and coding
mRNA 3’UTRs to influence tumorigenesis, presumably through titration
of miRNAs or other regulatory RNA binding proteins, is being
increasingly recognized. miRNA-mediated regulation of the tumor
suppressor PTEN can be modulated by the expression of the pseudogene
PTENP1 (Poliseno et al., 2010) or concomitant expression protein-coding
transcripts targeted by common miRNAs in a DICER dependent manner
(Tay et al., 2011). Similarly the 3’UTRs of versican (Fang et al., 2013a),
prohibitin (Manjeshwar et al., 2003), &-tropomyosin (Rastinejad et al.,
1993) and CD44 (Rutnam and Yang, 2012) have been shown to regulate
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tumorigenesis and metastasis in various cancer types, separating the
regulatory function of non-coding regions of transcripts from any proteinmediated effect.

Loeb et al. (2012) have suggested that the relatively few highly
bound targets of miR-155 identified by AGO HITS-CLIP would argue
against the endogenous miRNA sponge hypothesis, as very few
transcripts appear to bind the miRNA-AGO complex at high enough
levels to lead to sequestration. However, given that the threshold of
regulation by miRNAs has been shown to be determined by both the level
of target and miRNA (Mukherji et al., 2011), regulation by a low
abundance miRNA such as miR-335/* may be more sensitive to
endogenous sponges. The decrease in the steady state levels of DKK1
mRNA in lung metastatic derivatives occurs concomitantly with copy
number loss in the miR-335 locus, increased MEST promoter methylation
in LM2 cells and increased invasive capacity (Png et al., 2011). If DKK1
3’UTR functions as a sponge for miR-335/*, overexpression of this region
of the DKK1 transcript should enhance the invasive capacity of both
MDA-231 and LM2 335OE through sequestration of miR-335/* away from
its endogenous targets, while mutant constructs with disrupted seed sites
should have no effect on invasion.

An increasing body of work implicates altered miR-335 expression
in multiple tumor types, with low miR-335 levels detected in breast,
ovarian, neuroblastoma, and gastric cancer (Png et al., 2011, Polytarchou
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et al., 2012, Sorrentino et al., 2008, Tavazoie et al., 2008, Lynch et al., 2012,
Xu et al., 2012), and miR-335 up regulation reported in malignant
astrocytoma and meningioma (Shi et al., 2012, Shu et al., 2011). While
experimental validation of the role of miR-335* in in vivo metastasis is
currently on going, our discovery that miR-335* can function as a guide
strand opens up new directions in the search for regulated downstream
transcripts and for potential for therapeutic intervention in multiple
cancer settings. The data we have presented provides a first look at the
network of transcripts regulated by both miR-335 and miR-335* in breast
cancer, and provides direct biochemical evidence of multiple new targets
with as yet unknown functions in breast cancer metastasis.
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CHAPTER 5: CHARACTERIZATION OF RBM47, AN RNA-BINDING
SUPPRESSOR OF BREAST CANCER METASTASIS

INTRODUCTION
High-throughput crosslinked immunoprecipitation (HITS-CLIP)
was initially developed to identify in vivo directly bound targets of the
neuron-specific alternative splicing regulator Nova (Ule et al., 2003, Ule et
al., 2005b, Licatalosi et al., 2008). Since UV-irradiation leads to covalent
bond formation only between proteins and RNA that are in direct contact
(within Angstroms (Darnell, 2010)), the resulting sequence data can be
used to determine both the target RNAs bound by an RNA binding
protein (RBP) and the specific region within the transcript that is bound.
Furthermore, HITS-CLIP data can be used to validate the sequence
specificity of the protein in question with single-nucleotide resolution
(Hafner et al., 2010, Zhang and Darnell, 2011). The HITS-CLIP technique
has now been applied to multiple RBPs, particularly those involved in
neurological diseases, to identify both bona fide disease-related sets of
RNA targets and to elucidate normal biological functions.

The genome-wide nature of the data derived from HITS-CLIP has
lead to discovery of new regulatory functions for previously wellcharacterized proteins indicating that the technique can also be use
prospectively. For example, Nova HITS-CLIP has greatly expanded the
repertoire of Nova-regulated alternative splicing events to >600 (Zhang et
al., 2010a), and lead to the identification of a previously unknown role for
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Nova in the regulation of alternative polyadenylation (Licatalosi et al.,
2008) and steady-state target expression levels through direct regulation of
NMD exons (Eom et al., 2013). Additionally, CLIP has revealed
unexpected roles in miRNA maturation for hnRNP-A1. This extensively
studied RNA splicing regulatory protein was found to directly bind the
stem-loop sequences in pri-miR-18a to facilitate Drosha-mediated
processing (Guil and Caceres, 2007, Michlewski et al., 2010)

In this study, we propose using HITS-CLIP to identify the targets
and elucidate the biological function of a previously uncharacterized,
presumed RNA binding protein with direct links to breast cancer
metastasis. RNA binding motif protein 47 (RBM47) is so named due to the
predicted presence of three RNA recognition motifs (RRM domains). The
combination of one or more RRM domains allows for recognition of single
stranded RNA sequences of 8-10 nucleotides, although RRM domains also
been demonstrated to mediate protein-protein interactions (Maris et al.,
2005). The previously mentioned ELAVL proteins all contain three RRM
domains. Increased expression of the ubiquitously expressed ELAVL
family member ELAVL1 (HuR) has been shown to promote a more
tumorigenic phenotype in xenograft models of breast cancer (MazanMamczarz et al., 2008a), and has been associated with poor prognosis in
multiple cancers, including invasive ductal breast carcinoma (Denkert et
al., 2004, Heinonen et al., 2005).
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RBM47 was first identified by Ding et al, 2010 as a gene of interest
in the metastatic progression of breast cancer. Deep sequencing of
genomic DNA derived from a patient’s primary basal-like aggressive
tumor and subsequent cerebellar metastases revealed a point mutation in
the coding sequence of RBM47 that was highly enriched in brain
metastases (79.15% mutant allele frequency, FDR=0.03). This point
mutation leads to a G-deletion at nucleotide position 1280, a frame shift
and the introduction of a premature stop codon (Ding et al., 2010)
suggesting that loss of wild type function of RBM47 (or gain of function in
the mutant allele) was selected for during metastasis to the brain.
Additionally, RBM47 expression levels have been shown to decrease over
ten-fold during the epithelial-mesenchymal transition (EMT) of human
mammary epithelial cells expressing a tamoxifen-inducible Twist-ER
fusion protein (Shapiro et al., 2011).

RBM47 is currently an uncharacterized protein; therefore we
propose using HITS-CLIP to determine its RNA binding abilities.
Furthermore, by mapping robust RBM47 interactions on target RNAs we
aim to identify both the functional of RBM47 in RNA metabolism and to
identify targets through which RBM47 mediates its proposed antimetastatic functions.
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RESULTS
RBM47 expression is decreased in the metastatic derivatives of MDA-231
Re-analysis of published microarray data from MDA-231 and its
metastatic derivatives with tissue-specific metastasis to lung (4175LM2),
bone (1833BoM2) and brain (831BrM2) revealed down regulation of
RBM47 in all metastatic sub lines (data not shown) (Bos et al., 2009, Kang
et al., 2003, Minn et al., 2005a). In particular, RBM47 expression is
dramatically decreased in 831BrM2 (Figure 5.1A), with corresponding
decrease in protein expression as assayed by Western blot (Figure 5.1B).
RBM47 protein levels were also lower in lung and bone metastatic
derivatives when compared to the parental MDA-231 cell lines suggesting
that downregulation of RBM47 is a common feature associated with
increased metastatic potential. Data analysis and Western carried out by
Sakari Vanharanta, Joan Massagué laboratory, MSKCC.

Wild-type RBM47 functions as a metastasis suppressor
Doxycycline-inducible 831BrM2 triple reporter stable cell lines were
generated that express either wild type FLAG-tagged RBM47 (Tet-On
Flag-RBM47 WT) or a mutant RBM47 harboring the same frame shift
mutation identified by Ding et al., 2010 (Tet-On Flag-RBM47 MUT). Mice
were injected in the left ventricle with of 50,000 Tet-On Flag-RBM47 WT or
MUT cells, and fed a diet containing doxycycline (dox) starting three days
after injection. Metastatic spread to the brain was assayed by ex vivo
photon flux six weeks post injection. In control animals that were injected
with Tet-On Flag-RBM47 WT cells but did not receive dox in food, a high
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FIGURE 5.1: RBM47 expression is decreased in the highly metastatic
derivatives the breast cancer cell line MDA-MB-231. A: Q-PCR showing
decreased RBM47 transcript levels in 831BrM2 cells compared to MDA231. Expression level normalized to TATA box binding protein (TBP). n=3,
error bars = s.e.m, p-values calculated by t-test. B: Western-blotting
reveals decreased RBM47 protein levels in the highly metastatic
derivatives of MDA-MB-231 with tissue specificity towards the lung
(4175LM2), bone (1833BoM1) and brain (831BrM2). Loading control
tubulin. Western blot by Sakari Vanharanta, Joan Massagué laboratory,
MSKCC.
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degree of brain metastasis was evident that was suppressed by doxinduced expression of WT RBM47 (Figure 5.2A and 5.2B). Expression of
Mutant RBM47 had no effect on the metastatic potential of 831BrM2 cells
(Figure 5.2B). RBM47 expression levels were found also to be clinically
associated with human metastasis, with patients whose primary tumors
expressed low levels of RBM47 having significantly shorter time to distal
metastatic relapse to both brain (p=0.0025) and lung (p=0.0023, Figure
5.2C). All experiments and data analysis carried out by Sakari Vanharanta,
Joan Massagué laboratory, MSKCC.

Domain architecture of RBM47
The RBM47 gene is located on the negative strand of chromosome 4
at position 40,120,029-40,326,640. Refseq indicates two alternatively
spliced transcripts that are translated into 593 and 524 amino acid proteins
respectively (Figure 5.3A). Conserved domain analysis shows the
presence of three RNA recognition motif (RRM) domains in both RBM47
isoforms, with a variable region occurring between amino acids 374 and
414, C-terminal to the RNA binding motifs that corresponds to the
alternatively spliced exon. RRM1 and RRM2 contain RNP-1 consensus
motifs (RGYSFVMY and RGFAFVEY respectively) while RRM3 contains
an RNP-2 consensus motif (LYVRNL). The mutant RBM47 identified in
patient cerebellar metastases produces a truncated protein containing only
RRM1 and 33 amino acids of RRM2 (Figure 5.3B).
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FIGURE 5.2: RBM47 functions as a metastasis suppressor in vivo, with
low expression clinically associated with poor metastasis-free survival.
A: Mice were injected with clonal populations if BrM2 cells stably
expressing either WT or mutant RBM47 then fed a diet plus/minus
doxycycline to induce transgene expression. At 6 weeks post injection,
brains were imaged ex vivo to assess level of metastasis (photon flux). B:
Dox-induced expression of WT RBM47 in 831BrM2 inhibits metastatic
colonization of the brain in vivo when compared to non-dox treated
animals (6 weeks post intercardiac injection). Expression of Mutant
RBM47 has no effect on the metastasis (n=8). Kaplan-Meier curves for the
combined Memorial Sloan Kettering and Erasmus Medical Center breast
tumor cohorts (368 tumors) showing brain (C) and lung (D) metastasis
free survival of patients whose primary tumors expressed low levels of
RBM47. All experiments carried out by Sakari Vanharanta, Joan Massagué
laboratory, MSKCC.
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FIGURE 5.3: RBM47 gene and protein domain organization. A: The
RBM47 gene encodes two RefSeq annotated isoforms with alternative
5’UTRs and one alternative coding exon. The longer isoform of RBM47
was used for all subsequent analyses of RBM47 function. B: Conserved
domain analysis reveals the presence of three RRM domains (black) in
both long and short isoforms of RBM47, with a variable region (white)
corresponding to the alternative exon. Mutant RBM47 produces a
truncated protein due to a G deletion at position 1280 and subsequent
frame shift that introduces a premature stop codon in RRM2.
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Protein BLAST of RBM47 reveals sequence similarities to the known RNAbinding proteins
Protein BLAST of RBM47 reveals high sequence identity and
similarity with both apobec-1 complementation factor (A1CF, 58.5% and
72.65%, respectively) and hnRNP-Q/SYNCRIP (55.3% and 73%), proteins
that also contain three RRM domains. Identity and similarity were
calculated using the EBOSS6.3.1 matcher (Rice et al., 2000). RBM47
alignments with A1CF and hnRNP-Q (generated by ClustalW2 (Goujon et
al., 2010)) are shown in Figures 5.4. High sequence identity is evident in
the N-terminal regions spanning the RRM domains (red dashed line), with
more sequence divergence at the C-terminal ends.

Both A1CF and

hnRNP-Q have been shown to directly bind RNA and to regulate RNA
editing (Mehta et al., 2000, Blanc et al., 2001). Additionally, hnRNP-Q has
multiple functions in RNA metabolism including RNA localization,
splicing and stability (Bannai et al., 2004) (Chen et al., 2008)
(Weidensdorfer et al., 2009). Together this would strongly suggest that the
RRM domains in RBM47 are capable of binding RNA.

RBM47 is an RNA binding protein
RBM47 has been identified as a component of the protein-mRNA
interactome in two independent studies of oligo(dT) affinity purified
mRNA-RBP complexes in HeLa and HEK293 cells (Baltz et al., 2012,
Castello et al., 2012) although direct RNA binding activity has not been
confirmed. To test whether RBM47 can directly bind RNA, we made use
if the ability of UV-irradiation at 254nm to induce chemical crosslinks
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FIGURE 5.4: Protein alignment of RBM47 with A1CF and hnRNP-Q. A:
RBM47 is most similar in amino acid sequence to apobec1
complementation factor (A1CF). High sequence conservation can be seen
in the N-terminal regions, particularly those spanning the three RRM
domains (red dashed line), with more sequences divergence evident in the
C-terminal domain. B: Alignment of RBM47 to hnRNP-Q shows less
similarity overall, with the highest degree of sequence conservation in the
RRM domains. Alignments carried out using ClustalW2 (Goujon et al.,
2010), * fully conserved residue, : conservation across groups with
strongly similar properties, . conservation across groups with weakly
similar properties.
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between RNA and proteins that are in direct contact (on the order of
Angstroms apart (Darnell, 2010)).

Commercially available RBM47

antibodies were unsuitable for immunoprecipitation due cross-reaction
with multiple proteins, therefore 831BrM2 Tet-On empty vector control
and 831BrM2 Tet-On Flag-RBM47 WT stable cells lines (generated by
Sakari Vanharanta in the Massagué laboratory and henceforth referred to
as Tet-On and RBM47-WT) were grown for 3 days in the presence of
1ng/ml doxycycline before UV-irradiation and

harvesting. Non-

crosslinked RBM47-WT cells grown in the same manner were used as a
negative control. Lysed cells were RNaseA digested to reduce the modal
size of any bound RNA to that of the footprint protected by protein
binding, and stringently immunoprecipitated using an anti-Flag antibody.
Bound RNA was end-labeled with "-32P-ATP using T4 PNK, protein
separated by SDS-PAGE and complexes transferred to nitrocellulose.

Exposing the nitrocellulose to x-ray film (Figure 5.5A) revealed
radioactive signal at the predicted size of RBM47 only lanes
corresponding to dox-treated, UV-irradiated RBM47-WT cells. The lanes
for non-irradiated RBM47-WT and the UV- treated Tet-On Control cells
were

clear

of

radioactivity

indicating

UV-dependent

RNA

immunoprecipitation and lack of non-specific antibody pull down.
Western blotting of the nitrocellulose membrane with a second Flag
antibody (Figure 5.5B) showed no signal in the Tet-On control lanes
indicating the specificity of the Flag antibody, and strong, equal intensity
protein signal at the predicted size of RBM47 in both lanes corresponding
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FIGURE 5.5: RBM47 is an RNA binding protein. A: 831BrM2 cells stably
expressing tet-inducible WT Flag-RBM47 (RBM47-WT) or empty vector
(Tet-On) were UV-irradiated before lysis and stringent anti-FLAG IP.
Bound RNA was end-labeled with !-32P-ATP and IPed protein size
separated via SDS-PAGE. Transfer to nitrocellulose and subsequent
exposure to x-ray film revealed the presence of radioactively labeled RNA
only in those lanes corresponding to WT-RBM47 crosslinked cells,
indicating that RNA pull down was both UV and FLAG epitope
dependent. B: Western blotting of the same nitrocellulose membrane
reveals the presence of FLAG-RBM47 protein in both cross-linked and
non-crosslinked lanes at the same molecular weight as the radioactive
RNA.
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to dox-treated RBM47-WT. A second flag-reactive band is seen at a lower
molecular weight and is presumed to be a degradation or cleavage
product of the full length RBM47-WT. This experiment indicates the
presence of RNA in physiologically relevant contact with RBM47 in vivo,
and confirms RBM47 as an RNA binding protein.

Mapping direct RBM47-RNA interactions using a modified HITS-CLIP protocol
To identify direct RBM47 targets in 831BrM2 cells, a modified
version of the HITS-CLIP protocol was employed that was developed by
Aldo Mele in the Darnell laboratory (Figure 5.6). This protocol combines
polyA tailing and a specially designed RT-PCR primer that reduces the
number of linker ligation reactions while also utilizing cDNA
circularization to capture fragments that may prematurely truncate during
RT at the crosslink site (Konig et al., 2010). Both of these enhancements
can theoretically increase the complexity of the sequenced HITS-CLIP
libraries by reducing linker-ligation bias (Jayaprakash et al., 2011),
removing inefficient ligation steps, and by capturing fragments that
would normally not be PCR amplified due to lack of 5’ complementary
sequences.

Duplicate dishes of RBM47-WT and Tet-On Control cells were
grown in the presence of 1ng/ml dox for 3 days before UV-crosslinking
and harvesting for HITS-CLIP. A triplicate dish was harvested without
crosslinking for RNAseq analysis. The Flag-RBM47 HITS-CLIP protocol
differs slightly from the previously used AGO HITS-CLIP protocol in that
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anti-Flag antibody was used for IP, and 3’ linker ligation was omitted in
favor of CIP treatment and 5’ end labeling with "-32P-ATP (Figure 5.6A).
As seen in Figure 5.5A, the autoradiogram shows no radioactive signal in
both the Tet-On control and the non-crosslinked RBM47-WT control lanes
while high levels of RNAseA treatment in crosslinked RBM47-WT cells
reveals a sharp radioactive RNA band at the predicted size of RBM47.
Reducing the concentration of RNAseA added pre-IP to crosslinked
RBM47-WT lysates lead to a smear of radioactivity rising above the
predicted weight of RBM47, corresponding to RNA-protein complexes of
increasing RNA modal size. The red boxes indicate the region of the
nitrocellulose that was excised (~30kD, equivalent to ~100nt RNA),
proteinaseK treated, and from which the two RBM47-bound CLIP libraries
were independently prepared.

In order to clone the RBM47-bound RNA library and prepare it for
Illumina high throughput sequencing (Figure 5.6B), the isolated RNA
fragments (green bar) were first polyA tailed then reverse transcribed
using a primer with several important features. At the 5’ end of the RT
primer are two hexamers (purple bar); the first is a known-sequence 6-mer
index used for identification of multiplexed samples, the second is a
degenerate 6-mer barcode used to distinguish unique cDNA clones from
PCR duplicates. Downstream from the index and barcode is a 21nt partial
reverse complement to the Illumina forward sequencing primer (orange
bar), an abasic furan that serves as an ApeI cut site (x), and the full sense
sequence of the Illumina reverse sequencing primer (blue bar).
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FIGURE 5.6: Outline of the modified HITS-CLIP protocol used with
RBM47. A: 831BrM2 Flag-RBM47 WT and Tet-On control cells were
treated with 1ng/ml doxycycline for 3 days before UV irradiation to
induce covalent bonds between direct RNA-protein interactions. After cell
lysis and partial RNaseA digestion, RBM47-protein complexes were
stringently purified by IP with an anti-Flag antibody followed by CIP
treatment and radioactive labeling with 5’ "32P-ATP. Complexes were
separated by SDS-PAGE and transferred to nitrocellulose. Exposure of the
nitrocellulose membrane to x-ray film revealed the presence of radioactive
RNA in only those lanes with both Flag-RBM47 expression and UVcrosslinking. Treatment with high RNaseA (+++) reduced the radioactive
signal to a sharp band at the anticipated molecular weight of Flag-RBM47.
Low RNaseA treatment (+) of WT-RBM47 crosslinked cells leads to a
smear of radiation above RBM47 indicating the presence of RBM47-RNA
complexes of increasing RNA length. Small sections of nitrocellulose were
excised from two independent replicate experiments as indicated by red
boxes, and RBM47 bound RNA purified from the membrane by proteinase
K digestion. B: Purified RBM47 CLIP tags were polyA tailed then reverse
transcribed in the presence of BrdU, using a polydT-NV primer containing
Solexa primer sequences (forward – orange, reverse – blue) separated by
an abasic furan (), with a short 6nt degenerate region plus a 6nt index
sequence (purple). The resulting BrdU-cDNA was stringently purified by
IP, circularized and digested with ApeI to re-linearize the cDNA fragment
with Solexa sequences now flanking the original cloned RBM47-bound
fragment. These cDNAs were then PCR amplified, multiplexed and highthroughput sequenced.
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This is then followed by a stretch of T20 plus a 3’ VN to allow for
anchoring of the RT primer at the 5’ end of the polyA tail partially
overlapping into the purified RNA fragment. RT-PCR was carried out in
the presence of Brd-U (red *) to allow for stringent purification of the
resulting cDNA (red bar) from the RT reaction by anti-Brd-U IP.

While still on-bead, CircLigase was used to catalyze intramolecular
ligation, bringing the sequences needed for Illumina sequencing into the
correct orientation with respect to the cloned fragment, so that upon ApeI
linearization and Brd-U elution cDNA fragments are ready for PCR
amplification and deep sequencing. Unpublished data from our
laboratory has shown that more complex CLIP libraries can be generated
from samples with low total PCR amplification, therefore having a single
PCR step before Illumina sequencing in this modified protocol further
enhances the complexity if the final data set.

Summary of RBM47 HITS-CLIP data
The processing and bioinformatic manipulation of the data
obtained from RBM47-WT HITS-CLIP are summarized in Figure 5.7A.
Briefly, sequencing of the two pooled RBM47-WT HITS-CLIP libraries
gave a total of ~38.9 million reads. Reads were filtered based on quality
score, exact duplicates collapsed, and adapter sequences and 3’ polyA
stretches trimmed. Alignment to the human genome (hg18) left
~14.0million reads mapping to single locations. Splitting the data by index
assigned ~4.4million reads to replicate A and ~9.6million reads to
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FIGURE 5.7: Summary of RBM47 HITS-CLIP sequencing data and
reproducibility. A: Multiplexed sequences were filtered based on quality
score and exact sequence duplicates collapsed. Adapter sequences were
trimmed from both 5’ and 3’ ends, and A nucleotides trimmed from the 3’
end. Sequences originating from each replicate library were separated
using the 6nt index and reads aligned to hg18. Collapsing sequences based
on degenerate linker and genomic position generated ~1.5million unique
RBM47 tags for replicate A, and ~4.3 million for replicate B. B: Unique
tags from each replicate were pooled together to define regions of
reproducible RBM47 binding (BC2≥2 tags). Plotting the number of tags
each replicate contributes to a cluster reveals an extremely high degree of
correlation, indicating a high degree of reproducibility between data sets.
This correlation remains when increasing the stringency of cluster
definition to BC2≥10 tags.
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replicate B. Sequences were further collapsed based on degenerate linker
sequence and genomic start site to remove PCR duplicates, leaving
~2.14million Replicate A and ~7.98million Replicate B unique reads,
referred to as RBM47 tags.

Reproducibility of RBM47 HITS-CLIP data sets
To identify reproducible sites of RBM47-RNA binding, all RBM47
tags were clustered together to return binding sites with greater than or
equal to 3nt overlap between tags, and the minimal presence of one tag
from each replicate library (biological complexity=2 and tags≥2 or
BC2≥2tags, minimal definition of a cluster). 635,499 BC2≥2tags clusters
were identified on 10,547 genes (55% of annotated genes). Replicate
experiments were found be highly reproducible with strong correlation
between the number of tags per BC2≥2tags cluster from each experiment.
This strong correlation between replicate libraries remained constant
when cluster definition stringency was increased to BC2≥10tags (both
R2=0.99, Figure 5.7B).

Genomic distribution of RBM47 binding
While requiring reproducibility between replicates at any given
binding site reduces the potential for background noise in CLIP data sets,
multiple additional measures are routinely applied to increase stringency
of cluster definition. These include increasing the number of overlapping
tags (BC2≥10tags, 98,298 RBM47 clusters) or applying the previously
described significant peak threshold (statistically significant observed
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binding above that expected by random distribution of CLIP tags on a
transcript; BC2 sigpeak≥10tags, 30,277 peaks). Another measure of
robustness can be calculated by chi-squared analysis of tags per cluster
per experiment (detailed in (Darnell et al., 2011)) then applying an
empirical threshold on the returned p-value (BC2 '2 p≤0.01). For RBM47
HITS-CLIP the minimal tag number per cluster that passes this threshold
was 26, leaving 19,908 clusters. All resulting clusters were annotated and
the percentage of clusters per genomic location represented in a pie chart
(Figure 5.8A). The same increasing stringency filtering criteria were
applied to the previously described 831BrM2 AGO-mRNA HITS-CLIP
clusters for comparison (Figure 5.8B).

Annotation of BC2≥2tags clusters revealed predominant RBM47
binding in intronic regions (53%) followed by deep intergenic sequences
(21%). Binding to deep intergenic regions is considered to be a
combination of both real, unannotated transcribed targets and noise, since
many of the clusters result from mapping errors to low complexity
sequences and repeat elements. Given the uncertain nature of deep
intergenic binding events they were omitted from further analysis. The
remainder of BC2≥2tags clusters segregate almost equally into 3’UTR
(9%), the 10kb sequence immediately downstream of annotated 3’UTR
ends (presumed to be unannotated alternative 3’UTRs, 8%), and coding
sequence (7%). Only 2% of BC2≥2tags clusters map to 5’UTR regions
(Figure 8A). A similar distribution of binding is seen for AGO in 831BrM2
cells at this low stringency cluster threshold, BC≥2 tag≥2. Increasing the
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FIGURE 5.8: Genomic distribution of RBM47 clusters defined with
increasing stringency indicates robust and reproducible binding
predominantly in 3’UTR regions. A: Unique RBM47 tags from each
replicate were clustered requiring a minimum of 3nt overlap between
adjacent tags, then filtered with increasingly stringent criteria to reveal the
most robust binding locations within the genome. At the highest level of
stringency (Chi squared test of robustness), the majority of RBM47
binding is found in 3’UTR regions plus the 10kb region immediately
downstream of annotated polyA sites (DS 10kb). B: Filtering of the AgomRNA HITS-CLIP data set from 831BrM2 cells shows a similar shift in
distribution of binding from predominantly intronic to 3’UTR with
increasing stringency of cluster definition. The number of clusters retained
with each definition is shown below the pie chart.
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stringency of cluster definition for both RBM47 and AGO HITS-CLIP
clusters lead to a decrease in the percentage of tags mapping to introns
and deep intergenic regions, retention of coding sequence clusters and
enrichment for 3’UTR binding. A similar trend towards enrichment in
3’UTR binding through selective loss of intronic binding has been
reported for the distribution of neuronal Elavl HITS-CLIP clusters with
increasingly stringent biological complexity requirements (Ince-Dunn et
al., 2012).

Motif enrichment in RBM47 Binding sites
Robust HITS-CLIP binding sites have consistently been found to be
enriched in validated binding motifs of the RNA binding protein
interrogated. For example, the YCAY binding motif, which is necessary
and sufficient to confer Nova-dependent regulation on alternatively
spliced transcripts (Dredge and Darnell, 2003, Dredge et al., 2005, Jensen
et al., 2000) is highly enriched in Nova HITS-CLIP clusters (Licatalosi et
al., 2008). Furthermore, binding motifs can be identified at single
nucleotide resolution through analysis of crosslink-induced mutations
(CIMS) in HITS-CLIP data, with reproducible deletions in robustly bound
sites defining the crosslinked nucleotide for multiple RNA binding
proteins (Zhang and Darnell, 2011).

To identify the RBM47 binding motif from HITS-CLIP, word
enrichment was assessed in robust RBM47-binding sites. Sequences
corresponding to the entire footprint of BC2≥10tags clusters, the 50nt
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region centered on significant peaks (BC2 sigpeak≥10tags), and the 20nt
region centered on RBM47-deletion CIMS (FDR≤0.01 and ≥5 deletion
harboring tags, 537) were used for motif analysis. For each subset of
RBM47 binding sites a matching set of randomly generated background
sequences were generated with the same base composition and nucleotide
length. MEME analysis (Bailey and Elkan, 1994) was carried out using the
smaller CIMS data set.

Motif enrichment for each increasingly stringent subset of RBM47
binding sites consistently returned U10 as the most enriched 10mer (Figure
5.9A-C).

Additionally, this sequence was the most enriched motif

identified by MEME analysis of robust CIMS sites (Figure 5.9D). Analysis
of nucleotide bias around the CIMS site revealed an average base
composition of 27.5% A, 18.6% C, 19.9% G and 33.9% U, with 51.8% of all
CIMS occurring at a U residue (Figure 5.9E). Together this would strongly
suggest that RBM47 preferentially binds predominantly U-stretches or
AU-rich sequences (AREs) in target RNA.

RBM47 re-expression in 831BrM2 cells leads to steady state levels changes of
RBM47-bound transcripts
To gain insight into the potential functional role of RBM47 RNA
binding, transcript level changes associated with RBM47 re-expression in
831BrM2 cells were assessed. RNAseq libraries were prepared from one
dish each of Tet-On and RBM47-WT cells treated with 1ng/ml dox for
three days prepared at the same time as those used for HITS-CLIP.
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FIGURE 5.9: Motif enrichment in RBM47 binding sites with increased
stringency of binding site definition. Word enrichment in sequences
corresponding to all BC2≥10tags clusters (A), a 50nt footprint centered on
significant peaks BC2≥10tags (B), or in a 20nt footprint centered on
crosslink-induced deletions (CIMS FDR≤0.001 m≥5, C). All RBM47-bound
sequences were compared to randomly generated sequences of equal
number, length and base composition. D: MEME analysis of the 20nt
CIMS footprint revealed significant enrichment for a polyT motif (63/537
sites p=3.0e-19). E: Sequence composition anchored at RBM47 CIMS reveals
AU-rich sequence with the crosslink site most frequently mapped to
uridine.
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~169million 100nt paired-end RNAseq reads were mapped to the human
genome (hg18), ~51million from the Tet-On control cells and ~118million
from RBM47-WT cells. Fold change and associated p-value for each
transcript was calculated based on a binomial distribution of reads per
transcripts, and an FDR calculated using the Benjamini-Hochberg
correction for multiple hypothesis testing. Transcripts were considered
“expressed” given a minimum of two RNAseq reads per transcript in both
experimental conditions (16,466 genes with ≥2 RNAseq reads per
transcript).

Plotting read count per expressed gene from Tet-On cells against
those from RBM47-WT revealed a high correlation between steady state
transcript levels (R2=0.67) suggesting that global transcription was not
altered by the expression of RBM47 (Figure 5.10). To identify transcripts
with robust RBM47-dependent changes in expression level, genes were
filtered by fold change≥|2| and FDR≤0.01. A highly conservative filter
was then applied to identify genes with expression level changes greater
than two standard deviations from the linear regression line to isolate
those transcripts with robust total RNAseq counts in an attempt to reduce
noise inherent in the interpretation of expression level changes derived
from single replicate RNAseq libraries.

39 upregulated and 64 downregulated targets were identified, all of
which had evidence of RBM47 binding at a minimal definition of one
BC2≥2tags cluster. Increasing the requirement for RBM47 binding to ≥100
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FIGURE 5.10: RNAseq analysis reveals RBM47-dependent steady state
transcript level changes. The transcript levels of all expressed genes
(greater than two RNAseq reads in both samples, grey) correlate well
between Tet-On control and RBM47-WT expressing 831BrM2 cells. To
identify differentially expressed targets, genes were selected that showed
fold changes in RNAseq reads of ≥2 (light red) or ≤2 (light blue), FDR
≤0.01 and level changes greater than two standard deviations (dotted line)
from the linear regression (black line). Genes were then screened for direct
RBM47 regulation by the requiring ≥100 total RBM47 HITS-CLIP tags in
clusters (BC2≥2tags) per upregulated (dark red) and downregulated (dark
blue) transcript. R2=Pearson product moment correlation coefficient.
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total tags in BC2≥2tags clusters further refined the set of transcripts to 32
RBM47-bound and upregulated genes, and 46 RBM47-bound and
downregulated genes (Figure 5.10). RBM47 itself passed the threshold for
upregulation with a fold change of 240 and FDR 4.55e-15. Interestingly
2,060 RBM47 tags mapped to the RBM47 transcript, suggesting potential
for RBM47 auto-regulation. The RBM47-bound up- and downregulated
genes are listed in Table 5.1 and 5.2 respectively. The DAVID
Bioinformatics database was used to analyze the gene ontology (GO)
terms associated with RBM47 bound and regulated transcripts but no
enrichment in terms was found (FDR≤0.05).

For those genes positively regulated by RBM47, RNAseq transcript
level fold change was positively correlated to the total number of RBM47
CLIP tags in BC2≥2tags clusters bound to the transcript (R2=0.42, Figure
5.11A) while RBM47-downregulated genes had no correlation between the
number of RBM47 tags and transcript fold change. The majority of RBM47
binding in upregulated transcripts occurred in 3’UTRs (~85%), with
binding in downregulated transcripts more evenly distributed between
CDS, intron and 3’UTR (Figure 5.11B). RNAseq reads per gene in RBM47WT cells were plotted against the total number of tags in BC2≥2tags
clusters in the gene (Figure 5.12). No overall correlation was found
between the abundance of transcript and RBM47 binding (R2=0.06)
indicating RBM47 does not indiscriminately bind all upregulated
transcripts.
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TABLE 5.1: RBM47-bound transcripts showing RBM47-dependent
increase in steady state transcript level by RNAseq
!

Gene ID

Gene
DKK1
IL8

Fold
Change
8.77
6.93

22943
3576

7.94E-15
1.57E-14

RBM47
CLIP tags
20505
17390

1490

CTGF

2.66

4.58E-15

10543

27063
7009
5552

ANKRD1
TMBIM6
SRGN

8.01
2.23
2.60

1.14E-14
8.43E-15
5.52E-15

7590
7219
7001

6781
4312
23204

STC1
MMP1
ARL6IP1

2.24
4.37
2.50

4.56E-15
1.72E-14
3.61E-15

5005
4478
3925

55161

TMEM33

3.92

3.15E-15

3552

5055
481
1075

SERPINB2
ATP1B1
CTSC

6.96
2.73
3.55

6.97E-15
5.53E-15
4.11E-15

3038
2904
2445

3552
54502
7056

IL1A
RBM47
THBD

2.30
239.03
2.18

4.57E-15
4.55E-15
3.63E-15

2152
2060
1868

1974

EIF4A2

2.23

5.05E-15

1476

8878
57823
5954

SQSTM1
SLAMF7
RCN1

2.12
4.29
2.30

1.38E-14
2.26E-15
3.64E-15

1467
1324
1312

2919
378
9741

CXCL1
ARF4
LAPTM4A

5.33
2.02
2.17

5.52E-15
5.05E-15
4.56E-15

1132
971
914

3383

ICAM1

2.23

4.11E-15

729

5806
58505
55969

PTX3
OSTC
C20orf24

3.21
2.82
3.27

4.10E-15
4.55E-15
4.08E-15

645
556
527

10627
9550
6520

MYL12A
ATP6V1G1
SLC3A2

2.06
3.15
3.00

3.17E-15
3.62E-15
6.97E-15

367
214
192

3553

IL1B

2.82

4.57E-15

144

11009

IL24

2.32

5.51E-15

122
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TABLE 5.2: RBM47-bound transcripts showing RBM47-dependent
decrease in steady state transcript level by RNAseq.
Gene ID
667
6711
23499
3655
4853
23215
79026
64750
8829
7837
2317
3673
4134
10075
3069
4898
51520
3376
5591
6574
54443
7468
9448
3949
3609
7153
23524
81
7175
9793
8570
1305
11100
3371
2335
5339
5327
7094
10594
1063
5214
3675
4017
1786
3710
7916

Gene
DST
SPTBN1
MACF1
ITGA6
NOTCH2
PRRC2C
AHNAK
SMURF2
NRP1
PXDN
FLNB
ITGA2
MAP4
HUWE1
HDLBP
NRD1
LARS
IARS
PRKDC
SLC20A1
ANLN
WHSC1
MAP4K4
LDLR
ILF3
TOP2A
SRRM2
ACTN4
TPR
CKAP5
KHSRP
COL13A1
HNRNPUL1
TNC
FN1
PLEC
PLAT
TLN1
PRPF8
CENPF
PFKP
ITGA3
LOXL2
DNMT1
ITPR3
PRRC2A

Fold Change
-2.54
-2.50
-2.60
-2.22
-2.94
-2.14
-2.54
-2.08
-2.59
-2.62
-2.26
-2.76
-2.71
-3.15
-2.04
-2.23
-2.03
-3.01
-2.79
-2.53
-2.69
-3.20
-2.37
-3.25
-2.42
-2.77
-3.51
-2.85
-2.52
-2.85
-2.42
-2.50
-2.07
-3.20
-3.97
-3.64
-2.45
-2.85
-2.90
-4.36
-2.37
-3.02
-2.13
-2.46
-3.00
-2.72
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FDR
1.35E-98
1.58E-99
7.54E-100
3.02E-99
2.23E-99
7.92E-100
5.35E-100
5.43E-100
1.22E-99
1.36E-99
4.21E-99
3.00E-99
2.59E-99
9.90E-100
3.45E-99
2.21E-99
6.59E-100
3.18E-99
1.89E-99
1.64E-99
6.47E-100
1.40E-99
1.13E-99
2.77E-99
3.07E-99
1.46E-99
7.49E-100
9.69E-98
1.45E-99
1.04E-99
1.27E-99
7.48E-99
8.79E-100
3.19E-99
4.17E-99
1.99E-99
2.01E-99
1.47E-99
9.25E-100
8.81E-99
2.08E-99
3.003E-99
2.68E-99
5.84E-99
2.94E-99
1.35E-99

RBM47 CLIP tags
10437
5803
4672
4401
3766
3358
2991
2806
1659
1590
1590
1385
1227
1118
920
811
793
641
525
520
439
438
435
418
412
406
392
356
328
281
270
257
247
246
245
230
214
194
186
183
154
150
130
112
108
106

FIGURE 5.11: RBM47 binding in 3’UTRs positively correlates with
transcript up regulation. A: RBM47 CLIP tags per transcript were plotted
against RBM47-dependent transcript fold change for upregulated (red)
transcripts, revealing a positive correlation between the RBM47 CLIP tags
in clusters and RBM47-dependent fold induction. No correlation between
number of binding events and fold change was seen for RBM47-bound
downregulated targets (blue). B: The percentage of RBM47 CLIP tags in
BC2≥2tags clusters in each region of RBM47-bound and regulated
transcripts were calculated and averaged for up- and downregulated
genes. The ~85% of RBM47 binding associated with RBM47-dependent
transcript upregulation occurs in 3’UTRs, while binding is more even
dispersed along RBM47-bound and downregulated transcripts.
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FIGURE 5.12: RBM47 binding does not correlate with transcript
abundance. RNAseq reads/transcript in RBM47-WT cells are plotted
against RBM47 unique CLIP tags in BC2≥2tags clusters/transcript.
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Independent validation of RBM47 mediated transcript level changes
Validation of RBM47-mediated transcript level change was carried
out using a clonal cell line derived from the original RBM47 WT cell line
used for HITS-CLIP and RNAseq analysis. 831BrM2 Flag-RBM47 WT
clone#10 (RBM47-WT#10) has tightly regulated inducible RBM47
expression compared to the original non-clonal line, and was used in the
in vivo metastasis suppression assays outlined in Figure 5.2. Cells were
treated for 3 days with 10ng/ml dox and RBM47 induction validated by
Q-PCR and Western blot (Figure 5.13) with the original non-clonal
831BrM2 Tet-On cell line used as a negative control. Transcript level of
bound targets was assessed by Q-PCR comparing RBM47-WT#10 to TetOn control, and by comparing MDA-231 (RBM47 positive) to 831BrM2
(RBM47 negative, see Figure 5.1) to determine whether presence of
endogenous

RBM47

recapitulated

exogenous

RBM47-dependent

transcript level changes.

Comparison of RBM47 bound and regulated targets to previously identified
831BrM2 signature expression changes
An extensive reference data set of genes whose expression levels
change in 831BrM2 relative to the less metastatic MDA-231 cells (Bos et al.,
2009) was compared to the genes listed in Tables 5.1 and 5.2. None of the
genes identified as upregulated RBM47 targets had previously identified
as genes downregulated in 831BrM2 compared with MDA-231. A subset
of the RBM47-bound and upregulated transcripts had previously been
identified as being upregulated in 831BrM2, including CTGF, SRGN,
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FIGURE 5.13: Verification of dox-inducible Flag-RBM47 expression in
the clonal population of 831BrM2 Tet-On Flag-RBM47 WT used for
validation assays. A: Total RNA was prepared in triplicate from Tet-On
control and WT-RBM47#10 cells treated with 10ng/ml dox for three days.
Q-PCR for RBM47 revealed greater than 2000-fold induction of RBM47
transcripts level (CT values in Tet-On cells were >30). Expression levels
were normalized to TBP, p-value calculated by t-test. B: Protein lysates
were prepared in triplicate from dox-treated cells. Flag-RBM47 protein
expression is seen only in WT-RBM47#10 with HSP90 shown as a loading
control.
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STC1, MMP1, SERPINB2, CTSC, IL1A and IL1B (Bos et al., 2009),
suggesting that while RBM47 can positively regulate the levels of multiple
genes whose up regulation is associated with gain of brain metastatic
potential, loss of positive RBM47 transcript regulation in 831BrM2 may be
compensated for by some other undetermined transcriptional or posttranscriptional mechanism.

RBM47 binding to SERPINB2 (serpin peptidase inhibitor, clade B,
member 2) is shown in Figure 5.14A (black) with the corresponding
normalized RNAseq abundance data from Tet-On (red) and RBM47-WT
(green, RNAseq reads/million in that library). RBM47-dependent increase
in SERPINB2 transcript level is evident in the RNAseq data, and was
independently verified by Q-PCR (Figure 5.14B). The expression level of
SERPINB2 in MDA-231 and 831BrM2 cells was found to be consistent
with previous reports, with significant increase in transcript level in brain
metastatic cells (Figure 5.14C). Transcript levels of a second RBM47-bound
target, CTGF (connective tissue growth factor), were found to correlate
with

RBM47

expression

in

both

the

RBM41-WT#10

cells

and,

unexpectedly, between MDA-231 and 831BrM2 contrary to previously
reported expression level changes (Figure 5.15).

Comparing the published lists of transcripts upregulated in brain
metastatic cells with those identified as RBM47-bound and downregulated
revealed only one common gene, COL13A1. However this RBM47dependent negative regulation did not validate by Q-PCR (data not
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FIGURE 5.14: SERPINB2 transcript levels are positively regulated by reexpression of RBM47 in 831BrM2. A: The SERPINB2 gene is shown
overlaid with Flag-RBM47 HITS-CLIP data (black, y-axis= number of
overlapping tags in BC2≥2tags clusters). SERPINB2 is bound by RBM47
predominantly its 3’UTR, with low levels of binding occurring in clusters
on CDS exons and in introns. Shown above the HITS-CLIP binding map
are normalized RNAseq profiles from Tet-On control (red) and RBM47WT cells (green, y-axis=tags/million reads), with clear increase in
SERPINB2 expression in the presence of RBM47 (fold change=6.96,
FDR=6.97e-15). B: SERPINB2 expression levels were increased in WT
RBM47#10 when compared to similarly dox-treated empty vector Tet-On
control cells (fold change=8.62, p=0.0004). C: SERPINB2 expression levels
in MDA-231 (RBM47-positive) and 831BrM2 (RBM-47 negative) concur
with previously published reports of up regulation in brain metastatic
cells (fold change=3.23, p=0.0003). RNA prepared from three
independently treated cells lines, expression levels normalized to TBP, pvalues calculated by t-test.
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FIGURE 5.15: CTGF transcript levels correlate with RBM47 expression.
A: The CTGF gene overlaid with Flag-RBM47 HITS-CLIP data and
normalized RNAseq profiles from Tet-On control (red) and RBM47-WT
(green) as in Figure 5.14A (Fold change=2.66, FDR=4.58e-15). B: Up
regulation of CTGF in RBM47 expressing brain metastatic cells was
confirmed by Q-PCR (Fold change=2.35, p=0.048). C: CTGF expression
levels in MDA-231 and 831BrM2 correlate with endogenous RBM47
expression (fold change=0.67, p=0.027). RNA prepared from three
independently treated cells lines, expression levels normalized to TBP, pvalues calculated by t-test.
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shown). Q-PCR validation was attempted for several of the RBM47-bound
and downregulated targets that had shown the largest predicted fold
changes by RNAseq, including MACF1, CENPF/CUGBP2 and NOTCH2.
All transcripts were found to be unchanged in the presence of exogenous
RBM47 and when comparing MDA-231 to 831BrM2 cells (data not
shown). Closer inspection of the RNAseq data for downregulated
transcripts revealed an anomaly in the distribution of RNAseq reads along
the length of transcripts in the RBM47-WT library as illustrated in Figure
5.16 on the AHNAK transcript (fold change=-2.54, FDR=5.35e-100).

While a 3’-end bias is known to occur in polyA selected RNAseq
libraries (Levin et al., 2010, Tariq et al., 2011), it is not clear when
comparing single RNAseq libraries whether the apparent increased
rapidity of signal decay in the 3’-5’ direction in RBM47-WT cells results
from technical error in library preparation, or reflects a biological
consequence of RBM47 binding. RBM47 bound downregulated transcripts
were found to be significantly longer than all expressed transcripts (Figure
5.17). Longer transcripts have higher probability of high RNAseq reads
therefore statistical analysis of even small fold changes are more robust
and have lower FDRs (Oshlack and Wakefield, 2009). Visual inspection of
multiple non-RBM47 bound transcripts of similar genomic length and
equal differential expression by RNAseq revealed similar RNAseq profiles
suggesting that the apparent RBM47-dependent downregulation of long
transcripts is an artifact.
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FIGURE 5.16: RBM47-bound and downregulated genes show strong
3’end bias in the RNAseq profile. The AHNAK transcript (fold change=2.54, FDR=5.35e-100) is shown as an example of the rapid 3’-5’ decay of
RNAseq reads that is exaggerated in the RBM47-WT RNAseq data set
compared to Tet-On control cells.
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FIGURE 5.17: Cumulative distribution plots of genomic gene length of
RBM47-bound genes showing RBM47 dependent transcript level
changes. Genomic length of all expressed genes in the RNAseq data sets
are shown in black, the 32 RBM47-bound and up regulated transcripts in
red, the 46 down regulated genes in blue. RBM47-bound up regulated
genes are significantly shorter than the general transcript population
(p=4.661e-08), while down regulated are significantly longer (p<2.2e-16).
Gene length was calculated using coordinates from obtained from Refseq,
p-values calculated using the Kolmogorov-Smirnov test.
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Further RNAseq sampling, preferably prepared using a ribo-minus
protocol, needs to be carried out before any conclusions can be made
about the role of RBM47 in transcript down regulation.

Validation of RBM47-mediated expression level changes in transcripts not
previously identified as altered in metastasis
Ankyrin repeat domain 1 (ANKRD1) was the second most
differentially expressed RBM47-bound transcript identified by RNAseq
(fold change=8.01, 7590 RBM47 CLIP tags) (Figure 5.18A). The positive
regulation of ANKRD1 transcript levels by RBM47 was confirmed in
RBM47-WT#10 dox-treated cells (Figure 5.18B), while decrease in
expression was also seen in 831BrM2 relative to MDA parental cells
(Figure 5.18C). Dickkopf 1 (DKK1) was identified as both the most
upregulated of RBM47-bound transcripts (fold change = 8.77) and the
most highly bound RBM47-regulated transcript (20,505 RBM47 tags in
BC2≥2tags clusters). The majority of DKK1 RBM47 CLIP tags map to the
3’UTR (96.7%), with low level binding also evident on exons and the 5’
UTR (Figure 5.19A). Q-PCR revealed ~4-fold up-regulation of DKK1 in
dox-treated RBM47-WT#10 cells compared with similarly treated Tet-On
controls, independently confirming the RNAseq data (Figure 5.19B).
Reciprocal decrease in DKK1 transcript levels were seen in 831BrM2
compared to MDA (Figure 5.19C).
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FIGURE 5.18: ANKRD1 transcript levels correlate with RBM47
expression. A: The ANKRD1 gene overlaid with Flag-RBM47 HITS-CLIP
data (black) and normalized RNAseq profiles from Tet-On control (red)
and RBM47-WT (green) (Fold change=8.01, FDR=1.14e-14). ANKRD1 is
bound by RBM47 predominantly its 3’UTR, with lower levels of binding
occurring in clusters on CDS exons and along the entire length of multiple
introns. B: Up regulation of ANKRD1 in RBM47 expressing brain
metastatic cells was confirmed by Q-PCR when compared to similarly
dox-treated empty vector Tet-On control cells (Fold change=1.77,
p=0.023). C: ANKRD1 expression levels in MDA-231 and 831BrM2
correlate with endogenous RBM47 expression (fold change=0.70, p=0.04).
RNA prepared from three independently treated cells lines, expression
levels normalized to TBP, p-values calculated by t-test.
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FIGURE 5.19: DKK1 transcript levels correlate with RBM47expression.
A: The DKK1 gene overlaid with Flag-RBM47 HITS-CLIP data (black) and
normalized RNAseq profiles from Tet-On control (red) and RBM47-WT
cells (green) (Fold change=8.77, FDR=7.94e-15). Extensive binding of
RBM47 is seen in an extended region beyond the annotated polyA site that
is accompanied by low level RNAseq reads suggesting the presence of a
minor DKK1 isoform with an extended 3’UTR. B: Up regulation of DKK1
in RBM47 expressing brain metastatic cells was confirmed by Q-PCR
when compared to similarly dox-treated empty vector Tet-On control cells
(Fold change=4.07, p=0.0014). C: DKK1 expression levels in MDA-231 and
831BrM2 correlate with endogenous RBM47 expression (fold change=0.59,
p=0.0004). RNA prepared from three independently treated cells lines,
expression levels normalized to TBP, p-values calculated by t-test.
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Treatment of RBM47-WT#10 cells with &-amanitin to block
transcription indicates that RBM47 binding to DKK1 leads to transcript
stabilization, with the half-life of DKK1 mRNA increasing from 3.5hrs in
the absence of dox-induction to 12.1hrs in the presence of RBM47 (Figure
5.20, assayed by Sakari Vanharanta, Joan Massagué laboratory, MSKCC).
Given the extensive AGO binding on the DKK1 transcript identified by
AGO HITS-CLIP in Chapter 4, it was hypothesized that RBM47
stabilization of the DKK1 transcripts may in part result from disruption of
AGO regulation in the 3’UTR. Normalized AGO binding (tags/million
unique reads in that cell line) on RBM47-dependent upregulated
transcripts validated by Q-PCR (DKK1, CTGF and ANKRD1) is shown in
Figure 5.21. While the normalized AGO-mRNA peaks in MDA-231 (red)
and 831BrM2 (orange) are the same height on the DKK1 3’UTR (Figure
5.21A), DKK1 transcript levels are ~0.6-fold lower in 831BrM2 cells
(Figure 5.19C) and therefore, on a per transcript basis, AGO binding is
enhanced in RBM47-negative 831BrM2. Similarly, increase in AGO-mRNA
binding is clearly seen in the 3’UTR of CTGF (Figure 5.21B) and ANKRD1
(Figure 5.21C) in 831BrM2 cells. SERPINB2 was not bound by AGO in
either MDA-231 or 831BrM2 (not shown).

It has been previously demonstrated by PAR-CLIP that a positional
relationship exists between exogenous tagged-HuR and tagged-AGO
3’UTR binding sites, with the peak of binding for both proteins
predominantly overlapping at exactly the same nucleotide (Mukherjee et
al., 2011). This observation has been independently verified using HITS209

FIGURE 5.20: RBM47 expression leads to increased stability of the
DKK1 transcript. RBM47-WT#10 cells were cultured in the absence
(control) or presence of dox for three days before %-amanitin treatment to
block RNA polymerase II transcription. The presence of RBM47 increases
the half-like of the DKK1 transcript ~3.5 fold. Experiment carried out by
Sakari Vanharanta, Joan Massagué laboratory, MSKCC.
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FIGURE 5.21: Normalized Ago-mRNA binding maps in MDA-231
(RBM47 positive) and 831BrM2 (RBM47 negative) on RBM47-dependent
up regulated transcripts. A: Normalized Ago binding in MDA-231 (red)
and 831BrM2 (orange) is shown above RBM47 binding (black) on the
DKK1 transcript. DKK1 steady state transcript level is reduced in 831BrM2
cells (Figure 5.19C) so that on a per transcript basis, less Ago binding is
evident in MDA-231 cells (in the absence of RBM47). A reduction in Ago
binding in MDA-231 cells is evident on the CTGF 3’UTR (B) and ANKRD1
3’UTR (C).
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CLIP for endogenous protein binding sites in T cells (Darnell laboratory,
unpublished data), and has been suggested to either agonize or
antagonize AGO binding. To see whether such a positional relationship
exists between RBM47 and AGO, significant peak 3’UTR footprints of
AGO in 831BrM2 cells (+/-25nt centered on peak in BC≥2 tags≥10
significant peaks) were overlapped with 3’UTR significant peaks from
RBM47 HITS-CLIP (BC2≥10, 19,455 total). Of 2,832 AGO significant 3’UTR
peaks, 43% overlapped the footprint coordinates of RBM47 significant
3’UTR peaks by a minimum of 1nt. The position of RBM47 peak binding
was calculated relative to the peak of AGO binding in overlapping 3’UTR
clusters (Figure 5.22). While a slight enrichment in peak binding of RBM47
is seen in regions corresponding to the +/-10nt region of AGO peak
binding, RBM47 appears to bind in a much more dispersed pattern than
has been described for HuR with respect to AGO. This suggests that AGO
and RBM47 do not bind exactly the same sites within 3’UTRs rather that
RBM47 coats the entire footprint region in which AGO targeting occurs.

Analysis of paired-end RNAseq identifies extensive RBM47-dependent
alternative splicing
Reproducible binding of RBPs in intronic regions is predictive of a
role in pre-mRNA processing. To explore the relationship between RBM47
intronic binding and alternative splicing, the previously described paired
end 100nt RNAseq data sets were analyzed as described for the
identification of Muscleblind-like 2 (Mbnl2) regulated alternative splicing
in the mouse brain (Charizanis et al., 2012). Focusing on a comprehensive
212

FIGURE 5.22: Histogram of the overlap of RBM47 and Ago significant
peak binding in 3’UTRs. The center of all Ago significant peaks in
3’UTRs was determined and a +/-25nt footprint assigned centered on the
peak coordinate. The Ago coordinates were intersected with similarly
derived footprints of RBM47 significant 3’UTR peaks, resulting in 1,218
overlapping significant binding sites. The distance of the RBM47 peak
from the Ago peak was calculated as is shown as a histogram. While some
enrichment of overlap is seen in the -/+10nt region spanning Ago peak of
binding, RBM47 peaks are more dispersed on 3’UTRs with respect to Ago
binding than previously described patterns of HuR and Ago binding sites
(Mukherjee et al., 2011).
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data set of cassette exons derived from mRNA/expressed sequence tag
data, inclusion rates (IR) were calculated for each cassette exon as outlined
in Figure 5.23, and the change in inclusion rate ((I) upon RBM47
expression calculated. This method allows for the identification of
reciprocal splicing changes between two samples with high sensitivity
while normalizing for changes in RNA stability (Ule et al., 2005b). Positive
(I indicates enhanced inclusion in the presence of RBM47, while negative
(I indicates RBM47-dependent cassette exon skipping.

To select high confidence alternative splicing events from single
RNAseq libraries, alternative splices with ≥10 RNAseq tags mapping to
cassette exon junctions and (I≤|0.2| were considered for further analysis.
This gave 669 cassette exons with RBM47 enhanced inclusion and 756
cassette exons with RBM47 enhanced exclusion. To assess direct
regulation by RBM47, the genomic coordinates of the cassette exon locus,
from the start of the 5’ flanking exon (5’FE) across the 5’ flanking intron
(5’FI), cassette exon (CA), 3’ flanking intron (3’FI) to the end of the 3’
flanking exon (3’FE, see Figure 5.23), were cross-referenced to BC2≥2tags
RBM47-WT HITS-CLIP cluster data. Surprisingly, direct RBM47 binding
was evident in the genomic locus of a high proportion of alternative
splicing events showing RBM47-dependence. 480 included and 464
excluded splicing events showed evidence of at least one BC2≥2tags
cluster (Figure 5.24). The DAVID Bioinformatics database was used to
analyze the gene ontology (GO) terms associated with these 944 cassette
exons (located in 729 genes) using the total mRNA population present in
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FIGURE 5.23: Calculating change in inclusion rates of alternatively
spliced isoforms from paired end RNAseq data. A schematic of an
alternatively spliced exon with constitutive exons in blue (5’FE - 5’
flanking exon, 3’FE – 3’ flanking exon) and the alternatively spliced
cassette exon (CA) in red. Paired end RNAseq reads were mapped to the
genome allowing for split-segment alignment to splice junctions, then
further processed to infer unobserved exon junctions between aligned
paired reads. The number of reads spanning constitutive-cassette (5’FECA and CA-3’FE) and constitutive-constitutive splice junctions (5’FE-3’FE)
were used to calculate the inclusion rate (IR) of each cassette exon in a
comprehensive database. The change in inclusion rate (&I) was calculated
such that a positive ΔI indicates enhanced inclusion in the presence of
RBM47, while negative ΔI indicates cassette exon skipping. A &I of |0.2|
indicates a change in inclusion rate of 20%.
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FIGURE 5.24: The majority of RBM47-dependent !I≥|0.2|alternatively
spliced cassette exons are bound by RBM47. Cassette exons with greater
than 10 RNAseq reads mapping to splice junctions in both Tet-On control
and RBM46-WT libraries and with &I≥0.2 or &I≤0.2 are shown in light red
and light blue, respectively. Alternatively spliced exons with RBM47
binding in the genomic region spanning 5’-FE start to 3’FE end (minimum
one BC2≥2tags cluster) are shown in darker shades.
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831BrM cells as the background (16,466 genes with ≥2 RNAseq tags per
transcript). Proteins encoded by RBM47-bound alternatively spliced
transcripts were weakly enriched in GO terms related to the cytoskeleton
and RNA binding (p≤0.01, FDR≥0.01).

The large number of RBM47-bound transcripts with RBM47dependent altered splicing patterns indicates an extensive role for RBM47
in pre-mRNA processing. This is despite the relatively small proportion of
RBM47 intronic clusters that pass the increasingly stringent cluster
definition thresholds outlined in Figure 5.8. Analysis of the median tags
number per BC2≥2tags cluster in genic regions (Figure 5.25) clearly
demonstrates that individual intronic RBM47 clusters have a lower
median tag count than binding sites in 5’UTR, coding sequence and
3’UTRs. Given that pre-mRNA is estimated to be present at levels 1000x
lower than mRNA (Reid et al., 2009), lower levels of tag numbers in
intronic binding site are to be anticipated when compared to coding
sequence or UTRs. Interestingly, increasing the cut-off for the presence of
RBM47-binding in alternative splice locations by total tag numbers in all
BC2≥2tags clusters rather than total tags per individual cluster still retains
high numbers of RBM47-dependent alternative splicing events. For
example, a cutoff of ≥100 unique tags in BC2≥2tags clusters identifies 206
RBM47-dependent included and 196 excluded exons. Together this would
suggest a pattern of dispersed, low-level binding surrounding alternative
splices similar to those described for FUS (Ishigaki et al., 2012, Rogelj et
al., 2012) and TDP-43 (Tollervey et al., 2011), rather than the discrete,
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FIGURE 5.25: Distribution of RBM47 unique tag numbers in
BC2≥2tags clusters. The median tag number per cluster is lowest in
intronic binding sites, with 95% of all intronic clusters having less
than 5 tags per cluster. This explains the decrease in retained intronic
clusters seen upon increase in cluster stringency definition (Figure 5.8)
as applying a ≥10 tags per cluster threshold effectively eliminates
intronic binding, retaining only outlier clusters.
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robust binding sites identified by HITS-CLIP for other alternative splicing
regulators such as Nova (Licatalosi et al., 2008), MBLN-1 (Wang et al.,
2012), MBNL-2 (Charizanis et al., 2012) and PTBP2 (Licatalosi et al., 2012).

RBM47 binds multiple transcripts in the region of alternative splicing associated
with the epithelial to mesenchymal transition (EMT)
Extensive alterations in alternative splicing patterns have been
reported during the EMT transition of human mammary epithelial cells
expressing tamoxifen-inducible Twist (Shapiro et al., 2011), a transcription
factor

essential

for

developmental

mesoderm

specification

and

differentiation (Qin et al., 2012). RBM47 was among several RNA binding
proteins whose expression was found to decrease during EMT.
Interestingly, of the 168 alternative splicing events identified by (Shapiro
et al., 2011), 47 are bound by RBM47, with 36 having the same directional
change in exon inclusion with respect to the presence or absence of
RBM47 expression (Table 5.3).

Independent validation of RBM47-regulated splicing changes
Candidate RBM47-regulated alternative splicing events were
selected for validation based on greatest observed |(I| and ≥100 RBM47
HITS-CLIP tags in BC2≥2tags clusters in the cassette exon locus.
Validation was carried out using the clonal cell line RBM47-WT#10 and
831BrM2 Tet-On cells treated for 3 days with 10ng/ml dox. Alternative
splicing was assessed by semi-quantitative radioactive RT-PCR using
three independent RNA preparations from each cell line. In addition,
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TABLE 5.3: RBM47-bound and dependent splicing changes previously
identified as altered in EMT. Shown are RBM47-dependent splicing
changes whose direction corresponds that seen in Shapiro et al., 2011 with
respect to RBM47 expression. The number of RBM47 HITS-CLIP tags in
BC2≥2tags clusters in the 5’FE-3’FE genomic region of each alternative
splice is given.
Gene
ADD3
ARHGAP17
CD44
CD44
CLSTN1
CTNND1
CUGBP2
DAG1
EBPL
EPB41L1
FAM176A
FAM62B
FER1L3
HMGN1
HMGN1
KIF13A
MARK3
MARK3
MARK3
MATR3
MBNL1
NFYA
NIN
NISCH
PBRM1
PLEKHA1
PLEKHA1
PLEKHM2
PLOD2
PPFIBP1
RBM3
SEC31A
SEC31A
SEC31A
SLK
SPAG9
STX2
TEAD1
UBXN11
WARS
ZC3H11A
ZNF584

Chrm
chr10
chr16
chr11
chr11
chr1
chr11
chr10
chr3
chr13
chr20
chr2
chr7
chr10
chr21
chr21
chr6
chr14
chr14
chr14
chr5
chr3
chr6
chr14
chr3
chr3
chr10
chr10
chr1
chr3
chr12
chrX
chr4
chr4
chr4
chr10
chr17
chr12
chr11
chr1
chr14
chr1
chr19

5’FE Start
111880110
24850225
35188087
35167957
9723900
57285844
11247454
49482715
49163600
34249194
75641931
158245032
95145970
39641278
39642134
17880268
103027866
103027866
103027866
138642638
153645760
41154745
50296826
52489239
52571023
124176447
124176447
15918815
147279733
27720627
48318499
83984685
83984685
83982657
105757924
46409580
129849132
12840372
26505713
99912416
202031397
63611929

3'FE End
111883338
24838214
35193036
35189571
9718529
57319776
11331169
49489341
49135193
34263711
75606745
158235100
95138776
39639625
39638941
17872364
103036289
103039370
103039370
138671307
153648251
41159908
50291209
52493692
52559802
124179643
124179643
15924626
147277258
27723838
48319750
83969176
83969176
83969176
105768036
46407130
129842039
12843022
26500771
99897797
202037378
63618824
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Strand
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Clip tags
83
106
547
3896
20
475
139
15
85
4
263
310
969
35
49
62
136
206
206
1190
78
52
59
11
86
58
58
3
193
57
16
373
373
300
256
72
38
77
2
171
1668
4

Delta I
0.68
-0.27
0.26
0.65
-0.65
-0.27
-0.29
0.71
0.25
-0.24
-0.21
0.58
-0.29
-0.27
-0.21
0.56
-0.37
-0.49
-0.24
0.37
0.30
-0.72
-0.41
0.29
0.24
-0.31
-0.26
-0.44
-0.32
0.26
0.52
0.29
0.37
0.67
0.72
-0.36
0.42
-0.28
0.25
-0.35
0.25
-0.23

splicing patterns were assessed in the parental MDA-231 cells (RBM47
positive) and 831BrM2 cells (RBM47 negative) to identify those RBM47dependent alternative splicing events that may contribute to the more
aggressive metastasis seen in the absence of RBM47.

Analysis of the RNAseq data identified MDM4 exon 6 (ex6) as a
negatively regulated, RBM47-bound cassette exon ((I=-0.63, 145 RBM47
CLIP tags in BC≥2tags). Figure 5.26A shows the genomic locus of the
MDM4 gene, with normalized RNAseq reads from Tet-On control (red)
and RBM47-WT (green), and RBM47 CLIP tags in BC2≥2tags clusters
(black). RBM47 binding is present in the 5’ flanking intron of the
alternatively spliced ex6, as well as in the 3’UTR and several additional
non-alternatively spliced exons of MDM4. Zooming in on the region of the
alternatively spliced exon (Figure 5.26B) clearly shows reduction in
RNAseq signal corresponding to ex6 in RBM47 expressing cells. Semiquantitative RT-PCR of the region spanning MDM4 ex5-7 shows
significant RBM47-dependent exclusion ofex6 in dox-treated RBM47WT#10 compared to Tet-On control ((I= -0.27, p=4.4x10-4). The level of
MDM4 ex6 exclusion correlates with RBM47 expression in MDA-231 and
831BrM2 cells ((I=IRMDA-IRBrM2= -0.12, p=1.4x10-3, Figure 5.26C). RBM47dependent splicing changes associated with intronic RBM47 binding were
validated for alternative exons in MBNL1, MACF1 and KIFAP3 (Figure
5.27) with the anticipated changes in MDA-231 and 831BrM2 cells with
respect to RBM47 expression. Several alternative exons showing robust
RBM47 dependent changes in RBM47-WT#10 failed to show any splicing
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FIGURE 5.26: RBM47 binding correlates with RBM47-dependent exon
exclusion in MDM4. A: The genomic MDM4 locus showing RBM47 HITSCLIP binding in BC2≥2tags clusters in black and normalized RNAseq
tracks from non-RBM47 expression Tet-On control (red) and RBM47-WT
cells (green). RBM47 binding is evident in the 3’UTR of MDM4, and in the
intronic region between consitutive ex5 and the alternatively spliced ex6.
B: Close-up of the ex5-ex7 region of MDM4 showing clear decrease in
RNAseq signal corresponding to ex6 in RBM47-WT cells. Shown below
the gene are the cassette exons used for RNAseq alignment and IR
calculation. Two included isoforms are present including full or partial
ex6 (red) and the ex6 excluded isoform (blue). C: Independent verification
of splicing carried out by semi-quantitative radioactive RT-PCR
amplifying a region spanning ex5-ex7 in dox-treated Tet-On and RBM47WT#10 (top left pannel), and MDA-231 (RBM47 positive) and 831BrM2
(RBM47 negative, top right pannel). In all splicing RT-PCRs the first three
lanes consist of an equal-parts mixture of cDNA from all samples
amplified at increasing cycle number to ensure amplfication in the linear
range, and the fourth lane contains a –RT control from the same mix. The
middle cycle number was used to amplify cDNA from samples prepared
in triplicate from each cell line. The presence of both exogenous and
endgogenous RBM47 correlates with preferential ex6 skipping. Average
&I of RT-PCR reactions were calculated using ImageJ analysis of
autoradiograms ((Schneider et al., 2012), lower panels), with p-value
***≤0.001, **≤0.01 calculated by t-test.
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FIGURE 5.27: RBM47 expression correlates with RBM47-dependent
exon inclusion and exclusion in bound targets. A: RBM47 binding in the
region spanning ex4-ex8 of MBNL1 correlates with RBM47-dependent
exclusion of ex7, an NMD exon, in both RBM47-WT#10 and MDA-231
cells. B: RBM47 promotes inclusion of ex91 of MACF1. RT-PCR &IRBM47WT#10-TetOn=0.35, p=0.0003; &IMDA-831BrM2=0.22, p=0.00003. C: RBM47 promotes
the inclusion of an unannotated exon between ex19-20 in KIFAP3.
Inclusion rate (IR) of RT-PCR reactions were calculated using ImageJ
analysis of autoradiograms, p-value calculated by t-test where possible.
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FIGURE 5.28: Exogenous RBM47 expression correlates with RBM47dependent exon inclusion and exclusion not seen when comparing
MDA-2321 and 831BrM2. A: RBM47 binding in the intron between ex12
and ex13 promotes ex13 inclusion in SLK. This exon is excluded in both
MDA-231 and 831BrM2. B: LIMCH1 ex9 (based on variant 1) shows robust
RBM47-dependent exclusion in RBM47-WT (&IRBM47-WT#10-TetOn=-0.53,
p=2.18e-5), however no change in splicing pattern was seen between
MDA-231 and 831BrM2. Inclusion rate (IR) of RT-PCR reactions were
calculated using ImageJ analysis of autoradiograms, p-value calculated by
t-test where possible.
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changes between MDA-231 and RBM47 (Figure 5.28). Together these
results suggest a regulatory role for RBM47 in alternative splicing, with
direct binding correlating with both exon inclusion and exclusion.

RBM47alternative splicing RNA Binding Map
By coupling protein-dependent splicing changes to the binding
sites derived from HITS-CLIP it is possible to map on a composite premRNA patterns of binding associated with RBP-binding dependent exon
inclusion and exclusion. To generate an RBM47 RNA binding map, the
total number unique RBM47 CLIP tags within 1kb of each RBM47-bound
alternatively spliced exon-intron junction (|(I|>0.2, BC2≥2tags cluster)
were counted and assigned a weight to normalize for gene expression
level, then assigned to the closest splice site. For each 50nt window, the
weighted sum of CLIP tags was normalized by dividing by the total
number of tags mapping onto the cassette exon and flanking introns and
plotted as a function of distance from respective exon/intron junctions to
generate normalized complexity map (Ince-Dunn et al., 2012, Licatalosi et
al., 2008) (Figure 5.29).

Unlike the RNA maps generated for other alternative splicing
regulators such as Nova (Licatalosi et al., 2008) and FOX2 (Yeo et al.,
2009), the RBM47 normalized complexity map is strikingly symmetrical
with respect to binding around both included and excluded intron. While
some preferential binding to regions spanning the 250nt immediately
downstream of the 3’ FE and to the 3’FE itself is evident in those exons for
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FIGURE 5.29: RBM47-RNA normalized complexity splicing map. All
RBM47 unique CLIP tags mapping to the 944 identified alternative exons
showing RBM47-dependent splicing changes and the presence of at least
one BC2≥2tags cluster were placed onto a single composite pre-mRNA.
Tags numbers were normalized both to the number and distribution of
tags between transcripts, and to the number of transcripts showing
binding at any given position to determine common potential regulatory
sites. This map was generated twice, once for all included exons (red), and
then for all excluded exons (blue). The normalized complexity binding
map of RBM47 is strikingly symmetrical both in terms of binding in
upstream and downstream regions relative to the cassette exons, and with
respect to RBM47-dependent inclusion or exclusion.
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which RBM47 binding promotes exon inclusion (red), there is no clear bias
for upstream binding in the immediate vicinity of intron-exon boundary
of included alternative exons (see Nova binding map (Licatalosi et al.,
2008)). Peaks of binding are also observed in the 5’FE and at both of the
alternative intron-exon boundaries, extending 50nt into the exonic region
and greater than 500nt out from the junction in both the upstream and
downstream directions. A tail of low-level binding can be seen extending
into more distal intronic regions with a relatively constant normalized
peak height. Surprisingly, the RBM47 binding map for exon skipping
(blue) was remarkably similar to that of the RBM47 included exons, with
near symmetrical binding at the exon-intron boundaries and flanking
intronic regions and no bias towards binding in downstream regions with
respect to the cassette exon.

The RBM47 binding seen in validated alternatively spliced
transcripts occurs in multiple discrete clusters spanning the entire intron
rather than occurring in clusters in close proximity to the splice site. Given
the extended tails of binding seen in the RBM47 normalized complexity
map, it was feasible that a bias towards upstream binding in excluded and
downstream binding in included cassette exons could exist outside the
1kb boundary of the RNA map. In order to look for binding patterns
across large intronic distances, RBM47 tags in BC2≥2tags clusters located
in the 5’FE- 3’FE region were counted, and a percentage binding in each
sub-region calculated. This percentage was then averaged across all
RBM47-dependent included or excluded alternative events (Figure 5.30).
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No clear bias towards upstream or downstream binding was evident in
the RBM47 HITS-CLIP profile. Additionally, no bias towards binding one
or both introns with respect to inclusion or exclusion was detected. It has
been suggested that internal cassette exons are predominantly excluded
when flanked by two long introns while the presence of a shorter
neighboring intron can rescue exon inclusion (Fox-Walsh et al., 2005),
however no bias was found in distribution of intron lengths or ratio of
intron lengths around RBM47-regulated cassette exons (data not shown).

It remains a possibility that due to the single replicate RNAseq
experiment and the relatively low threshold set for evidence of RBM47
binding noise is present in the current data set that obscures the RNA
binding “rules” associated with RBM47 regulated alternative splicing.
Increasing the stringency of identification of altered transcripts with
replicate RNAseq libraries and increasing the threshold set for evidence of
direct RBM47-binding, coupled with further RT-PCR validation should
refine the list of regulated events to allow for further investigation into the
rules governing RBM47-mediated inclusion or exclusion of alternative
exons.
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FIGURE 5.30: No extended positional bias is evident in RBM47 binding
flanking regulated alternative exons. The percentage of RBM47 CLIP tags
in BC2≥2tags clusters mapping to the 5’ flanking exon, 5’ intron, cassette
exon, 3’ flanking intron and 3’flanking exon were averaged across all
RBM47-dependent inclusion and exclusion events. The average
distribution of CLIP tags around the cassette exon is no different between
included and excluded events.
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DISCUSSION
In collaboration with the Massagué laboratory at MSKCC, we have
been shown that RBM47 is a novel, potent breast cancer metastasis
suppressor, and that decrease in RBM47 expression is clinically associated
with poor metastasis-free survival to both brain and lung. Understanding
the normal function of RBM47 is key to understanding how this antimetastatic effect is mediated. In this study we have validated the RNA
binding ability of RBM47 and, by mapping the entire network of RBM47bound transcripts, we have determined that RBM47 is a multifunctional
RBP with roles in both transcript stabilization and the regulation of
alternative splicing.

Motif analysis of robust RBM47 CLIP clusters revealed a preference
for polyU-rich sequences, consistent with a Class III AU-rich binding
element (ARE). Class I AREs contain 1-3 copies of an AUUUA pentamer
surrounded by U-rich regions, class II contain multiple overlapping copies
of AUUUA (usually 5-8), while class III are more loosely defined in that
they lack the AUUUA pentamer but instead contain predominantly U-rich
sequence (Chen and Shyu, 1995). ELAVL1/HuR, by binding AREs in the
3’UTRs of GM-CSF and c-fos (Vakalopoulou et al., 1991) can promote
increased half-life of both transcripts ((Fan and Steitz, 1998). By coupling
HITS-CLIP binding maps with RNAseq analysis of RBM47-dependent
steady state transcript level changes, we have identified a subset of targets
in which robust RBM47 3’UTR binding correlates with both up regulation
of steady state transcript levels and, in the case of DKK1, stabilization of
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the transcript. The data presented here would suggest that RBM47, like
ELAVL1 functions as a transcript stabilizing 3’UTR ARE-binding protein.

PolyU binding sites have been identified via HITS-CLIP (or its
variations) for hnRNP-C (iCLIP (Konig et al., 2010)), ELAVL1 (PAR-CLIP,
(Lebedeva et al., 2011, Mukherjee et al., 2011), HITS-CLIP Darnell lab
unpublished data), nELAVL (Ince-Dunn et al., 2012), U2AF65 (Rogelj et
al., 2012), and PTBP2 (Licatalosi et al., 2012). Such low complexity
targeting is difficult to reconcile with the specificity of target selection
shown for each RBP, indeed for many low complexity motif binding
proteins the presence of a canonical motif is neither necessary or sufficient
to predict binding (for example, binding of FUS to its consensus motif
GGUG in both mouse and human brain (Lagier-Tourenne et al., 2012)).
This would suggest other modulatory factors in target choice such as RNA
accessibility and secondary structure (Hoell et al., 2011) or recruitment via
protein-protein interactions. Identification of RBM47 interacting proteins
may help to further elucidate the mechanism by which specific targets are
selected for stabilization or alternative splicing.

In order to identify RBM47-bound transcripts whose RBM47dependent

regulation

has

the

potential

to

influence

metastatic

progression, transcript levels were assessed both in the exogenous overexpression setting (RBM47-WT versus Tet-On control cells) and in the
endogenous setting (MDA-231 versus 831BrM2). We have identified three
RBM47-bound targets whose transcript levels positively correlate with
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RBM47 expression: CTGF, ANKRD1 and DKK1. Given the stringent cutoffs placed on RBM47-dependent expression level changes as measured
by RNAseq this is unlikely to be an exhaustive list of metastasis associated
RBM47-regulated transcripts. Interestingly, for each of the RBM47 targets
validated a decrease in the total AGO binding in 3’UTRs was observed in
MDA-231 cells compared to 831BrM2, suggesting that RBM47 may
mediate its stabilizing effect in part by displacing AGO from regulatory
regions on common targets.

The complex interplay of RBPs in both agonistic and antagonistic
modulation of miRNA regulation is becoming increasingly apparent. For
example, PUF proteins have been shown to activate miRNA-mediated
silencing of hbl-1 by let-7 in C.elegans (Nolde et al., 2007) and to facilitate
miR-221/222 silencing of p27 in human fibroblasts by binding to and
altering local 3’UTR secondary structure (Kedde et al., 2010). As discussed
in Chapter 3, the RRM domain containing ELAVL family members have
been ascribed both agonistic, required for let-7 mediated c-Myc repression
(Kim et al., 2009a), and antagonistic roles in AGO-mediated transcript
regulation, binding to miR-16 to inhibit targeting of COX-2 (Young et al.,
2012) and stress-mediated relief of CAT-1 mRNA repression by miR-122
(Bhattacharyya et al., 2006). For c-Myc and CAT-1 regulation, regulatory
HuR 3’UTR binding sites are located in regions not overlapping targeting
miRNA seed sites, consistent with PAR-CLIP data suggesting enrichment
of miRNA seed sequences adjacent to but not within HuR binding sites
(Lebedeva et al., 2011). In vitro studies have shown that HuR
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oligomerization is required for the attenuation of miRISC target cleavage
through displacement of the RISC complex from target mRNA (Kundu et
al., 2012). Spreading of HuR binding along transcripts may help to explain
more recent PAR- and HITS-CLIP data that have indicated a significant
enrichment for overlapping HuR and AGO binding sites within 10nt of
each other suggesting direct competition for binding sites ((Mukherjee et
al., 2011), Darnell Lab unpublished data). The peak overlap of RBM47 and
AGO in 831BrM2 cells does not share this discrete enrichment, rather
RBM47 binding is distributed more evenly throughout AGO peaks
suggesting a potentially less site specific co-regulation of targets.

The RRM domains of RBM47 bear high similarity (63.4%, (Rice et
al., 2000)) to the single RRM domain containing protein dead end 1
(Dnd1), a U-rich element binding RBP predominantly expressed in
primordial germ cells (Youngren et al., 2005). Endogenous Dnd1
expression in zebrafish germ cells and ectopic expression in human cells
has been shown to broadly relieve miRNA repression through direct
binding of target mRNA in regions proximal to or partially overlapping
the targeting miRNA seed sequence (Kedde et al., 2007). Modulation of
mRNA repression without changes in miRNA expression level has been
observed in germ cells of Arabidopsis thaliana (miR-159, (Alonso-Peral et
al., 2012)), zebra fish (miR-430, miR-221/222, miR-372, miR-1 and miR-206
(Kedde et al., 2007, Mishima et al., 2006)) and mouse oocytes where
deletion of Dicer1 (Ma et al., 2010a) or Dgcr8 (Suh et al., 2010) fails to lead
to de-repression of mRNA levels. Downregulation of DND1 has been
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associated with increased target sensitivity to miR-21 in transformed
keratinocytes (Bhandari et al., 2013) and in increased proliferation with
reduced apoptosis in oral squamous cell carcinoma of the tongue (Liu et
al., 2010), suggesting that the miRNA modulatory function of Dnd1 is not
limited to germ cells and can be tumor suppressive in transformed
somatic cells.

If RBM47 is able to modulate accessibility of AGO to common
target 3’UTRs, loss of RBM47 in metastatic progression may allow for gain
of function for multiple miRNAs by unmasking regulatory seed sites
without requiring extensive alteration of miRNA expression patterns.
Such transcript-wide increase in AGO binding in the absence of RBM47
can be inferred from the AGO binding maps of MDA-231 and 831BrM2,
although this is highly correlative data. It would be interesting to assess
direct AGO HITS-CLIP binding maps in the presence and absence of
RBM47, either by RBM47-WT +/-dox induction or by RBM47 knockdown
in MDA-231. Careful normalization of AGO binding with respect to target
expression levels should enable assessment of RBM47-dependent
disruption of AGO binding both on a genome-wide and RBM47-target
specific level. Furthermore, given that AGO HITS-CLIP in 831BrM2 cells
has already delimited the discrete AGO binding sites on targets such as
DKK1, ANKRD1 and CTGF, the relative ability of individual seedmatched miRNA to repress target transcripts in the presence or absence of
RBM47 can be assessed. Of note, additional miR-335/* mimic transfection
into MDA-231 failed to decrease relative luciferase activity in full length
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DKK1 3’UTR reporter assays (data not shown), consistent with a buffering
of transcript level by endogenous RBM47 and suggesting that knockdown
of RBM47 in MDA-231 cells may be required to unmask the regulatory
potential of miR-335/* on the DKK1 transcript.

Defining high confidence RBP targets by HITS-CLIP has relied
upon stringent filtering to discern robust and reproducible binding sites.
Non-reproducible binding, or reproducible binding with low tag
numbers, could stem from alignment errors, low-affinity transient binding
captured by crosslinking that presumably does not represent the major
function of the RBP, or in the case of Flag-RBM47 may reflect fortuitous
binding events occurring due to non-stoichiometric levels of protein and
target RNA. While requiring reproducibility between replicate HITS-CLIP
libraries at any given binding site reduces the potential for background
noise, applying increasingly stringent thresholds to RBM47 clusters lead
to a dramatic loss in the number of retained intronic clusters and a relative
enrichment in 3’UTR binding. A similar shift in proportional binding has
been reported for nELAVL with increasing stringency placed on biological
complexity of peaks, but importantly, intronic nELAVL binding has been
shown demarcate functional sites of regulation with respect to alternative
splicing (Ince-Dunn et al., 2012).

HITS-CLIP derived RNA binding maps associated with the
inclusion or exclusion of alternatively spliced cassette exons have revealed
a strong bias towards exon exclusion when binding occurs in the cassette
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exon or upstream flanking intronic sequence, and exon inclusion with
evidence of cassette exon-adjacent downstream intronic binding. Such
patterns have been described for Nova (Ule et al., 2003, Ule et al., 2006,
Licatalosi et al., 2008), FOX1/2 (Yeo et al., 2009), nELAVL (Ince-Dunn et
al., 2012), Mbnl-1 (Wang et al., 2012) and Mbnl-2 (Charizanis et al., 2012)
leading to the suggestion that this position dependent regulation may be a
common feature of RBPs involved in alternative splicing regulation
(Licatalosi and Darnell, 2010). Nova has been shown to promote exon
skipping by inhibiting the action of U1 snRNP (Ule et al., 2006), therefore
the discrete intronic binding seen in the immediate vicinity of
alternatively spliced cassette exons and flanking constitutive exons may
reflect the mechanism by which this and other RBPs regulate alternative
splicing.

The binding map of RBM47 does not show clear up/downstream
binding bias within the 500nt flanking alternatively splice exon-intron
junctions and is instead strikingly symmetrical with respect to cassette
exon inclusion or exclusion. The lack of a positional relationship between
RNA binding and splicing outcome has previously been described in
mouse embryonic stem cells for the well-characterized splicing factors
SRSF1 and SRSF2, although for both of these proteins enrichment in
binding was also seen on the constitutive exons consistent with binding to
exonic splicing enhancers (Pandit et al., 2013). Relatively symmetrical
normalized complexity maps have been generated from HITS-CLIP data
for both PTBP1 (Xue et al., 2009) and PTBP2 (Licatalosi et al., 2012),
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however these maps demonstrate some asymmetric binding enrichment at
intron-exon boundaries and lack the long tails of intronic binding seen
with RBM47.

Most similar to the RBM47-intronic binding patterns described here
are those associated with alternative splicing of FUS and TDP-43. For both
of these proteins multiple reproducible intronic peaks of low total tag
number (in many cases below the 10 tag threshold at which ~90% of
RBM47 intronic signal is in lost) are correlated with respective proteindependent regulation of alternative splicing ((Tollervey et al., 2011, Rogelj
et al., 2012, Lagier-Tourenne et al., 2012). It has been suggested that
binding to long introns in regions greater than 2kb from the exon-intron
boundary is a salient feature of both TDP-43 and FUS regulation of premRNA stability and splicing (Lagier-Tourenne et al., 2012, Polymenidou
et al., 2011), however alternative splicing of cassette exons in both human
and Drosophilia is generally associated with long intron length (Fox-Walsh
et al., 2005). The median length of RBM47-bound introns was found to be
significantly longer than the total population of both constitutive and
cassette exon-associated introns, with bias towards binding in the distal
regions (data not shown). However, the same significant increase in
bound intron length was also found when analyzing AGO intronic
binding in 831BrM2 cells, suggesting that the preference for binding to
long introns is not a unique feature of RBM47.
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RBM47 intronic binding is associated with extensive patterns of
altered alternative splicing, with several of the candidate RBM47regulated transcripts validated here also showing loss of RBM47-specific
alternative splicing patterns in 831BrM2 compared to MDA-231. This
would suggest that loss of RBM47 pre-mRNA splicing regulation might
contribute towards enhanced metastatic potential in 831BrM2 cells.
Shapiro et al. (2011) have reported extensive alternative splicing
associated with a breast cancer cell line model of EMT, the majority of
which they attribute to down regulation of PTB and ESRP1/2, and up
regulation of RBFOX2 through comparison with previously published
CLIP data sets to enrichment of binding motifs within a 250nt flanking
region of regulated splice sites. RBM47 is also downregulated in this
system, and based on the HITS-CLIP and RNAseq data presented here,
has the potential to directly regulate approximately 25% of the reported
EMT-associated splicing changes. The polyU RBM47 enriched-motif
derived from HITS-CLIP clusters was not among the significantly
enriched 5-mers in the sequences adjacent to EMT-associated splices,
however this is not unexpected given the relatively deep intronic RBM47binding patterns discussed above. Together this data strongly suggests
that RBM47 is a novel regulator in the EMT-associated splicing program,
whose downregulation may promote a more invasive phenotype in
831BrM2 cells.

The RBM47-regulated transcript MDM4 encodes a p53 binding
protein with significant homology to MDM2, a potent negative inhibitor
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of p53 (Shvarts et al., 1996). Multiple alternatively spliced MDM4
transcript variants have been described (reviewed in (Mancini et al.,
2009)), with exclusion of the RBM47-regulated exon 6 leading to a
truncated but functional variant termed MDM4-S. MDM4-S associates
with p53 with a 10-fold higher affinity than full-length MDM4 leading to
enhanced suppression of p53 transcriptional activity, making MDM4-S a
potent oncogene (Rallapalli et al., 1999, Rallapalli et al., 2003), however an
opposing role for MDM4-mediated p53 stabilization under conditions of
cellular stress has also been described (Di Conza et al., 2012). How
MDM4-S and MDM4 interact with the mutant p53 expressed in MDA-231
is unknown. It has been shown that decreased Mdm4 expression in mice
can improve overall survival in a WT p53 Rb+/- background, but not in a
hypomorphic p53 mutant Rb+/- background where the mutant p53 has
partial capacity to induce apoptosis but is an inefficient transcriptional
activator (Fang et al., 2013b). Full length MDM4 has been reported to
interact with multiple other proteins, including MDM2, p21 and CK1&,
using domains deleted from the truncated MDM4-S. These domains also
contain multiple targets for post-translational modification (Mancini et al.,
2009), therefore any potential pro-metastatic benefit of decreasing MDM4S in 831BrM2 may be independent of any p53 regulation.

RBM47 was found to bind to and regulate the alternative splicing of
several other known RBPs that themselves have alternative splicing
regulatory functions, including MBLN1 and PTBP2 (data not shown).
MBNL1 is abundantly expressed in skeletal muscle, brain and heart, and
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has been implicated in the genetic disease myotonic dystrophy (DM1)
(Miller et al., 2000). RBM47 intronic binding is associated with inclusion of
exon 7. Exon 7 is required for MBNL1 dimerization and enhances but is
not required for binding to CUG repeats (Tran et al., 2011), however
inclusion or exclusion does not alter MBNL1 splicing activity (Lin et al.,
2006). Interestingly, inclusion of exon 7 represents a fetal isoform of
MBNL1, with failure of postnatal downregulation of exon 7 inclusion seen
in mouse models of DM1 and human DM1 skeletal muscle tissue (Lin et
al., 2006).

That RBM47 is able to regulate other splicing factors may in part
explain the presence of RBM47-dependent alternatively spliced transcripts
that do not show evidence of direct RBM47 binding by HITS-CLIP. It will
be interesting to investigate whether modulation of individual transcript
RBM47-dependent alternative splicing is able to enhance metastatic
ability. Given the relatively dispersed RBM47 binding observed in
regulated introns, using oligonucleotides targeted to block RBM47
binding in MDA-231 cells may be difficult, however steric-blocking
oligonucleotides may be of use to prevent RBM47-enhanced cassette exon
inclusion (reviewed in (Kole et al., 2012)).

The tissue-specific expression pattern of endogenous RBM47 is
currently unknown. BioGPS (Wu et al., 2009a) reports high expression in
thyroid, prostate, small intestine and colon in addition to several immune
cell types, while kidney has the highest expression (RPKM) seen in the
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RNAseq Atlas (Krupp et al., 2012). Interpretation of the cytoplasmic
subcellular localization of RBM47 reported in the Human Protein Atlas
(Uhlen et al., 2010) is limited by the use of a single antibody known to
have non-specific cross reactivity. The extensive intronic binding evident
in the HITS-CLIP binding map and the role of RBM47 in regulating
alternative splicing of a subset of targets would indicate that RBM47 is at
least in part nuclear. Development of an antibody with high specificity
and affinity for RBM47 will be crucial to establishing the expression
patterns of RBM47 in normal and disease tissues, to determine
endogenous subcellular localization and for endogenous HITS-CLIP.
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CHAPTER 6: GENERAL DISCUSSION

Summary
HITS-CLIP has been used to study RNA regulation in a variety of
systems, including neurons, T cells and stem cells, but prior to this study
HITS-CLIP had not been applied to study RNA regulation in human
cancer. Here we have described the first study of differential RNA
regulation with respect to the acquisition of the aggressively metastatic
phenotype, using HITS-CLIP as a genome-wide approach to identify
AGO-regulated targets. In this study, we have assessed the role of RNA
binding proteins in metastasis suppression using an elegant human
xenograft based system developed by the Massagué laboratory that
accurately models breast tumor dissemination and metastatic colonization
of distal tissues (Bos et al., 2009, Kang et al., 2003, Minn et al., 2005a, Minn
et al., 2005b). This system has previously been used to identify antimetastatic miRNAs whose expression levels correlate with human
metastatic relapse (Png et al., 2011, Png et al., 2012, Tavazoie et al., 2008),
however the identity of directly regulated targets of these miRNAs is
difficult to infer from correlative changes in expression levels and reporter
assays.

Using AGO HITS-CLIP in MDA-231 breast cancer cells and its
highly aggressive metastatic sub-lines with tissue tropism to lung, bone
and brain, we have generated transcriptome wide maps of AGO-mRNA
interactions which delineate sites of regulatory action of AGO on target
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mRNA in a genome wide manner. In so doing, a valuable resource has
been generated that allows for narrowing of the sequence space in which
to search for regulatory miRNA seed sites on any given AGO-regulated
transcript in MDA-231 cells. Additionally by comparing the binding maps
generated in these four cell lines, we have identified sites of differential
AGO-mRNA binding that correlate with changes in expression levels of
target mRNAs with known roles in metastasis. Furthermore, through
analysis of the simultaneously derived AGO-miRNA libraries from HITSCLIP, we have identified several miRNAs with whose CLIP profiles are
altered with respect to metastatic potential. Decrease in the AGO-miRNA
counts of the miR-99a/let-7c/125b-2 cluster members were found to be
specific to lung metastatic cells, while divergent decrease (lung) and
increase (brain and bone) in the representation of miR-142-3p suggests
further potential for miRNA regulation with respect to tissue tropism.

Unexpectedly, the miRNAs previously identified as endogenous
suppressors of metastasis were weakly represented in the AGO HITSCLIP profile of MDA-231 cells, indicating a previously unappreciated
lower limit of sensitivity of the AGO HITS-CLIP approach. Therefore to
identify the full repertoire of regulated transcripts for one such antimetastatic miRNA, differential AGO HITS-CLIP was carried out in lung
metastatic cells stably expressing pri-miR-335, expression that is sufficient
to significantly inhibit lung colonization, or a non-targeting control
shRNA. As a result, we have uncovered a previously unappreciated
regulatory role for miR-335*, the presumed passenger strand of pre-miR244

335, expanding the potential for anti-metastatic target recognition and
potential therapeutic modulation of metastasis. Additionally, we have
identified several hundred transcripts miR-335/* seed containing de novo
AGO binding sites, with the validation of several previously unknown
miR-335/* targets providing proof of principle that de novo AGO-mRNA
binding is an indicator of gain of miR-335/* regulation.

By

applying

HITS-CLIP

prospectively

to

a

previously

uncharacterized protein whose downregulation in primary breast tumor
correlates with poor metastasis-free survival to lung and brain, RBM47,
we have demonstrated that is a multifunctional RNA binding protein with
roles in both transcript stability and alternative splicing. Through analysis
of robust and reproducible RBM47 RNA binding sites we have shown a
preference for RBM47 binding to AU-rich sequences, with the most robust
binding occurring in the 3’UTRs of target mRNA. In a sub-set of these
targets, including DKK1, ANKRD1 and CTGF, we have demonstrated that
RBM47 binding is positively correlated with increase in target mRNA
steady state levels, which in the case of DKK1 was shown to be due to
enhanced transcript stability. Furthermore we have established a role for
RBM47 as a regulator of alternative splicing, with binding of RBM47 in
intronic regions flanking RBM47-dependent alternative splice cassette
exons promoting both exon inclusion and exclusion.
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Comparison of AGO and RBM47 HITS-CLIP binding maps reveal
convergence on regulatory nodes of the Wnt pathway
While each dataset generated by HITS-CLIP is informative with
respect to the individual RBP and targets it regulates, by undertaking
multiple experiments within the same relatively homogenous population
of cells it is possible to overlay binding maps to identify regions of
potential agonistic or antagonistic regulation. By comparing AGO and
RBM47 binding maps in 831BrM2 cells the 3’UTR of DKK1 was identified
as a common target. DKK1 is a member of the DKK family of secreted
Wnt inhibitors that binds to and sequesters the Wnt co-receptors LRP5/6,
and can interact with Kremen1/2 to block Wnt signaling (Niehrs, 2006).
Two other nodes of the canonical Wnt pathway were identified as either
targets of RBM47 splicing or as miR-335 responsive genes (Tavazoie et al.,
2008, Oskarsson et al., 2011) (Figure 6.1).

Wnt signaling is required for mouse mammary stem cell renewal
(Alonso-Peral et al., 2012) and maintenance of the cancer stem cell
phenotype in murine and human squamous cell carcinomas (Malanchi et
al., 2008). Interestingly, Wnt signaling is required for metastatic outgrowth
of breast cancer cells in the lung via periostin recruitment of Wnt ligands
from the stroma in the murine MMTV-PyMT breast cancer model
(Malanchi et al., 2012). In human epithelial stem cells (hESC) Wnt
signaling has been proposed to promote survival and differentiation
(Blauwkamp et al., 2012), however other reports indicate that Wnt
signaling is required for self-renewal of hESCs and inhibition of
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differentiation (Singh et al., 2012). The pro- or anti-metastatic role of Wnt
signaling and DKK1 expression is both tumor type and distal-organ
specific (Menezes et al., 2012). As a negative regulator of bone formation
(Pinzone et al., 2009), DKK1 expression has been found to enhance bone
metastasis of multiple tumor types including prostate (Hall et al., 2005)
and breast (Bu et al., 2008). Conversely, DKK1 secreted from human
mesenchymal stem cells can inhibit MCF-7 breast cancer cell growth (Qiao
et al., 2008), while down regulation of DKK1 enhances the motility, foci
formation and soft agar colonization of nontumorigenic-epithelial breast
cells, and leads to partial EMT (Mitra et al., 2010).

We have shown that DKK1 expression is decreased in lung and
brain metastatic sub-lines of MDA-231, an expression level change that
was not previously reported as part of respective metastasis signatures
due to stringent >3-fold cut-offs of expression level change. DKK1
expression is known to be regulated at the transcriptional level by
canonical Wnt signaling (Gonzalez-Sancho et al., 2005), vitamin D3
(Aguilera et al., 2007), and by epigenetic silencing through CpG island
hypermethylation and histone deacetylation in multiple human cancers
including colorectal (Aguilera et al., 2006) and breast (Suzuki et al., 2008).
Post-transcriptionally, DKK1 has been reported to be negatively regulated
by

a

family

of

related

miRNAs

(miR-93.hd/291-

3p/294/295/302/372/373/520; (Zovoilis et al., 2009, Zhou et al., 2012)),
miR-335 (Zhang et al., 2011) and miR-29a (Kapinas et al., 2010), with AGO
binding in MDA-231 and derivatives supporting a role for the first two
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regulatory events in this system. The data presented here indicates that
RBM47 is a novel, direct positive post-transcriptional regulator of DKK1.
Preliminary data from our collaborators at MSKCC indicates an RBM47
dose-dependent decrease in the expression of the endogenous Wnt target
AXIN2 after Wnt3a stimulation (data not shown). Taken together, these
data suggest downregulation (4175LM2) or loss of RBM47 (831BrM2) may
lead to decreased DKK1 expression and increased activation of the Wnt
pathway in metastatic derivatives.

We also identified DKK1 as a robust target for AGO regulation,
with two of the AGO-binding sites shown to be pre-miR-335 dependent.
No impact on DKK1 transcript level or 3’UTR luciferase reporter activity
was evident upon miR-335/* mimic transfection suggesting that DKK1
levels may already be maximally downregulated in these cells, that our
assay was not sensitive enough to detect subtle changes or that this 3’UTR
may function as a neutral target or competitive endogenous miRNA
sponge. Pre-miR-335 is among a cohort of anti-tumorigenic miRNAs
reported to down regulate the Wnt pathway in HEK293 cells, although the
directly regulated targets in this system were not elucidated (Anton et al.,
2011). Additionally, the miR-335 responsive gene TNC (Tavazoie et al.,
2008) has been shown in 4175LM2 cells to enhance Wnt signaling through
promotion of LGR5 expression, and this Wnt signaling is required for
lung metastasis outgrowth (Oskarsson et al., 2011). LGR5 forms a complex
with LRP6 and Fzd5 that is rapidly internalized and degraded upon costimulation with R-spondin1 and Wnt3a (Carmon et al., 2012). TNC is
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itself a Wnt target gene, with activated )-catenin upregulating TNC in
embryonic mouse lung through direct binding to the TNC promoter
(Cohen et al., 2009). Reduction of DKK1 in 4175LM2 cells may result in the
upregulation of TNC in these cells via enhanced Wnt signaling, however
the mechanism by which miR-335/* re-expression mediates TNC
downregulation is unknown as analysis of AGO HITS-CLIP data indicates
that TNC is not directly targeted by miR-335/*.

Additional links to Wnt signaling were found when analyzing the
HITS-CLIP data associated with RBM47-bound alternatively spliced
transcripts. The RBM47 splicing target microtubule actin cross-linking
factor 1 (MACF1) is required for Wnt-mediated induction of TCF/LEF
induction of Wnt target genes in Rat-1 embryonic fibroblast cells through
proposed interactions with LRP6, APC, B-catenin and GSK3) (Chen et al.,
2006). In hair follicle stem cells Wnt signaling has been shown to inhibit
GSK3) phosphorylation of MACF1, promoting MACF1 association with
microtubules and enhancing cell polarization and motility during wound
repair (Wu et al., 2011b). RBM47 regulates both the inclusion of the
alternatively spliced exon shown in Figure 5.27B, located between the EFhand and Gas-2 related (GAR) domains of MACF1, and an additional
exon between the GAR domain and the GSR-repeat domain (data not
shown). The functional consequence of these in-frame exon inclusions on
MACF1 activity is unknown. Given that RBM47 is known to be
downregulated in EMT of breast cells (Shapiro et al., 2011) it is interesting
to speculate that loss of RBM47 regulation of these exons might lead to
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enhanced microtubule association and motility in metastasis, particularly
when coupled with RBM47-enhanced DKK1 inhibition of Wnt signalingdependent MACF1 phosphorylation. Taken together, the data presented
here suggests that RNA binding proteins influence multiple nodes of the
Wnt pathway. Concomitant loss of RBM47 and pre-miR-335 promote
enhanced Wnt signaling, a previously unrecognized event in breast cancer
metastasis (Figure 6.1).

Future Directions
In the work presented here, a cell culture model system was
selected to interrogate the role of RNA binding proteins in metastasis. As
a first step in the analysis of RNA regulation in metastatic versus primary
cancers, the approach was chosen given the extensive previous molecular
characterization of the xenograft and culture system, its demonstrated
recapitulation of human breast cancer progression, and technical necessity
due to the lack of RBM47 antibodies. However, multiple studies
investigating a diverse array of RBPs have shown that HITS-CLIP can be
successfully applied to whole tissues in order to identify in vivo sites of
RNA regulation, with particular focus on neurological disorders.
Preliminary studies obtained in the course of this thesis work have shown
that it is also possible to apply HITS-CLIP technology to snap-frozen,
human brain and to surgically resected tumors, specifically in the
mapping of ectopic Nova on endogenous transcripts in neurons or in
primary serous ovarian tumors, respectively (Christina Marney, Darnell
Lab unpublished data). The ubiquitous expression of AGO and the
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FIGURE 6.1: Multiple nodes of the DKK1/Wnt pathway are regulated
by RBM47 and AGO-miR-335/* with respect to metastatic potential. In
the parental MDA-231 cells that show a relatively poor ability to
metastasize, RBM47 expression leads to stabilization and up regulation of
DKK1 transcript, DKK1 binds to LRP5/6 leading to inhibition of the Wnt
signaling pathway. This allows GSK3) to phosphorylate the RBM47
splicing target MACF1 preventing it from associating with microtubules.
Additionally, higher levels of pre-miR-335 leads to indirect repression of
TNC expression, while DKK1 3’UTR is able to bind miR-335/* potentially
without negative regulation of the DKK1 transcript. In the highly
aggressively metastatic lung and brain metastatic sub-lines, both RBM47
and pre-miR-335 levels are reduced, leading to destabilization of the
DKK1 transcripts and derepression of Wnt signaling. Loss of pre-miR-335
allows for TNC-dependent LGR5 expression leading to further potential
enhancement of Wnt signaling, while loss of GSK3) phosphorylation of
MACF1 allows for association with microtubules that in hair follicle stem
cells allows for cell polarization and directional movement. MACF1 may
also promote translocation of Axin to the cell membrane. Figure adapted
from (Schuijers and Clevers, 2012)
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heterogeneous nature of primary tumors might make interpretation of
tumor-derived AGO HITS-CLIP binding maps challenging. With careful
selection of high density tumor-cell containing biological samples and
paired analysis of normal adjacent tissues, and ongoing improvements in
the sensitivity of the HITS-CLIP protocol, future studies of AGO and
RBM47 with respect to metastasis progression may be possible in primary
tumors and distal metastases.
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